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Abstract 
Trace elements participate in numerous biological processes and understanding their 
activity is essential in monitoring various diseases. Zinc has long been recognized as a 
fundamental component of various tissues, being highly concentrated in the retina and an 
essential structural component of many proteins. It plays a crucial role in many biological 
activities including homeostasis, immune function, oxidative stress, and aging disorders. 
During aging, the systemic metabolism of iron, zinc and copper changes, and this 
disruption in metal homeostasis appears to be associated with age-related disorders such 
as Alzheimer’s disease (AD) and Age related macular degeneration (AMD). As 
understanding the role of these metals is critical in finding the underlying causes for such 
diseases, and providing proper diagnosis and treatments, the distribution of these crucial 
elements in AD and AMD has been investigated.  
A rapid, accurate technique using sector field inductively coupled plasma mass 
spectrometry (SF-ICP-MS) was developed for the preparation and analysis of small 
volume (30 µl) biological samples. Analytical performance was evaluated using Serum 
UTAK certified reference material and the method was applied to Zn, Cu and Fe 
determination in 81 human serum samples from AD and AMD patients. No significant 
difference was found in Zn and Cu levels between AD and AMD patients, whereas Fe in 
AMD patients was slightly higher than AD patients. The results showed a decrease in 
serum Zn and Fe, and a notable increase in serum Cu in both AD and AMD patients 
compared to healthy controls. Elemental bio-imaging using laser ablation inductively 
coupled plasma mass spectrometry (LA-ICP-MS) was successfully employed for Zn 
imaging in 12 rat retina sections given either a conventional or a Zn-containing diet. A 
new data processing method, involving fitting Gaussian peaks to individual LA-ICP-MS 
line scans, was established. The RPE/retina peak area ratio was used to evaluate the 
differences in Zn content between supplemented and non-supplemented rats. In general, 
the difference between the three differentially fed rat groups was not statistically 
significant for the relatively small group of twelve rats investigated here. Thickness of 
Zn bands was also found to vary between controls and supplemented rats. This technique 
has the potential to support biologists in recognising possible new biomarkers for disease, 
related to specific trace elements.  
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1 Introduction 
 
1.1 Introduction to aim, objectives and hypothesis 
It is known that metal ions, mainly trace elements, are a vital component of life. Certainly, 
the homeostasis of metal ions including iron (Fe), copper (Cu) and zinc (Zn), is vital for 
many biological activities. Understanding their activities is essential in monitoring 
various diseases. Elemental concentration in serum/plasma has been the most frequently 
used biomarker of Zn and other trace element status. Serum Zn, Cu and Fe were selected 
as possible markers for monitoring and early detection of AD and AMD. Both AMD and 
AD are multi-factorial diseases influenced by age, gender and combinations of 
environmental and genetic risk factors. The most common characteristic in both diseases 
is the occurrence of amyloid ß (Aß) deposits in the brain of AD patients and in the drusen 
of AMD patients. Patients with advanced AMD have been found to be at an increased 
risk of developing AD. Therefore, parallel studies on the pathogenesis of the two diseases 
have led to a putative association between the two conditions. Zinc has long been 
recognized as a fundamental component of various tissues and cells, being highly 
concentrated in the eye, especially in the retina and RPE cell complex. Zinc has 
significant functions in retinal cell metabolism and specific retinal processes. The 
systemic metabolism of Zn, Cu and Fe changes during aging, and this disruption in metal 
homeostasis appears to be associated with age-related disorders. The most commonly 
used approach to restore Zn homeostasis disrupted in AMD patients is oral 
supplementation. Understanding the role of these metals is critical in finding the 
underlying causes for such diseases, and providing proper diagnosis and treatments. 
In general, the focus of the research group is concerned with the discovery of elemental 
bio-markers in relation to specific disease states. The overall aim of this study is to 
understand the Zn biology associated with AMD. Since it is well known that there is a 
link between AD and AMD, and other trace elements play a crucial role in 
neurodegenerative and age-related diseases, the work has been expanded to include 
consideration of AD.  
Several experimental approaches have been successfully employed to study metal ions 
such as Zn, Cu and Fe in biology, an area known as metallomics. Therefore, this work 
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will focus on developing a metallomics approach to studying Zn biology and the relation 
of Zn in a progressive age-related disease. However, understanding the specific biological 
functions of metals, and the explanation of their biological path is still challenging and a 
motivation for further analytical developments. 
In the following section the hypothesis, aim and objectives of the study will be presented. 
The chapters in this thesis were not carried out in chronological order. Although the initial 
plan was to look at Zn in serum, tissues and cells, some experiments were started before 
others according to the availability of the instruments and the arrival of the samples. At 
other times, simultaneous experiments were carried out in parallel during the same period. 
All samples have been received from Dr. Imre Lengyel and his students (Institute of 
Ophthalmology, University College London). 
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1.1.1 Hypothesis of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Secondary Hypothesis (I): 
▪ Is there a correlation between Zn, Cu, 
Fe levels in AD and AMD serum 
samples? 
 
▪ Do increased and/or decreased levels 
of Zn, Cu & Fe contribute in these 
diseases? 
▪ Does Zn supplementation affect 
either the amount or the 
distribution of Zn in the retina 
and RPE in rats?   
 
▪ Do changes in the level of Cu 
influence Zn levels? 
▪  
Secondary Hypothesis (II): Secondary Hypothesis (III): 
▪ Does variation in Zn concentration 
have an effect on embedded human 
RPE cells? 
 
▪ Does Zn concentration vary in 
different cell compartments? 
     
Primary Hypothesis: 
• Is a higher or  lower level of Zn in the circulation and/or eye tissues/cells associated with an increased incidence of 
AMD? 
• Is there a significant difference between Zn levels in the blood stream and /or eye tissue of AMD patients and 
controls? 
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1.1.2  Aim and objectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
• To determine and compare the 
distribution level of Zn, Cu &Fe in 
serum of 43 AD patients and 38 AMD 
patients.  
 
The overall goal of the present study is to establish the role of zinc and other elements in some age 
related diseases by monitoring Zn in various biological materials: 
Serum  
ICP-MS 
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• To develop a readily adaptable method to 
determine trace elements in a very small 
amount of serum (30µL).  
 
Tissue 
LA-ICP-MS 
Chapter 3 
• To employ a novel data processing approach to 
examine the relative differences in Zn 
accumulation between these retinal compartments. 
Cell 
ICP-MS 
• To measure Zn concentration in 
different cell compartments (the 
cytosol, cell membrane, nuclear 
fraction and cytoskeletal). 
Chapter 4 Chapter 5 
• Future work would include an 
online cleaning system to 
remove the high levels of Zn 
found in the cell partitioning 
buffers. 
 
• This work will be carried on in 
the future to compare the effect 
of Zn levels on different types 
of cultured, embedded RPE 
cells.  
 
• To test if Zn level has an 
effect on embedded human 
RPE cells cultured on 
Millicell membrane and 
treated with 0-125µM Zn 
during the culture process. 
LA-ICP-MS 
• To image the distribution of Zn across the retina and 
RPE in 12 sections of aged rats that had received a 
conventional or supplemented diet, to investigate if 
there is Zn enrichments in the aging retina of the rat. 
Zn supplementation levels were approximately 
equivalent to those given to human AMD patients 
in AREDS 1 study to examine how this treatment 
affects the condition.  
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1.2 Introduction to trace elements in human health 
Trace elements are naturally occurring components that are distinguished from noble 
gases, major and minor elements in the periodic table.1 Major elements such as H, O, C 
and N comprise around 96% of total human body, while minor elements e.g. Na, K, Ca, 
Mg, P, S and Cl make up 3.8% of in the human body. There are 73 naturally occurring 
trace elements present in the body and 18 of them are classified to be essential trace 
elements such as Li, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, W, Mo, Si, Se, F, I, As, Br and Sn.1 
Nevertheless, other metals (frequently heavy metals) are known to be potentially toxic. 
The presence of some elements might have adverse effects on living systems by being 
toxic, mutagenic or carcinogenic.2 For instance, these elements have been included in the 
context of carcino- (As, Cr, Pt), immuno- (Au, Co, Cr, Ni, Pt), embryo-/terato- (Hg), 
spermio- (Cd, Pb, Tl), and  nephro- (Cd, U) or neurotoxicity (Al, Hg, Mn).3 
 
1.2.1 Importance and functions of trace elements 
Trace elements are important in various significant biological functions in the human 
body. They are needed for several metabolic and physiological processes and the amount 
required per day ranges between 50 µg and 18 mg.4 Metals play a crucial role in the 
functions of enzymes, co-factors, catalysis, mitochondria, neurotransmission, structural 
stability, oxygen transportation, and cellular signalling. In addition, the stability of the 
metals is believed to be essential for functioning of the central nervous system (CNS) and 
regulating and participating in many cellular mechanisms.5,6 Numerous proteins include 
metal atoms as part of their structure. It has been estimated that around 33% of all proteins 
are bound with a cofactor metal ion such as Cu, Fe, An, Se or Mo for carrying our their 
physiological function.7  
The activity of a wide range of biomolecules, in particular proteins, is controlled by metal 
ions, where they are responsible for both catalytic and structural functions. Nevertheless, 
excess and insufficient level of both non- essential and essential metals could be either 
toxic or resulting in metabolic failure.4 
Absorption, excretion and tissue retention are controlled by homeostasis mechanisms of 
essential elements. The performances of essential functions require safe and sufficient 
supply of essential trace elements. Although various elements are believed to be essential 
6 
 
B
io
lo
g
ic
al
 f
u
n
ct
io
n
 
Optimal function 
Marginal 
toxicity 
Marginal 
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for human health, many others are known to be toxic.  When the essential elements appear 
in an organism in excessive quantities and exceed the range of adequate exposure, the 
elements will become toxic. In contrast, insufficient intake could damage cellular as well 
as physiological function and most probably lead to different types of diseases. Figure 
1.1 explains the relation between a biological function and the dietary intake 
concentration of a trace element. The diagram is generally applicable to most essential 
trace elements although each element has its individual precise curve, which varies from 
others.1,4 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Dose-response curve for essential trace elements. Modified from Mertz, 
1981 and reproduced with permission from American Association for the Advancement 
of Science (AAAS).4  
 
 
1.2.2 Deficiency and toxicity 
Inadequate nutrition could cause deficiency of trace elements. Iron deficiency is world’s 
most common nutritional illness.8 Moreover, deficiencies can initiate from genetic or 
inherited disorders with trace element metabolism implicated in the pathogenesis. An 
example of such neurological disorder is Menkes disease and Wilsons disease. Both 
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diseases are genetic disorder caused by Cu deficiency where Cu transport is interrupted 
and is lethal in early childhood. Also, acrodermatitis enteropathica is an uncommon 
genetic autosomal recessive disorder, characterized by reduction in Zn absorption which 
results in its deficiency.9,10 It has been reported that Zn deficiency adversly affects 
macrophages, phagocytosis and produces toxic effects on the functions and  the growth 
of the T and B cells.11 
On the other hand, if excessive amounts are ingested the essential elements can also be 
toxic. For instance, Mn is an essential trace element; however, it is evident that 
overexposure and inhalation of dust or fumes in the work environment can cause 
psychotic behaviour that resembles Parkinson symptoms, known as manganism.12,13 
Trace elements' deficiency and toxicity depend on a number of other factors including: 
gender, age, chemical form, interaction with other elements, dietary source and 
nutritional state.14 
According to a study of nutrient intake (institutionalized, with a mean Mini-Mental State 
Examination,MMSE), it has been reported that patients with severe AD consumed less 
Zn than controls owing to poor Zn intake.15,16 Therefore, if the normal diet of these elderly 
patients is Zn deficient, adequate supplementation is required to maintain good health.17 
Total Zn intake requirement per day is around 2.2 mg for an adult if the bioavailability is 
100%, and various national health institutions reported the dietary reference value for 
men estimated between (9.4-15 mg/day) and for women (7- 12 mg/day).18,19 
Elevated Cu level in AD patients could be explained by the increase of ceruloplasmin. 
Ceruloplasmin is synthesized in the liver and the majority excreted by bile and the rest 
eliminated by urine. Thus, elevated Cu level could be an indicator of the liver’s failure to 
clear Cu in the elderly and therefore, it is important to perform clinical studies of liver 
function in AD patients to investigate the reason for the high Cu level.20 On the other 
hand, Cu deficiency in tissues does more harm to the antioxidant enzyme system and 
immune system, and decreases hemoglobin level, thus raising oxidative stress and 
inflammatory response.11 Deficiency in some vitamins and micronutrients that play an 
important role in antioxidant and metabolism (such as Vitamins B1, B2, B6, B12, C, and 
folate), have been linked with cognition impairment in old people.21 As Cu and Fe could 
be a dietary risk factor, Loef and Walach22 revealed an association between high Cu, Fe 
and saturated fatty acid (SFA) intake and cognitive decline. Accordingly, old people who 
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are not at risk of anaemia should avoid diet rich in Cu, Fe together with SFA (0.9 mg/day 
could be sufficient according to World Health Organization (WHO) recommendation).23 
Interestingly, Mediterranean-type diets have been attributed to decreasing the rate of 
AD.24 Hence, in this study, the focus will be primarily on Zn and other trace elements 
such as Cu and Fe. 
  
1.2.3 Zinc (Zn) 
Zinc is a metallic transition ubiquitous trace element, and is the second most abundant 
bio-metal in the human body following Fe. It is an essential trace element in human body 
and crucial for the biology of living organisms. It can be found in large quantities in 
body’s tissues and organs such as bone, muscle, liver, teeth and skin. 25 Around 95% of 
total body Zn is bound to intracellular proteins and cell membrane. 26 The mean 
concentration of Zn in human plasma is approximately 15 µmol L-1 (100 µg dL-1). 27 
However, this small pool is very mobile and key to Zn homeostasis. Serum Zn is bound 
to albumin (75–80%), α-2 macroglobulin (30%) and transferrin and ceruloplasmin     
(10%). 28,29  
It is well known that Zn is required for over 300 enzymes as a catalyst, regulatory ions or 
structural component.25 Unlike Fe and some biometals, the free divalent cationic form 
(Zn2+) does not produce oxidation-reduction reactions under physiological condition and 
thus it is relatively non-toxic.28 Although it is only required in small amounts, Zn is vital 
for a vast number of fundamental biological functions.30 Zinc plays a vital role in gene 
and protein expression, enzyme catalysis, lipid metabolism and several cellular processes, 
such as protein synthesis, signalling pathway, cell division, DNA replication and 
transcription.31,30 In addition, Zn protects intracellular components from oxidative stress 
caused by inflammation, infection and toxins. For instance, Zn indirectly acts as an 
antioxidant and it is involved in stabilization of cell membrane structure, contribution of 
super oxide dismutase (SOD) component and maintenance of metallothionein (MT) 
concentration in tissues and cell membrane.32 Albumin is the main protein of human 
blood plasma  and acts as the major transport protein for Zn in plasma. It can be adversely 
affected by chemical stresses such as oxidative stress occurring in the ageing 
degenerative diseases including Alzheimer's disease.33 Zinc can cross the blood brain 
barrier, thus it plays a crucial role in maintaining normal brain function34. Most of brain 
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Zn is bound to MTs, while free Zn only corresponds to 10% which exist in neurons.34 
The depletion of free Zn from neurons could cause cognitive abnormalities34,28 and 
associated with diseases such as Alzheimer’s disease.35 Accordingly, one of the disease 
modifying approaches in the treatment of Alzheimer’s disease aims to prevent Zn 
dyshomeostasis.35  
The main source of Zn intake is food, such as fish, shellfish, egg, red meat, dairy products 
and nuts; and a small portion from drinking water.28 Another source of food that contains 
high levels of phytates including seeds, nuts, legumes, cereals and soya based products 
are less available for absorption as these foods chelate dietary Zn and Fe, making them 
less bioavailable. The adults Recommended Dietary Allowance (RDA) of Zn is 8 to 
15mg/day, however, doses that exceed 25 mg can cause anemia and Cu deficiency.36 
Significant deficiency of zinc can cause oxidative stress and which in turn damage 
proteins, lipids and DNA.37,38 Zinc deficiency could cause some diseases, such as malaria, 
lower respiratory tract infection and diarrhoea.39 In contrast, excess level of Zn could lead 
to Zn toxicity that could cause some symptoms like nausea, vomiting and diarrhea.40 
 
 
1.2.4 Copper (Cu) 
Like Zn, Cu is an essential trace element and found in all tissues and organs of the human 
body. Copper plays an essential role as a cofactor in multiple cellular processes including 
respiration, connective tissue formation and Fe metabolism.41 Copper containing 
enzymes are widely distributed in the body such as super oxide dismutase [SOD] and 
ceruloplasmin.40 Both Zn and Cu bind to metallothionein (MT), a main regulator of 
storage and transport of these metals.42 They work as a catalyst in redox reactions, 
transport oxygen and protect the cell against oxidative damage.43 Liver is the main site 
for Cu storage and homeostasis. It is also found in other organs such as heart, brain, 
intestine and stomach.44 In plasma, Cu is mainly bound to ceruloplasmin (95%), while a 
small portion is bound to plasma albumin and amino acids.45,46 The free Cu in blood could 
be harmful to the cell because it is a potent oxidant which could produce reactive oxygen 
species (ROS) in cells and disrupt homeostasis which may result in toxicity.25  High 
concentrations of Cu and Fe are related to many diseases, such as cancer, cardiovascular, 
Alzheimer’s and Parkinson’s diseases and long-term disruption of Cu homeostasis can 
cause genetic disorders.47,48 However, a high Cu intake does not necessarily result in Cu 
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overload due to strong Cu regulation if the exposure of Cu is kept within the homeostatic 
range.49 It is also known that an imbalance between Cu and Zn could be an indication of 
vascular complications, infection and other disease. 50 Therefore, a proportionate intake 
of Zn and Cu should be maintained.51 
 
1.2.5 Iron (Fe)  
One of the most significant trace elements is iron that plays different biological roles in 
the human body, such as enzyme activities, electron transport, oxygen transport and DNA 
synthesis.25 In addition, Fe is crucial for energy metabolism, electron transport chain, and 
oxygen transport. Fe has potential for the development of free radicals and is required for 
ROS generation.11 It is clear that Fe-related oxidative damage is closely connected with 
several diseases. The two active forms of Fe are redox forms which are Ferric [Fe3+] and 
ferrous [Fe2+] ions.52 Ferritin is a protein that stores Fe inside the human cell. The ferritin 
plasma level could be a useful indicator for stored Fe.53 Iron plays an essential role in 
tissue oxygenation since it is considered to be an integral part of haemoglobin which 
works as an oxygen carrier in red blood cells.52 In addition, Fe plays an important role in 
neurotransmission since it is included in lipid and cholesterol biosynthesis which are 
components of neurons. It is clear that Fe has a good relation to brain activity due to high 
oxygenation and myelin levels in the brain.52 It is also reported that Fe overload could 
lead to neurodegenerative disease.54 
 
1.2.6 Zinc, copper and iron interaction 
Zinc, copper and iron participate in several biological activities. They affect each other’s 
homeostasis as some of them are sharing the same transporters and binding proteins 
including metallothionein (MT). These connections are well recognised for Cu and Zn, 
which compete for MT binding.55,23 It has been indicated that Cu-Zn- MTs in AD brains 
show a decrease in Cu bound to isoforms of MT (MT-1 and MT-3).56 In addition, Fe 
mainly, but also Zn and Cu, are shared by another transport mechanism which is divalent 
metal transporter 1 (DMT1).55,57  
Zn is mainly bound to Albumin, but also to transferrin (10%).29 As transferrin is the main 
transporter of Fe, excessive Fe can decrease Zn absorption, and vice versa. Moreover, 
alterations in ceruloplasmin (the major Cu carrier) and transferrin levels may result in 
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abnormal metabolism of both Fe and Cu. Besides the role of ceruloplasmin as a transport 
protein, it also functions as an enzyme, catalysing the oxidation of Fe. The Cu 
concentration was found to be notably higher in Fe deficiency (anaemia) in comparsion 
to control.58 Zinc, copper and iron are potentially interfering with each other with regard 
to metabolism, distribution and absorption, and in regulating the cellular response and 
health effects. Copper is known to react with a selection of nutrients, including Fe and 
Zn. Excessive amounts of Fe supplementation (more than 25 mg) might decrease Zn 
absorption. On the other hand, extreme absorption of Zn may suppress Cu and Fe 
absorption. To illustrate, high Zn intakes (150–450 mg per day) have been linked with 
low Cu status, changed Fe function and other chronic effects.58 Therefore, changes in 
nutritional habits may affect the homeostasis of macro- and micronutrients and this 
challenging factor would need to be analysed systematically with reliable techniques. 55,58 
However, another study suggested that high dietary Zn may not interfere with the levels 
of Cu in human tissue or plasma.58 
The alteration of Fe concentration in the brain can cause a dysregulation of the other trace 
element and thus changed homeostasis. Iron also has been reported to disturb Cu and Ca 
homeostasis.59 Moreover, pathophysiological circumstances such as inflammation have 
an influence on the homeostasis of Zn, Cu and Fe in parallel. These examples obviously 
indicate the importance of analysing and evaluating several trace elements in parallel.55 
Zn as well as Cu perform as an intracellular scavenger of the reactive oxygen species 
(ROS) and performs an important function in bone mineralization.11 Using trace element 
ratio instead of single trace element as markers for the elemental status could be 
potentially useful. It was recently observed that Cu/Zn ratio was positively associated 
with markers of age and general inflammation, mainly those associated with 
neurodegenerative disorders.55 Another study reported the link between blood Cu/Zn 
ratio with age, gender, and disease.60 Therefore, the ratios might help as aging markers, 
which should be further tested in other population groups.  
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1.3 Introduction to metallomics  
1.3.1 Definitions of terms 
The term metallome is relatively new, and was first introduced in 2001 by R. J. P 
Williams, who refers to it as a distribution of free metal ions in biological materials. 
Subsequently, the term metallomics has been suggested as the study of metallome.61 This 
study focuses on interactions and functional connections of metal ions and other metal 
species with genes, proteins, metabolites, and other biomolecules in biological systems.62 
In general, the terms “metallome” and “metallomics” have been used in different contexts, 
the former expression is described from a chemical viewpoint as the full complement of 
metals and metalloid species present in cell or tissue type and analysis therefore referred 
to as metallomics.61 From a biochemical perspective, the main area of interest is to 
examine pathophysiological mechanisms of diseases by identifying how the metals are 
bound with biomolecules (metalloproteins or metalloenzymes), and studying the 
mechanisms of enzymatic and biochemical reactions.63 One of the most significant areas 
of research is investigation of the structural and functional roles of metal ions linked with 
proteins, which is usually stated as metalloproteomics.64 Although metallomics has been 
recognized as being in its primary phase, compared with genomics and proteomics, 
metallomics has already obtained a vast quantity of information which will be useful in 
the rapid development of metalloproteomics.65 
 
1.3.2 Importance of metallomics 
Metallomics and metalloproteomics have been given considerable attention in the last 
few years. The expansion of these areas of interest into biochemistry and biomedical 
study has produced a new research area.66 In addition, the identification of metal cofactors 
in a protein, which is called qualitative metallomics, may lead to better understanding of 
protein function and accordingly many biological processes. As a result, the role of vital 
and toxic metals in health and disease are more likely to be observed. Added to this, a 
wide-range of novel metal drugs, remedies could be discovered.63,67 Common examples 
of metalloproteins are ferritin and metallothioneins. Metallothioneins (MTs) are a family 
of cysteine-rich, low molecular weight proteins that bind to transition metals. MTs play 
a crucial role in homeostasis and controlling intracellular metals where they link easily 
with essential trace metals such as Zn and Cu. They also provide resistance against the 
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toxicity of heavy metals in cells, e.g. Cd and Hg. MTs are considered biomarkers for  
intracellular Zn ions, hence it is recommended not only to quantify MT in a biological 
matrix, but also to detect Zn or other important metals binding with MTs.68,69 The 
homeostasis of metal ions is important in central nervous system. On the other hand, 
metal dyshomeostasis and accumulation of Cu, Zn and Fe in the human brain has been 
connected to the pathogenesis of many neurodegenerative diseases, such as Alzheimer’s 
and Parkinson’s disease.47,70 In such diseases, the interaction of Cu or Zn with target 
proteins is altered. Also, ferritin metabolism is altered and Fe ions were found to increase 
oxidative stress.70 As can be seen from Figure 1.2 the majority of a biological system 
comprises an expansive range of structures, distributed in simple (free ions) or complex 
form (genomics, proteomics, metabolomics and metallomics or metalloprotein), either 
strongly or weakly bound.61,62 61 
 
 
Figure 1.2 Diagrammatic model of the biological system, showing the correlation 
amongst genomics, proteomics, metabolomics and metallomics. Reproduced from 
Lobinski et al., 2010, with permission from De Gruyter.61 
 
Many factors may affect metal ions in biological systems. One factor is that the total 
concentration (quantitative metallomics) of intracellular metals that exists in the cytosolic 
pool is in the micromolar to picomolar concentration range.71,3 Trace elements have been 
implicated in the pathogenesis of various neurodegenerative disorders. The concept of a 
disturbance of metallostasis or loss of metal homeostasis, has recently been demonstrated 
as a crucial factor in the pathway leading to Aß toxicity and Alzheimer's disease (AD).72  
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1.4 Introduction to some important diseases of ageing 
1.4.1 Alzheimer's disease 
Alzheimer's disease (AD) is the most common cause of dementia that occurs most 
frequently in elderly people. It is a progressive neurodegenerative disorder, gradually 
damaging the regions of the brain, leading to memory loss, impaired speech, difficulties 
in learning and orientation, and other cognitive abilities.73,20 AD affects  over 27 million 
people worldwide74 and the likelihood of developing AD is forecast to double every 5 
years after the age of 65.75 AD affects 3–15% of people aged less than 75 years, however 
this percentage increased up to 30-40% for people aged 85 years and older.76,77 
 
1.4.1.1 Signs, diagnosis and stages 
The significant pathological hallmark of AD disease is characterized by the formation of 
extracellular amyloid beta peptide/ protein (Aβ) deposition and neurofibrillary tangle 
(NFT) within neuron and thus decreased synaptic density and loss of neurons in the 
cognitive centres of the brain.78,18,79 Tau protein is the main component of NFTs.79 A vast 
Aβ production produces Aβ aggregation and finally leads to senile plaques formation. 
Neurofibrillary tangles (NFT) are accumulation of abnormal hyper-phosphorylated 
protein tau, which performs a role in intracellular transport. The existence and 
distribution of Aβ and NFT in the brain is utilized for AD diagnosis and determines the 
stage of this disease.75,80 (see Figure 1.3). In addition, metal ions including Zn2+, Cu2+, 
Fe2+ which play a role in the etiology of this disease, participate in oxidation and free 
radical production as represented in Figure 1.4. Early stage detection of AD is of much 
interest to the researcher, as that may help to clarify the mechanisms of AD and to 
improve AD patient’s quality life.81 Mild cognitive impairment (MCI) is usually 
considered a preclinical stage of AD with acquired deficiency in multiple cognitive 
functions. Patients with MCI show increased risk of developing AD and about 20% of 65 
years old people may have MCI.73,82 It has been indicated that 10-15 % of MCI cases 
convert to dementia annually.83 Accordingly, comparative studies between MCI and AD 
patients in order to track the progression of neurodegeneration as well as understanding 
the pathogenesis of disease to detect potential biomarkers for early diagnosis is 
important.82 Eventually, severe cognitive decline known as dementia has an adverse 
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impact on daily living activity of patients. Dementia in AD gradually worsens and in the 
late stage patients rely completely on others in their basic living activities. 84,74 
Figure 1.3 Normal Vs. Alzheimer’s disease brain. Reproduced with permission 
 from Bright Focus Foundation programme, 2017.84 
 
 
Figure 1.4 Contribution of metal dyshomeostasis in AD disease. Reproduced with 
permission from N. Braidy et.al, 2014.74 
 
16 
 
1.4.1.2 Risk factors 
Despite extensive research, the cause of Alzheimer’s disease is still unclear and that is 
the main barrier for treating and/or preventing AD. However, multiple factors could play 
a vital role in AD degeneration.85,86 Age is the most influential risk factor of AD, and 
with predominance of an aging population in the world the risk factor of AD increases 
remarkably. Aging and AD are recognized by damaging of blood brain barrier function, 
gradual and progressive decline in cognitive function and shortages in memory and other 
mental capacities.87, 88 The number of nerve cells in the brain are reduced with growing 
age, and production of free radicals and markers of oxidative stress increase in neuronal 
cells.88 
Numerous studies have suggested the contribution of different cellular processes 
including oxidative stress in the pathogenesis of AD.80,82,87, 72,70 Oxidative stress and 
inflammatory response induced by Aβ deposition results in further formation of Aβ fibrils 
and neurofibrillary tangles which causes oxidative damage to the cells and its function. 
Therefore, the availability of nutrients in the neuron drops and the process of 
inflammation is stimulated. This leads to neurotransmitter deficiency and overall death 
of neural cells and failure in their function, as a whole contributes to Alzheimer's disease 
progression.80,87 
Micronutrient deficiency (especially those linked to antioxidant and amino acid 
metabolism mechanisms) such as vitamins B1, B2, B6, B12, C, and folate, have been 
correlated with MCI in old age.23,21 Cholesterol and high fat intake (e.g., saturated fatty 
acids) enhances the formation of Aβ in the animal model brain and elevate oxidative 
stress, thus they were associated with the increase risk factor of AD. In addition, some 
evidence has indicated the strong relationship between AD and cardiovascular 
diseases.80,23,21, 89 Overall, a number of risk factors including chronic oxidative stress, age, 
Aβ production, neurofibrillary tangles accumulation, inflammation, abnormal 
accumulation and distribution of different metals and other genetic components, play a 
significant role in the development of AD. Other risk factors have been identified to 
evaluate AD risk, such as: female gender, positive family history, hypertension, coronary 
vessel disease and increased body mass index.23 Medication for AD does not cure the 
disease but only offers modest benefits. Therefore, effective strategies to delay or prevent 
AD are needed.23 
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1.4.1.3 The role of metals in relation to Alzheimer’s disease 
While metal ions play an important role in biology, disruption of metal homeostasis is a 
key element in the pathway leading to Aβ toxicity and AD. Consequently, that will result 
in neuronal dysfunction, neurotransmitter deficits, and eventually, neuron death.90 Redox 
metals in the brain play various essential roles for maintenance of cellular function. 
However, the impaired regulation of redox reaction at a molecular level of metals such 
as copper (Cu), zinc (Zn) and iron (Fe) is identified in Alzheimer’s disease (AD) due to 
development of cytotoxic reactive oxygen species (ROS) which lead to neuronal 
damage.74 In addition, the β- plaques isolated from AD affected brain tissue were 
observed to contain sequestered biometals, which could implicate those metals as 
potential pathological cofactors in AD.52 Alzheimer’s disease disrupts the brain 
metallostasis, causing redistribution of metals into inappropriate compartments, in 
particular Fe, which is the most excessively available transition metal in the brain. There 
are tightly organized mechanisms in order to control Fe in the brain. However, 
dysregulation, Fe overload and Fe deficits are harmful to the brain.91 Therefore, targeting 
the transition metals such as Zn, Cu, and Fe that have an impact on molecular mechanisms 
of disease could be an alternative approach to treat this disease.79,90 
In old age nutritional deficiency is common, this further decrease in AD Zn levels could 
in turn affect levels of the ion in brain tissue and entrap Zn within the plaque leading to 
exaggeration of amyloid pathology. Copper and zinc is highly developed within AD 
plaques (1055µM) compared to normal age- matched neuropil (350 µM).92 The continual 
development of specialized tools and a rising interest of the role of metal ions in normal 
biological functions and diseases will deliver much needed insight into potentially a wide 
range of disorders.5 
 
1.4.2 Age related macular degeneration 
Age related macular degeneration (AMD) is an inflammatory, chronic eye disease, 
attacking the macula and causing severe and irreversible vision loss in elderly people.93,94 
As can be seen from Figure 1.5 (A) the macula is a small spot located near the central 
part of the retina, and it is the light-sensitive tissue at the back of the eye that provides 
the clearest, most distinct vision. In general, the damage done to the macula develops 
over time, gradually decreases the quality of the central vision, often referred to as 
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macular degeneration.95,96 Due to this progressive deterioration of central vision, the 
quality of life and the ability to perform some daily activities such as reading, driving and 
recognising faces will probably be affected.97,98 Early AMD affects about a quarter of 
people above the age of 65 years99, while the prevalence of advanced AMD increases 
severely with age, and is estimated to be doubled by 2020 in North America and Europe.97 
In the UK, vision loss that is caused by AMD accounts for approximately 42% between 
the age of 65–74 years, nearly two-third of those aged between 75-84 years, and around 
75% over the age of 85.99 
1.4.2.1 Types and stages of AMD 
The two vision threatening types of AMD are dry form, also known as non-exudative or 
geographic atrophy, and wet form, also known as exudative or neovascular. The vast 
majority of AMD patients are attacked by geographic atrophy form, whereas the 
exudative AMD is less common and appears only between 10-20% in AMD patients. 
Although both forms are responsible for reducing the vision loss, advanced AMD 
(neovascular form) is the most severe form and accounts for 90% of legal blindness.93,97,98 
The early sign of dysfunction of retinal pigment epithelium (RPE) and retina are 
characterised clinically by the presence of pigmentary changes in the RPE and 
accumulation of yellow deposits called drusen.100 Drusen are located between the RPE 
and the inner choroidal layer in the Bruch’s membrane (BM).97,99,101 It has been identified 
that vitronectin, an abundant glycoprotein found in serum and extracellular matrix, can 
be considered as the main component of drusen.100 In the early stage multiple small or 
intermediate drusen deposits (63μm-125 μm) will appear and the progression risk of 
AMD in this stage is low (between 0.4%-0.3%) over a period of 5 -10 years (Figure 1.5, 
B).98,99 However, if extensive drusen (>125 μm) are present in both eyes, the risk might 
increase up to 47.3%, and this stage is usually considered as intermediate age related 
macular degeneration.98,99 In the advanced period of dry AMD, the RPE degenerates 
slowly and may lead to complete atrophy to the photoreceptors and choriocapillaris layer 
of the choroid (Figure 1.5, C). 94,97 During the late stage of wet AMD, the damage to the 
macula occurs rapidly as the growth of abnormal blood vessels, called choroidal 
neovascularisation (CNV), could cause bleeding and formation of scar tissue into sub-
retinal space97,98,99  (Figure 1.5, D). A detailed diagram showing the stages and types of 
AMD pathology within the layers of the eye are illustrated in Figure 1.6.  
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Figure 1.5 (A) The macula is a small component of the eye found in the central area of the 
retina (healthy eye),  (B) Macula of early AMD with numerous small and intermediate soft 
drusen, (C) Macula of advanced dry AMD with geographic atrophy, (D) Macula of 
Advanced wet AMD  with a choroidal neovascular membrane with sub retinal haemorrhage. 
(A) My eye, Vision Express, 2015. (B-D) Reproduced from Chakravarthy et al., 2010,  with 
permission from BMJ Publishing Group Ltd.93,98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 AMD Pathophysiology. This diagram highlights: the several layers of the 
normal retina (a); a cross-section of the human eye (b); and the stages/types of AMD 
(c), (d), (e). Reproduced from Ambati et al., 2103, with permission from Springer 
Nature publications.102 
  
20 
 
1.4.2.2 Suggested treatments and pathology mechanism 
Several potential options have emerged as a treatment for exudative age related macular 
degeneration, including laser photocoagulation, photodynamic therapy (PDT), surgical 
intervention, and anti-angiogenic drugs (such as anti-vascular endothelial growth factor 
medication VEGF).93,97,103 The development of anti-VEGF agents, in particular, has 
provided an indication to stop the progression of wet AMD and also improve the visual 
acuity.97 However, no effective treatment has been proven for geographic atrophy or 
restoring visual loss in AMD patients.94,104 ,105 Therefore, the attention has focused on 
attempts to stop the progression of the disease by inhibiting the damage that leads to this 
condition.104 
As the retina and retinal pigment epithelium contain high level of oxygen and 
polyunsaturated fatty acid as well as the chronic exposure to light, both of which are 
strong sources of free radicals, thus the accumulative results of oxidative stress play a 
principal role in initiating macular degeneration.95,98,106,107 As a consequence of oxidative 
damage, biochemical and structural changes could occur that produce inflammation and 
angiogenesis (development of new blood vessels), especially in genetically predisposed 
patients.97,99 Hence, an antioxidant balance that can be obtained from diets, Zn or vitamin 
supplementations can possibly maintain a healthy retina and the factors which result in 
stimulating oxidative stress should be avoided. 
 
1.4.2.3 Risk factors 
It is clear that there are several factors - genetic as well as environmental - which may 
contribute to the process of AMD. 
1.4.2.3.1 Age 
The incidence of many diseases increases significantly with age. AMD develops as 
people grow older and that is considered one of the most important and strongest risk 
factor.99,108 With age, Bruch’s membrane (which is located between the retinal pigment 
epithelium (RPE) and choroid) grows to be thick, as a result of accumulation of deposits. 
Therefore, the formation of lipid and protein deposits in the central and peripheral retina 
probably plays a main role in AMD development.109 
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1.4.2.3.2 Gender and ethnicity 
The prevalence of neovascular AMD in women over 75 years has been shown to increase 
two-fold compared to men of the same age.110 However, another study has suggested that 
the effect of gender on AMD development was not statistically significant.111 
AMD is commonly found in white people than people with colored skin.112,113  Although 
some studies such as the National Health and Nutrition Examination Survey III 
(NHANES III)114 have shown that drusen appeared in same rate in white and colored 
individuals. These studies also demonstrate an increased prevalence of advanced AMD 
in white people compared with others.99 It is proposed that increased level of melanin 
may increase the possibility of the free-radical scavenging of the retinal pigmented 
epithelium and Bruch’s membrane, hence reducing the risk of advanced age-related 
macular degeneration.99 
 
1.4.2.3.3 Genetics 
Increasing evidence has been reported to show that the variation in some genes is strongly 
associated with several diseases. Genetic investigations have indicated that the gene 
coding for Factor H, a major regulatory glycoprotein in the complement-mediated 
immune system, was the first important gene to be involved in the pathogenesis of 
AMD.115,116 Moreover, Tyr402His variant and several noncoding variants in the 
complement factor H (CFH) gene were found to increase the risk of advanced AMD over 
sevenfold.117,118 As mentioned earlier, an early sign of AMD is the formation of subretinal 
pigment epithelial deposits (sRPEds) which can be focal (drusen) or diffuse (basal linear 
and laminar). These deposits contain more than 140 combined proteins including factor 
H and other components which are secreted by various cell types including the RPE.119,120 
Both factor H and the accumulation of high concentration of Zn in the external retina are 
considered risk factors for AMD. However, their contribution in the progression of AMD 
is still ambiguous.121,122 Under oxidative stress through light exposure, the secretion of 
Zn from the Zn-rich RPE cells is raised. As Zn has been found in sRPEds and Bruch's 
membrane in AMD, it is suggested that the pathological release of Zn from surrounding 
tissues such as the RPE–choroid complex may be implicated in formation of 
deposits.109,119 Zn binds more strongly with the His402 allotype than the Tyr402 allotype. 
Patients with the His402 allotype will be at higher risk of AMD since this form of 
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complement factor H is more likely to cause large oligomer formation. Added to this, 
increased deposit formation has recently been linked with the His402 polymorphs in 
patients.121 
 
1.4.2.3.4 Smoking 
Smoking is related to a number of eye diseases, such as nuclear cataract and thyroid eye 
disease.123 Numerous case-control studies,124,125 population-based studies126 (e.g. the 
Beaver Dam Eye Study and the Blue Mountains Eye Study127), studies of both physicians128 
and nurses129 have strongly confirmed that smoking is the strongest environmental risk 
factor associated with AMD. This factor is the only preventable one as there is a direct 
relation between AMD development and the number of cigarettes smoked124,108. It is also 
evident that current smokers had a significant four-fold increased risk of advanced AMD 
compared to non-smokers, and there was a threefold higher risk of geographic atrophy in 
past smokers.127 Moreover, cigarette smoking appears to have toxic effects on the retina130 
and often great adverse consequences in people with low High-density lipoprotein (HDL) 
cholesterol level, and low fish consumption.127 
 
1.4.2.3.5 Exposure to sunlight 
Chemical and light stimulated oxidative damage to the photoreceptors and thus the 
function of RPE is adversely affected.131 The retina is mainly prone to oxidative stress 
owing to its high consumption of oxygen and its continual exposure to intense 
light.106,107,131 The Beaver Dam Study and others suggested that the exposure to high level 
of sunlight, in particular the UV light, may cause ocular damage and therefore increase 
the risk of developing AMD.132 
 
1.4.2.3.6 Dietary fat 
Several studies 133,125 identified a link between AMD progression and diets with high 
level of fat, although some types of fatty acid may be protective.131,125,134 The Beaver 
Dam study confirmed that the risk of early AMD increased by 80% among patients with 
the highest intake of saturated fat and cholesterol.107,135 
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1.4.2.3.7 Unsaturated fatty acid 
Omega-3 long-chain polyunsaturated fatty acids, in particular, docosahexanoic acid 
(DHA) and eicosapentaenoic acid (EPA), and monounsaturated fatty acids134 play a vital 
role in AMD prevention.131 DHA is a key fatty acid as it is found in high concentrations 
in the retinal tissue.136 It has an effect on retinal cell signaling mechanisms and the 
photoreceptor membrane works by changing thickness, fluidity, permeability, lipid phase 
properties and the activation of membrane- bound proteins.131 
Regular consumption of DHA and EPA was attributed to decrease the risk of advanced 
AMD by 38%.131 In addition, the Mountains Eye Study revealed that fish intake three 
times a week could reduce the risk of both early and late AMD.137,138 The effects of DHA 
and EPA supplementation on AMD development has been tested in the Age-Related Eye 
Disease Study AREDS II.131 
 
1.4.2.3.8 Cardiovascular disease 
AMD is assumed to share common risk factors with cardiovascular diseases such as  
dietary fat, smoking 130, high cholesterol level and hypertension. 127 On the other hand, 
raised concentration of HDL cholesterol, which is normally assumed to be 
cardioprotective is often associated with reducing AMD risk.139 Some studies indicated 
a direct correlation between AMD and hypertension140 and  increased level of cholesterol 
in the serum141 and diet. 
Drusen is also postulated to share several molecular components with atherosclerosis 
plaques, such as lipids, vitronectin, apolipoprotein E, calcium, and complement 
constituents.100  One study presented data suggesting a strong association between 
advanced AMD and both carotid artery atherosclerosis142 and cardiovascular deaths.143 
 
1.4.2.4 The relation between age related macular degeneration and mortality 
A study based on large population indicated the relation between visual impairment 
(visual acuity less than 20/40) and increased mortality. According to AREDS, 91% of 
participants who had worse than 20/40 visual acuity at baseline in one eye were 
recognised in AMD category 4.143 A hypothesis analyzed the reason for mortality and 
proposed that nuclear cataract and AMD category 4 may be linked with the main cause 
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of death which is cancer and diseases of the circulatory system, respectively.139 
Furthermore, vision loss could affect mortality directly, if it leads to accidents, for 
example, fatal fall, automobile accident or depression that in turn are reported to increase 
mortality.143 
 
1.4.2.5 The role of antioxidant supplementations and dietary intake in AMD 
Observational studies which evaluated the effect of dietary antioxidants on the risk of 
age-related macular degeneration have been investigated, with inconsistent results.  
A recent European Union study carried out by cross-sectional population had proposed a 
two-fold increase in the risk of advanced AMD due to intense exposure to sunlight 
combined with low concentration of antioxidants in their serum.98,144 Therefore, the 
antioxidant nutrients are assumed to be protective through their role as antioxidant, these 
include lutein, zeaxanthin, β-carotene, vitamins C, E, B and Zn.131  A major National Eye 
Institute study and the Age-Related Eye Disease Study (AREDS) showed that 
supplements of antioxidant vitamins C (500mg), E (400 IU), beta-carotene(15 mg), zinc 
oxide (80 mg), and copper (as cupric oxide 2 mg) decreased the risk of developing 
advanced AMD by 25%, and the risk reduction for those taking antioxidants alone or Zn 
alone account for 17% and 21%, respectively.107,145 By contrast, other studies found no 
certain effect of antioxidant supplementation on patients with early nonexudative AMD 
or active exudative.93,104,108 Additionally, three randomised controlled trials found that 
vitamin E or β- carotene supplements failed to have a beneficial effect on AMD.108 
 
1.4.2.6 The role of zinc in AMD 
1.4.2.6.1 The positive role of zinc in the pathogenesis of AMD 
Zinc is involved in numerous biological processes including stabilisation of cell 
membranes, RNA/DNA metabolism, regulation of gene expression, protien synthesis,  
supporting immune function, cell growth, and motivation of the activity of numerous 
enzymes in the body.134,146,147 These significant properties of Zn may have therapeutic 
benefits in a range of diseases in humans. Zn has been successfully used as a treatment 
for two fatal genetic diseases, acrodermatities enteropathica and Wilson's disease. Zn 
supplementation can also treat acute diarrhea in children, chronic hepatitis C, common 
cold and several bacterial infections in the elderly.134 
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The human retina is rich in Zn, hence it is essential for retinal cell survival, visual cycle 
and the controlling of antioxidant enzymes.119 Zinc supplementation decreases oxidative 
stress, decreases the generation of inflammatory cytokines134, and elevates its 
concentration in the plasma. This in turn enhances the immune system and provides 
superior protection in AMD2. Based on the large Age-Related Eye Disease Study 
(AREDS), a strong association was found between Zn supplements intake and preventing 
the progression of AMD.95,119,134,148 
The recommended dietary allowance for Zn is 12–15 mg/day in the USA and 8–9.5 
mg/day in the UK. A recent large-scale study observed that a healthy balanced diet 
providing the necessary Zn and vitamins is associated with a 35% reduction in the risk of 
AMD95 and  are much better than supplementation (AREDS).94,145 Yet, for people who 
are already suffering from Zn deficiency due to malnutrition, Zn supplementation would 
be strongly recommended.94 
A wide variety of sources contain Zn e.g. red meat, oysters, beans, nuts, shellfish, whole 
grains, cereals and seeds.147 However, the bioavailability of Zn is affected by other 
components. Non-digestible plants, including phytate and some dietary fibers bind with 
Zn to form insoluble complexes, thereby Zn absorption is inhibited. Another factor that 
influences the bioavailability of Zn supplements is the formulation. Zinc oxide, which is 
commonly used in supplements for AMD, has very low bioavailability, whereas Zn salt, 
e.g. zinc acetate has relatively high bioavailability.101,147 As a  result, that may cause Zn 
deficiency which is characterised by several symptoms, for example, growth retardation, 
cognitive impairment, immune dysfunction, eye and skin lesions, and the generation of 
inflammatory cytokines.134 
 
1.4.2.6.2 The negative role of zinc in the pathogenesis of AMD 
 
It is postulated that the formation of lipid and protein deposits in the focal or peripheral 
retina may be a major factor in the progression of AMD.109 As Zn is highly concentrated 
in the eye, particularly in the RPE/choroid complex where the sub-RPE deposits are 
formed, it is argued that the accumulation of Zn binding proteins and other components 
may play a role in formation of sub-RPE deposits and therefore in development of AMD. 
Moreover, Zn binding proteins may precipitate accidentally in Bruch's membrane in the 
late stages of AMD.101 Studies that have shown the effect of Zn supplements on 
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decreasing the development of AMD yielded conflicting results.94 Lengyel and Peto 
(2008) proposed that no clear link was found between antioxidants, Zn supplements and 
reduced risk of AMD.94,101 In addition, another systematic review supported the lack of 
benefits of supplementation in primary prevention of AMD.104 
In 2001, the Age-Related Eye Disease Study (AREDS) established a supplement 
containing high doses of vitamins C and E, betacarotene, and the minerals Zn and Zu 
(called AREDS formulation). The American Academy of Ophthalmology recommends 
using the AREDS formulation as it can slow the progression to advanced AMD. 
However, it appears from some literature that there are adverse effects of high doses of 
Zn supplementation.94,101,106,107 Added to this, there have been concerns that the high dose 
of Zn in AREDS can lead to Cu deficiency and other side effects as well as increasing 
the risk of lung cancer in smokers with high dose of beta-carotene.94,106,107 Therefore, in 
2006 AREDS2 was launched and improved AREDS formulation by reducing the Zn 
dose, removing beta-carotene and adding some other nutrients. The study also examined 
how different combinations of the supplements performed. While waiting for the 
availability of AREDS2 results, the AREDS formulation remains the treatment of choice 
for patients with intermediate AMD and advanced AMD in one eye.149,40 
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1.5 Introduction to analytical techniques 
1.5.1 Sector field inductively coupled plasma-mass spectrometry 
Inductively coupled plasma mass spectrometry (ICP-MS) is powerful, reliable and 
commonly used for trace element analysis due to its ability to identify and quantify most 
elements in the periodic table in numerous matrices.150,151 This highly sensitive analytical 
technique is used for isotope ratio measurements and fast simultaneous multi-elemental 
analysis at low volume consumption. In addition, ICP-MS offers a wide linear range, 
reduced interferences and very low detection limits down to ppt level.152,153 Moreover, 
the capability of coupling ICP-MS with other sampling methods including solution 
sample nebulisation, laser ablation154 and chromatographic155 and other separation 
techniques156,157 make this technique a versatile tool of exceptional quality. Thus, ICP-
MS is considered an ideal method for Zn, Cu and Fe determination in biological samples. 
The basic instrumentation of ICP-MS will be discussed briefly in the following section. 
The following section briefly discussed basic instrumentation of ICP-MS. 
 
 
1.5.1.1 Instrumentation 
The Instrument will be briefly described in this section, and the five major parts of SF-
ICP-MS, as used in the research presented in this Thesis, are as following:  
• Sample introduction system 
• The plasma (ionisation) 
• The interface 
• The mass analyser 
• The detector 
A schematic diagram of an ICP-MS instrument is shown in Figure 1.7. 
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Figure 1.7 Schematic diagram of the reverse Nier-Johnson magnetic sector field ICP-
MS instrument. 
 
1.5.1.2 Solution-based sample introduction 
Although many different sample introduction systems are combined with ICP-MS, the 
most common ICP-MS work is performed on liquid samples by using an analytical 
nebulizer. While each method may be primarily different, they have the similar aim of 
sweeping the sample of interest into the ICP torch in an aerosol form for analysis. The 
introduction of solid samples into the ICP via laser ablation (LA) will be covered in 
section 1.5.2. The solution nebulisation system consists of a peristaltic pump and a 
nebuliser which converts a flowing liquid into a stream of aerosol droplets. The produced 
aerosols tend to cover a wide particle size distribution (approximately 0.1 – 25 µm158) 
and thus the function of the spray chamber is to separate large droplets from small ones. 
Only the small droplets, (typically those <10 μm in diameter153) are swept by a flow of 
argon gas to the sample injector and then ionised by the plasma, whilst the large droplets 
Detector 
Exit slit 
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fall out via gravity and exit by a drain tube to waste. While a typical flow rate of the 
nebuliser is around 1 ml min-1, micro-flow nebulisation with uptake rates of between 20-
600 μL min-1 are significantly useful especially in biological and clinical fields, where 
only limited amounts of sample may be available.152,159 
 
1.5.1.3 The plasma – formation and ion generation 
In the ICP-MS, the ionisation source is represented by the plasma and is an electrically 
conducting gaseous mixture, formed by using inert gas (typically Argon) that flows 
continuously throughout the quartz torch. RF generator, radio frequency (RF) coil, a torch 
and argon gas are the main requirements for plasma generation. The ICP torch consists 
of three concentric tubes: sample injector, middle and outer tube as illustrated in Figure 
1.8. The central tube is the injector, transferring the sample aerosol into the plasma. The 
two middle and outer tubes transport the gas flows which both produce and cool the 
plasma in the torch. The top end of the torch is surrounded by a Cu induction coil, which 
provides a high radio-frequency (RF) electric current of around 27-50 MHz.160 While the 
RF generator supplies RF power to the coil, a magnetic field is generated.  A flow of 
argon gas is introduced between the two outermost tubes of the torch and a high voltage 
spark is applied for a short time to introduce free electrons into the gas stream. These 
released electrons are accelerated in the magnetic field and collide with other argon atoms 
causing further ionisation.152 As long as the magnetic field is maintained by the RF, ions 
and electrons will continue to collide. The typical temperature of the plasma in the ICP-
MS ranges between 6000-8000 K and it is maintained at normal atmospheric pressure. 
Under these conditions, the sample passes through the central channel of the plasma, 
where it is de-solvated, atomised and ionised, and these newly formed ions then travel to 
the mass spectrometer via the vacuum interface region. Most elements in the plasma have 
an ionisation efficiency of about 100%, which makes the ICP-MS an efficient and 
versatile tool capable of detecting most elements in the periodic table.152,160 
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Figure 1.8 Cut-through schematic of an inductively coupled plasma torch. 
 
The interface is the region between vacuum and plasma. While the ICP plasma operates 
at atmospheric pressure (760 Torr) and the mass analyser as well as detector operates at 
high vacuum (10-6 Torr), an interface region is necessary.153 The function of the interface 
is to direct the produced ions from the atmospheric pressure plasma and reduce the 
pressure so the ions can be extracted in the higher vacuum region, where the ion focussing 
lenses, mass analyser and detectors are situated. This interface consists of two high 
thermal conductivity metal cones; the most popular are made of nickel or platinum. The 
first cone that is positioned at the end of the plasma is called the sampler cone with an 
orifice of approximately 0.8-1.2 mm. The second one sits behind the sampler cone and 
has a marginally smaller orifice diameter (0.4 - 0.8 mm) that is referred to as the skimmer 
cone153 (see Figure 1.9). A mechanical roughing pump reduces the pressure between the 
two cones to 1-2 Torr, creating a region of intermediate pressure between the 2 regions. 
When the sample passes through this orifice, the gas flow speed increases and exceeds 
the speed of sound where supersonic ion expansion occurs between the sampler and 
skimmer cone owing to the sudden drop in pressure and thus particle density. This results 
in a shock wave formation behind the sampler cone, comprising a region known as the 
zone of silence.  
After the ion beam passes through the interface region, a series of electrostatic ion optics 
lenses are used to focus and accelerate the ions before they enter the mass analyser. In 
addition, the ion optics prevent photons, or neutral species from entering the mass 
analyser and detector as it could cause signal instability and thus high backgrounds.153,160 
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Figure 1.9 Schematic drawing of the cone interface region. 
 
1.5.1.4 Mass analyser 
The mass spectrometer consists of a mass analyser and detector that detect as well as 
separate the ions based on mass to charge ratio. Mainly three types of mass analysers are 
used in ICP-MS; magnetic sector, time of flight and quadrapole. The quadrupole mass 
analyser is possibly the most commonly used due to its speed, stability and low cost. 
However, it can only be operated in a low-resolution mode and requires a collision 
reaction cell to eliminate polyatomic interferences. Whereas, a magnetic sector provides 
the best sensitivity as it has the ability to separate most polymeric interferences by 
operating at high resolution in the region of 10,000. As a high resolution sector field mass 
spectrometer was the main instrument used in the project, further discussion will be 
confined to this type.160 
In magnetic sector instruments two designs are use, the reverse Nier-Johnson design and 
forward (or standard). The ICP-MS configuration used in this work is a Thermo Element 
2 XR with a reverse Nier-Johnson geometry, with the magnetic analyser placed prior to 
the electrostatic analyser (ESA). The initially circular ion beam becomes rectangular as 
the ions are focused and pass through a slit into the magnetic sector of the instrument. 
The slit can be used to control the resolution by adjusting the width of the slit, and thus 
the ion beam dispersion. Two slits are used to control the resolution, recognized as the 
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entrance and exit slits. The entrance slit is located between the ion optics and the mass 
analyser, whereas the exit slit is located between the electrostatic analyser and the 
detector. Resolution is defined in the equation below, where R is the resolution, m is the 
mass of the analyte of interest and ∆m is the peak width of the mass at 5% peak height.  
R =
𝑚
∆𝑚
    
The three resolution settings of the instrument are; low resolution (R~300), medium 
resolution (R~4000) and high resolution (R~10000). Although high resolution allows for 
greater separation of peaks as the slit width is narrow, the number of ions transmitted is 
reduced, and thus the sensitivity is dropped as low as 1-2% of the counts seen for low 
resolution.151,152,161 
The double focusing principle for both designs (forward or reverse) consist of two 
analysers, a traditional electromagnetic and an electrostatic analyser (ESA). The 
magnetic field, which is dispersive with regards to momentum (and therefore ion mass), 
separates ions of different masses then focuses all the ions with diverging angles of 
motion from the entrance slit. Inside a curved magnetic field of a given strength, ions of 
different mass travel on different trajectory dependening on their mass to charge ratio. 
When the magnetic field is held constant, the ions of varying m/z can be focused onto an 
intermediate slit,varying the acceleration voltage, and hence the velocity of the ions, thus 
stopping the transmission of any ions of higher or lower m/z than the desired analyte. The 
ions exiting the magnetic sector have different kinetic energy, depending on the formation 
position in the plasma. Thus, this energy dispersion leads to peak broadening and loss of 
resolution. To overcome this, a second mass analyser, an electrostatic analyser (ESA), is 
employed after the magnetic sector.  The ESA, which is dispersive only with respect  to 
ion energy, then focuses all the ions onto the exit slit, where the detector is located.162 
The ESA consists of two curved plates, which have opposing voltages applied to them. 
The inner plate has a negative charge which attracts the positively charged ions, whilst 
the positively charged outer plate repels them, thus focussing and deflecting the ions. 
When the energy dispersion of the magnet and the ESA are equal in magnitude but 
opposite in direction, by using a combination of the magnetic and electrostatic sectors, 
the ion beam allows for the focussing of ions based on the m/z ratio. Their combined 
usage is referred to as double focussing.152 
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There are two main scan modes used with double-focusing mass spectrometers, magnetic 
scan (B Scan) and electric scan (E Scan).161 E Scan is the default mode used by the 
Element XR. In this  mode, the magnetic field moves initially to the start mass and is then 
kept constant whereas the acceleration voltage and corresponding ESA voltage are both 
changed together. This enables rapid scanning; however, the maximum range for E-scan 
is limited (30% of the start mass). B Scan is the opposite, the accelerating voltage and the 
electrostatic sector (ESA) voltages are kept constant and the magnetic field is varied. 
Although B Scan mode is much slower compared to E scan, it is not limited in range. 
Consequently, it is preferred for the analysis of large, continuous mass ranges, as is 
required for mass calibration.161 
 
1.5.1.5 The Detector 
After the ion beam passes through the exit slit, it enters the detector and is converted to 
electrical signals. The Element XR contain two types of detectors; a Secondary Electron 
Multiplier (SEM) and Faraday Cup. SEM, the most common detector, consists of a series 
of 19 metal dynodes. The ion beam is directed towards a conventional dynode before 
entering the SEM, resulting in an electron is ejected from it. When the electron hits the 
first dynode surface, one or more electrons are released. The influence of the first dynode 
generates secondary electrons, which hit the second electrode, producing more electrons, 
and so on along the length of the detector. Consequently, the number of electrons grows 
and the original signal is amplified. This results in a very high pulse of electrons being 
produced from the final dynode which is converted into an electrical signal and 
communicated to the computer in units of counts per second (cps). The SEM detector can 
operate in two modes of counting depending on the signal intensity. In counting mode, 
both sections of the SEM detector are switched on. This mode is useful for trace analysis 
where signal is expected to be less than 5 x 106 cps. Whereas, the analogue mode can be 
used for higher count rates, allowing for detection between 5x106 and 1x107 cps. 161 In 
this mode, the second section of the SEM is switched off to protect the dynode from 
exposure to the huge signals, and thus extend the lifetime of the SEM. If higher signal 
intensity is required, the dynamic range of the instrument could be further increased by 
the use of a Faraday cup.152 
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1.5.2 Laser ablation 
Laser ablation (LA) is frequently used as a direct sample introduction for solid samples 
with ICP-MS. LA-ICP-MS has experienced a series of improvements since its first 
introduction by Gray in 1985.163 However the general principle and various components 
of a typical laser ablation system have not changed.160 This powerful technique is capable 
of reliable and rapid analysis to obtain information on the spatial distribution of trace and 
ultra-trace elements in many different types of solid samples.164,165,166,167,168 Although 
geological applications typically cover around 30-50% of all LA-ICP-MS papers154, the 
attention to biological applications169,170,171,172,173 in the last few years has significantly 
increased. The basic instrumentation of laser ablation will be discussed briefly in the 
following section. 
 
During the ablation process, a laser pulse is directed onto the sample using a high-power, 
short-pulsed laser focused onto the sample surface by mirrors and lenses. The aerosol 
plumes that contain atoms, ions, and particles are formed and released from the laser 
ablation crater. These particles then are transported to the ICP by a stream of carrier gas, 
where it is vaporized, atomized, and ionized and subsequently analysed in the mass 
spectrometer.174 
 
1.5.2.1 Instrumentation 
A typical LA sampling system involves; a laser beam, a series of optical devices, a 
viewing system, an ablation cell, and a transport connection between LA and ICP-MS. 
Figure 1.10 shows a schematic of a typical laser ablation setup.175 
 
1.5.2.2 Types of laser source 
Many types of laser sources have been successfully used for laser ablation, including 
Ruby, excimer and neodymium-doped yttrium–aluminium–garnet (Nd:YAG). The most 
commonly used of these is Nd:YAG due to its ease of use, reliability, low cost and 
robustness.175 It comprises of a rod containing a single yttrium aluminium garnet (YAG) 
solid crystal fixed with neodymium ions. The use of UV lasers has become more 
widespread than IR.  The fundamental wavelength of this laser is 1064 nm, which is 
poorly absorbed by several matrices. Thus, harmonic generation is necessary to allow 
Nd:YAG laser to operate at shorter wave length, such as 266nm, and 213nm.160 A 
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Nd:YAG functioning at 193nm has recently been introduced and is commercially 
available.  
 
 
 
Figure 1.10 Schematic of a laser ablation system. 
 
Overall, shorter wavelengths provide better ablation features for sample introduction to 
ICP-MS and better signal intensity.176 The absorbance features of the sample matrix are 
the key factor in choosing the appropriate wavelength, as this affects the ablation 
production. For example, Becker suggests that 266 nm is sufficient to ablate completely 
soft biological tissues as it is easy to ablate.177 The most common laser pulse duration 
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available in economical systems of LA-ICP-MS in early work is nanosecond. However, 
there is now a developing trend towards the use of shorter pulse width depending on the 
analytical measurement, such as pico- and femto-second. Russo et al.178 reported that 
picosecond laser pulses could give improved accuracy and enhanced ablation efficiency 
compared to nanosecond laser pulses. In addition, the improvement of femtosecond over 
nanosecond explains the significance of laser pulse duration and related effects on the 
ablation process.179 
 
1.5.2.3 Laser focusing 
In order to direct and focus the laser beam onto the sample, a series of mirrors or prisms 
and objective lens are required. These mirrors that have insulator optical coating on a 
highly polished surface and high transmission for other wavelengths are proven to be 
robust and long lasting. The shape and the size of the ablation crater are often adjustable. 
Normally the ablation craters are either conical or cylindrical in shape and few µm in 
diameter. Some advanced laser systems allow the use of spot sizes down to 1 micron or 
below.154,175 
 
1.5.2.4 The ablation cell 
The sample is located inside a laser ablation cell while ablation takes places. A variety of 
different ablation cells have been designed and developed for LA-ICP-MS. Each ablation 
chamber consists of a few basic components: a sample holder, ports for carrier gas entry 
and exit, fused silica window to allow the laser beam to pass through. Most ablation cells 
are mounted on an adjustable platform usually under computer control, to allow sample 
positioning in different directions, hence the target is easily and precisely selected. The 
cell is connected to the ICP via plastic tubing and the ablated materials typically 
transported to the ICP through this tube. Tubing is usually over a metre in length and 
about 3-4 mm internal diameter. While the laser is firing in continuous mode, the stage 
is moved in a specific pattern; generally parallel lines to create images. When the ablated 
materials reach the mass spectrometer, the acquired spectra can be transformed into two-
dimensional colour maps and signal intensity displayed as a function of the image 
dimensions.174 
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1.5.2.5 Carrier gas  
During the ablation process, the generated materials are swept to the ICP via a carrier gas 
that flows continuously through the cell to provide an inert atmosphere for ablation. A 
careful selection of carrier gas is required as it plays an important role in particle size 
distribution and production. Argon (Ar) carrier gas was traditionally used for initial LA 
experiments. Nevertheless, many users have replaced the use of Ar gas with Helium (He) 
gas owing to improved ablation and transport properties. Horn and Günther compared 
different carrier gases and their influence on the size distribution and thus transport 
efficiency. They concluded that utilizing He as a carrier gas during ablation produces 
smaller particles distributions than in argon, and therefore transported to the ICP with 
better efficiency which leads to sensitivity improvement. The physical properties of the 
He carrier gas such as lower density, higher thermal conductivity and higher ionization 
energy, contributed to the change in particle size distribution to smaller particles.174,180 
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2 Trace Determination of Zn, Cu and Fe in  
Human Serum Samples from Age Related 
Macular Degeneration and Alzheimer Patients 
using ICP-MS 
 
2.1 Introduction 
 
The liquid fraction of the whole blood after the removal of cells (white, red) and platelets 
is termed as plasma, which constitutes 55% of the total blood volume.181 Serum is 
obtained from blood plasma after separating the main blood clotting protein (fibrinogen) 
that mainly consists of water that has a high concentration of proteins, hormones, 
inorganic salt and variety of minerals.181,25 According to their biochemical importance 
and ease of accessibility, serum and other biological samples including blood, plasma 
and urine have been selected by many clinical and analytical researchers.182 Minerals play 
a key role in supporting many biological functions, hence  biomonitoring of trace 
elements in human biological fluids would provide essential information on the 
nutritional studies and the health of individuals.183 The concentration level of all minerals 
is maintained constantly through the homeostasis process in order to avoid the increase 
or decrease of the nutrients which cause either toxicity or deficiency. As there are many 
illnesses associated with an excess or shortage of the minerals, understanding the 
interaction of minerals in the body represents a comprehensive vision of diagnosis, 
screening and treatment of illnesses.183,184,185  
The essential trace elements, Fe, Zn, and Cu play crucial role in retinal structure, and 
pathology. They are principally involved in numerous retinal functions for instance, 
retinal cell metabolism, the visual cycle, photo transduction, and the process of 
neurotransmission.186 Several experimental studies have indicated that the alteration of 
Zn, Cu and Fe homeostasis and inflammation in the retina may lead to retinal dysfunction 
and therefore initiate the age related macular degeneration (AMD) abnormality.187,188,189 
As noted in section 1.4.2, AMD is a chronic eye disease, which mainly attacks the macula 
thus causing severe and irreversible vision loss in elderly people.94 The main focus in this 
study is on one of the AMD types which causes damaging of blood vessels that grow 
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underneath the retina, known as Choroidal Neovascularisation (CNV). CNV can lead to 
the leakage of blood and accumulation of serum in the eye leading to irreversible vision 
loss in a short period of time.190 In their 2016 paper, Gwairi et al.190 noted that there is a 
link between AMD and serum lipids levels.  
Accumulation of Fe in the retina and the changes occurring during homeostasis 
mechanism is an indication of aging and believed to contribute to retinal degeneration 
such as AMD disease.186 Hahn et al.191 have revealed that, Fe levels rise with aging in the 
mammalian retina and this increase is higher in women in comparison with men. The 
level of Fe and Cu seems to respond slowly with the change in the plasma level, whereas, 
the pool of Zn in the retina exchanges quickly with plasma.186 In the body, Fe is mainly 
bound with ferritin in serum and it is a reflection of Fe stores. Various authors have 
reported that, when the ferritin level in serum increases, Cu level increases in the blood, 
whereas Zn concentration decreases in the plasma or serum.186,192,193 
Alterations in serum/plasma trace elements have been reported in patients with 
neurodegenerative and other diseases.194,195 Essential and toxic metal ions have been 
found to influence neuron degeneration. Dysfunctional homeostasis of some elements 
and their relevant enzymes have led to the formation of amyloid beta (Aß) plaques which 
are implicated in Alzheimer's disease pathogenesis.196,79 It is evident that accumulation 
of Aβ and tau proteins in both amyloid plaques and neuronal tangles are associated with 
neurodegenerative process in the brain of Alzheimer's patients. The defective antioxidant 
defence could also result in oxidative damage in AD patients.196 Zinc, copper, and iron 
appear to participate in the interaction of the major protein constituent of AD.197 Of these 
metals, Zn in particular is found at a high level in senile plaques (SP)78 in AD patients 
and, therefore accelerates the oligomer aggregation of amyloid beta peptide together with 
a number of metallothioneins and metalloproteases.70,78,198 Due to the lack of 
understanding of the exact role of the element in the etiology and the pathogenesis of the 
disease82 several studies have been undertaken to measure the metal concentration in 
brain tissues199, serum82,15,200,201,72 and cerebrospinal fluid.202,5 As serum can be taken 
from a large number of patients in different AD stages hence the focus in this study will 
be in serum. According to the meta-analysis by Ventriglia 2015202, six studies have 
investigated the level of Zn in the serum of AD patients by using ICP-MS, whilst others 
found AAS sufficiently sensitive for the Zn levels (~1 ppm) in the serum. Various 
conflicting studies have shown different results regarding the serum Zn level in AD 
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patients. Some studies showed an increase in Zn level in the serum of AD patients.201 
Other studies81,83,203,204,205 observed no significant differences in serum Zn between AD 
and healthy control. On the other hand, in 2015 Ventriglia et al.202 reported in the meta-
analysis that AD patients had a significant decrease in serum Zn level in comparison with 
healthy controls.196,15,72,17 A possible reason for decreasing serum Zn level in AD patients 
might be the accumulation of Zn in the brain as amyloid plaques trap Zn and deplete it in 
other body compartments.15 
 Zn deficiency and variation in AD patients could be related to the interaction with Cu 
metabolism.202 Another cause of reduction of serum Zn in AD patients is due to dietary 
Zn deficiency. In contrast to whole blood, serum/plasma level of minerals reflects short-
term changes and may be influenced by present dietary intake.195 Moreover, Several 
factors such as age and gender could affect AD, and Rembach et al. 2014 72 found that 
serum Zn concentration dropped around 0.4% per year with age but they did not indicate 
a correlation between serum Zn and gender. Conversely, a recent meta-analysis did not 
observe a significant difference in serum Zn level between AD patients and healthy 
controls according to age.202 Bjorksten et al. found serum Zn levels in men aged under 
60 years higher than women.206,207 Wang et al. added in his meta-analysis that differences 
in serum Zn concentration related to different gender ratio, whereas differences in Fe 
level appeared to be due to the difference in mean age.208  
Both Cu and Fe demonstrate considerable increases in serum levels with age.85 Copper 
absorption was greater in women (71%) than in men (64%) aged 20-59 years, but became 
constant in men and women aged 60-83 years.209 It appears that there is no significant 
difference in Fe serum level between AD patient and healthy control, however, case-
control and autopsy studies reported an elevated level of Fe in the brain in AD patients.22 
Most of the study’s results revealed serum Cu concentration to be significantly higher in 
AD patients in comparison with controls208,20,210,211 but remaining unchanged in the brain 
and CSF.22 In circulation, Cu is strongly bound to the main Cu transporter protein 
ceruloplasmin and is a marker of plasma Cu level and inflammation.209 Therefore, 
Agarwal et al.20 measured serum ceruloplasmin level to find out if there is a positive 
relation between Cu and ceruloplasmin. They found a significant increase in serum 
ceruloplasmin in both genders of AD patients as compared to healthy individuals as 
control. Variation in Zn, Cu and Fe concentrations are affected by different factors such 
as age, gender, hormonal state, diet, the length of fast, time of day and geographic 
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area.206,85 Squitti et al.23 recognized other factors that could estimate AD risks like family 
history, physical activity, body mass index, systolic blood pressure and total cholesstrol 
level. Therefore, the investigation should occur on a bigger scale in different populations 
and should take the age, gender, and other factors into account.  
Several analytical methods have been used in the past to measure trace and ultra-trace 
elements in serum. Flame or graphite furnace atomic absorption spectrometry 
(FAAS/GFAAS)212,213,214,215 neutron activation analysis (NAA)212,216 and proton induced 
X-ray emission spectrometry (PIXE)182 were generally the main techniques used for this 
application. In the last decades, a powerful alternative technique ICP-MS has been 
extensively used for multi-element determination in human serum 
samples.183,83,213,217,218,219,220,221,222,223,224 It is the most popular, efficient, robust and 
suitable methodology for this requirement because it is fast, highly sensitive, flexible and 
easy to use, with a low detection limit and wide linear dynamic range, and is capable of 
simultaneously quantifying multiple elements in a short time precisely and 
accurately.221,220,225  
 
2.1.1 Aim of the work 
The comparison of serum analysis in AMD and AD patients and its possible correlation 
is not reported to date. Therefore, the main purpose of the present work is to compare the 
distribution level of serum Zn, Cu and Fe between age related macular degeneration 
patients (AMD) (of the Choroidal Neovascularization  (CNV) type), and Alzheimer 
patients (AD) using SF-ICP-MS. A wider aim was to develop a method suitable for the 
determination of transition metals, specifically Zn, Cu and Fe, in minimal sample volume 
(50µL and below), the method to be readily adaptable for automation,  and to run 
unattended for long periods.  Use of a denaturing reagent mix compatible with the 
nebuliser keeps the sample introduction system clean and free flowing for long periods. 
Minimal sample volume consumption during analysis is important to conserve the sample 
(often available in limited quantitities, as in this work) and offer the possibility of repeat 
analyses.   
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2.2 Methodology 
2.2.1 Ethics and sample collection  
Ethical approvals (09/H0710/10) and (08/H0805/6) were obtained from health research 
authority, NRES committee London-Harrow (Ethics applications and approvals are 
included in the appendix). All the necessary safety precautions were taken before 
handling the serum samples.  
Low concentration of elements in the biological samples and the risk of contamination 
during sample collection could make this type of evaluation challenging as well as 
difficult to perform. For example, stainless steel needles are most probably used in the 
clinics and these needles could be a vast source of contamination. Thus, siliconized 
needles are recommended to use.59 A 1.0 mL sample of blood was drawn from both AMD 
and AD patients into blue capped trace metal free vacutainers (Becton Dickinson, 
Oxford). The serum was collected by centrifuging the blood at 2500 rpm for 20 min.  An 
aliquot (100 µL) was transferred into a 1 mL clean polypropylene (Eppendorf) tubes and 
then stored immediately in -80 °C freezer until analysis. All samples were labeled with 
the disease type, patient’s code number and date. A range (81) of human serum samples 
were obtained from Dr. Imre Lengyel, Institute of Ophthalmology, University College 
London.  
 
 
2.2.2 Instrumentation and statistical methods  
 The analysis of the elements of interest (Zn, Cu, Fe) was made within a single sampling 
with no alteration in instrument operating conditions, in addition to the selection of 
resolution mode. Due to the range and complexity of the interferences, medium resolution 
was required (R = 4000) to avoid spectral interferences; specifically, 64Ni on 64Zn, 54Cr 
on 54Fe and 40Ar16O on 56Fe and to ensure the accurate analysis of Zn, Cu, and Fe. The 
analysis was performed on a sector-field inductively coupled plasma mass spectrometer 
(SF-ICP-MS) (Thermo Scientific, Element 2 XR, Bremen, Germany). The instrument 
was fixed with platinum sampler and skimmer cones (ICPMS cones Ltd., Chester, UK), 
and a sample introduction system equipped with a conical glass concentric nebulizer 
(Glass Expansion, Victoria, Australia), a Cyclonic spray chamber (Glass Expansion, 
Victoria, Australia) and a 0.5 mm i.d. probe (Elemental Scientific, Omaha, USA). The 
sample flow rate was set to provide a flow rate of approximately 400 μL/min. Daily, the 
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ICP-MS gas flows and torch positions were tuned to optimise conditions, achieving high 
signal intensity and low oxide ratio. Typical operating parameters and instrument 
conditions for ICP-MS are summarized in Table 2.1. Data obtained from sample analysis 
by the mass spectrometry techniques described in this chapter were collected, organised 
and analysed by using statistical tools in Microsoft Excel 2016. Other software such as 
Minitab® and Origin 2015 were used for plotting some schematic diagrams. 
 
Table 2.1 ICP-MS typical operating parameters for Zn66, Cu65 and Fe57 
Parameter Condition 
Radio frequency (RF) power 1252 W 
Cool gas flow rate 15.50 L/ min 
Auxiliary gas flow rate 0.88 L/min 
Sample gas flow rate 1.05 L/min 
Resolution Medium 
Torch X position 4.6 mm 
Torch Y position 3.8 mm 
Torch Z position -2.5 mm 
Sampler cone Pt 
Skimmer cone Pt 
 
 
2.2.3 Reagents and chemicals 
Ultra-pure water (18 MΩ) was obtained from a Milli-Q Element system (Millipore, 
Watford, UK). 10 ppm multi-element solution 2 (MES 2; Ag, Al, As, Ba, Be, Bi, Ca, Cd, 
Co, Cr, Cs, Cu, Fe, Ga, In, K, Li, Mg, Mn, Na, No, Ni, Pb, Rb, Se, Sr, Ti, V, Zn) was 
purchased from SPEX Certi prep Ltd (Middlesex, UK) and diluted to 1 ppb. The 
instrument was calibrated by external single element standards solution (1000 ppm) Zn, 
Cu and Fe (Qmx Laboratories, Essex, UK). 1000 ppm Gallium was used as internal 
standard (Qmx Laboratories, Essex, UK). The sample preparation included the following 
reagents: 70% ultra-pure nitric acid and 25% ultra-pure Ammonia solution purchased 
from Romil Ltd (Cambridge, UK), Triton X-100 (Sigma-Aldrich, Poole, UK) and 
Butanol (Fisher Scientific, Loughborough, UK). Two Standard reference materials were 
used: SeronormTM trace elements serum, level 1 (6 × 3 mL) (Alere, UK) and serum 
control-trace elements normal range (5 × 5 mL) (UTAK Laboratories Inc., Valencia, 
44 
 
USA). Accurate weighing of chemicals was performed on a five-figure balance (AND, 
San Jose, CA, USA) and a vortex mixer (Labnet Intl. Inc., Edison, NJ, USA) was used to 
ensure the homogeneity of the sample. 100% disposable Bio-clean Pipette tips were 
purchased from VWR (Lutterworth, UK) and Anachem Ltd, (Luton, UK). 2 ml colorless 
micro centrifuge tube (Elkay, UK) and 15 and 50 mL polypropylene metal-free tubes 
with natural HDPE lid (VWR) and Nalgene Teflon™ PFA bottles (Thermo Scientific, 
USA) were used for sample preparation, storage and ICP-MS analysis tubes.  
 
2.2.4 Challenges in sample preparation and contamination control 
Sample preparation is one of the most critical steps in the analytical procedure, as it 
requires special care to reduce the risk of contamination to bare minimum or losses of 
analytes by either precipitation and/ or volatilization. Contamination is certainly the most 
common source of error in the determination of trace elements. Zinc is a relatively 
difficult element to analyse due to its presence in the environment and that could increase 
the risk of contamination and lead to high background level. The major difficulty is to 
keep the blank level as low as possible with such ubiquitous elements especially if clean 
laboratory facilities are unavailable. Hence, careful preparation of blanks, standards and 
samples are highly important. Some general precautions have been taken into account 
while preparing and analysing samples for trace elements by ICP-MS, as follows: 
• Care was taken to minimise operator contact with samples during their 
preparation and analysis, and time and number of steps were minimised.  
• Disposable powder-free nitrile gloves were worn all the time. Cream and 
cosmetics were avoided and hair was covered. 
• A selection of clean metal-free tubes, PFA bottles and 100% bio clean pipette tips 
have been used and all sample storage containers were pre-cleaned to remove 
additional contamination. Also, the pipette tips were rinsed with the same reagent 
or 2% HNO3 prior to use. 
• Every sample and their associated standards were prepared on the same day or at 
most a day before analysis. 
• Deionized water, ultra-pure acids and other high purity reagents were used. This 
was done by choosing the lower levels of the metal of interest in any reagents.  
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• Exposure to metallic parts was avoided, and nebulizer, probe and cyclonic spray 
chamber were washed thoroughly before using the ICP.  
• The colorless caps of the ICP analysis tubes were drilled to minimise contact with 
lab atmosphere and they were soaked in 10 % HNO3 then rinsed with Milli-Q 
water prior to analysis. 
• During the analysis period, every single sample was opened individually and the 
system was washed thoroughly between each sample with freshly prepared 
washing solution. 
• The samples and standards were isolated from potential contamination source and 
protected from dust and fibers as much as possible. 
 
2.2.5 Method development of sample preparation 
The determination of elements in complex matrices by ICP-MS has been challenging, in 
particular at trace and ultra-trace levels.226 The matrix composition of serum with high 
salt and 6-8% protein content is unsuitable for direct analysis by ICP-MS,214 hence 
sample treatment before analysis is required. Sample preparation can be divided into two 
main types, sample dilution or digestion.227 Some researchers have chosen to dilute 
samples with 0.5% HNO3
220 or water185,223 and others used a mixture of sample diluents 
including ammonium hydroxide and Triton X.184,224,227 Additionally, different digestion 
procedures are commonly used in sample preparation.183,219,228     
Five serum samples and Seronorm were initially diluted 50-100 fold with 0.5% HNO3. 
However, because of continuous blockage, especially with PFA nebulizer (PFA-ST 
Elemental Scientific, Omaha, USA), the procedure was changed to the digestion 
described below.  
The general digestion procedure was performed by adding 70% HNO3 to measured 
volume of Seronorm and heating at 70 °C for 1h, followed by addition of 30% H2O2 
(Sigma-Aldrich, Poole, UK) and heating to the same temperature for a further 4 h. The 
sample was then evaporated to dryness under a stream of nitrogen by using a TurboVap 
Concentration Workstation (Biotage, Uppsala, Sweden). Next, the dry sample was 
reconstituted in 2% HNO3 prior to analysis. During the digestion procedure, the lids of 
the Eppendorf vials were pierced by using a sterile needle to prevent pressure build up. 
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In order to avoid using metal needles as it could contaminate the sample, a small pipette 
tip was inserted into the side of the lid, so it was not fully closed (slightly opened). 
However, this step increased the signal intensity of Zn in the blank instead of decreasing 
it, but the blank of the elements Cu and Fe remained the same in both cases. The general 
procedure applied to Seronorm was modified and summarised in Table 2.2 with different 
dilution factors, digestion and evaporation methods. Based on previous 
publications,83,219,221,220 different dilution factors (20, 30, 40, 60,100 and 1000 fold) were 
used in the present investigation. Satisfactory results were achieved with dilution factors 
60 and 100-fold. However, results using the dilution factors 20, 30 and 40-fold were 
unsatisfactory as the resulting serum sample volume of 1.0- 3.0 mL was not enough for 
two replicate measurements, whereas dilution factor of 1000-fold provides serum sample 
volume of 50 mL but is more diluted than required for precise measurements and close 
to the detection limit. 
Although digestion has the benefit of eliminating protein that reduces instrumentation 
clogging and matrix effect, however, it could introduce a potential source of 
contamination.219  
Microwave-assisted digestion is considered an alternative sample preparation method for 
serum, as it can be much faster than using conventional heating. However, there are a 
number of disadvantages which restrict using this method. (i) The digestion vessel should 
be cleaned before and after the digestion procedure, and the transfer of samples in vessels 
could introduce potential external contamination. (ii) A closed-vessel during the digestion 
process can produce high pressure and temperature and that could lead to potential loss 
of analytes on sample venting and poor sample throughput. (iii) Extra safe handling 
techniques are needed due to the high pressure and temperature. (iv) Some microwave-
assisted digestion systems are limited to batches of 12 vessels, so that makes the analysis 
for large number (e.g ≥200 samples) of samples impractical. 25 
 
Several experiments on Seronorm were applied as a test, using the procedures described 
in Table 2.2  
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Table 2.2 Different methods for digestion procedure 
 
The Turbo Vap evaporation procedure was not successful regardless of the dilution factor 
and the digestion procedure. This may be due to the nozzle that was made of metal and 
thus the blank reading was higher than the samples. In order to reduce the risk of metal 
contamination, another method of evaporation was used.230 The metal nozzle was 
substituted by 100% pure virgin grade polypropylene pipette tips and the stream of high 
purity argon gas was directed manually to the samples while they were placed in a hot 
block (70 °C) to increase the process of evaporation. Due to frequent hovering of hands 
over the samples to check the level and adjusting the pipette tips inside centrifuge tube in 
the open lab atmosphere, this procedure was not a good option due to contamination 
issues. Leaving the sample overnight in the oven at 70°C was not a good choice either.  
The only option was to evaporate the samples overnight on a hot plate in a closed fume 
hood at 70 °C. The common drawback of this procedure was mainly related to sample 
burning due to overnight heating. The samples were over-dried as well as hard such that 
it was not possible to completely dissolve after reconstitution. Moreover, small bubbles 
were created possibly due to the high temperature during the overnight heating. 
Consequently, the bubbles transferred to the probe and the nebulizer during analysis and 
that caused frequent clogging and inconsistent spraying. As a result, the calibration 
standards were not in good linearity and, therefore, the results were affected. To tackle 
these issues, the temperature was reduced from 70 °C to 45 °C, and the probe and 
Tests 
no. 
Dilution 
factor 
Digestion 
procedure 
Evaporation Reconstituted 
 
1 
20, 30, 40, 
60, 100 and 
1000-fold 
Add 300 µL 
HNO3 and 100 
µL H2O2
 83,229 
TurboVap, Manual 
evaporation under a 
stream of nitrogen 
through 1ml colorless 
pipette tips, overnight in 
the hot block, overnight 
in the oven. 
2% HNO3, 
Water 
2 60, 100-fold 
Add 100 µL 
HNO3 and 100 
µL H2O2 
Overnight in the hot 
block (70 °C) 
2% HNO3, 
Water 
3 60, 100-fold 
Add 150 µL 
HNO3 and 100 
µL H2O2 
219 
Overnight in the hot 
block (70 °C) 
2% HNO3, 
Water 
4 
35, 50 and 
100-fold 
Add 35 µL 
H2O2 and 100 
µL HNO3 
No evaporation 
procedure 
Water 
48 
 
nebulizer were taken apart and washed thoroughly through a standalone pump with the 
following solutions: 70% methanol, 25% ammonia, 2% HNO3 and deionized water in 
between each reagent. In addition, the samples were sonicated prior to analysis, and the 
probe was cut to a very small length (around 20-25 cm). After attempting the previous 
solutions and repeating the Seronorm samples numerous times with different dilution 
factors, the results were still unreliable and the overall mean of Seronorm did not match 
with the certified reference value. In order to check the quantity of sample delivered to 
the ICP-MS, sample centrifuge tubes were weighed before and after each run and the 
difference was recorded. The amount of the sample weighed varied, therefore a different 
PFA nebulizer and spray chamber were tested in order to determine the source of 
problem. The PFA nebulizer was found to be cross threaded and was sent for 
refurbishment and a new nebulizer was used. In addition, a final procedure was tested by 
omitting the evaporation step and hence reducing the acids used for digestion as shown 
in Table 2.2.  
20 samples of AD patients were analysed by using the proposed method with Y and Sc 
as internal standard.  Even though the number of bubbles were significantly reduced by 
this procedure, still it was not practical to use. The centrifuge tube must be weighed at 
different stages: including empty tube, after the addition of H2O2/ HNO3, digestion, 
addition of internal standard and finally reconstitution with water. Most of the 
experiments gave good agreement with the certified reference value for Cu and Fe but 
not for Zn. Some selected examples of the method development results on Seronorm level 
of Zn, Cu and Fe in different batches with various preparation procedures will be included 
in the results and discussion (section 2.3.4, Table 2.7). Interestingly, it has been reported 
by Maekawa et al. 231 that selenium concentration in Seronorm (Trace Elements Serum) 
level 2 batch was inaccurate, and it could be the same case with Zn in Seronorm. It seems 
that a combination of reasons contributes to conventional serum digestion being difficult 
and unreliable. As a result, an alternative sample preparation method was applied.  
 
During method development nebulizers constructed from PFA and glass were used, but 
the glass nebulizer performed more reliably, therefore it was retained for the subsequent 
work. 
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2.2.6 Recommended procedure of sample preparation 
A direct dilution preparation method, which will be considered for this work, had the 
advantage of being cheaper, reducing the sample preparation steps which result in 
consuming less time and introducing less cross-contamination. Yet, the heavy matrix of 
serum still could create a problem. However, based on different studies, it is evident that 
alkaline media provide a good alternative to conventional acid digestion for several 
biological materials, in addition to increasing the performance of some analytical 
techniques such as ICP-MS.184,224,227,232 
Serum samples stored at -80 ºC were thawed at room temperature for approximately 1-2 
h. After complete defrosting, samples were vortexed about 10 seconds to ensure complete 
homogenization. High dilution factors such as 50 or 100 can be used for Cu, Fe and Zn 
metals because of their high concentration level in serum.233  50 µL of serum samples 
were transferred to 15 mL polypropylene metal-free tubes and diluted 100-fold up to 5 
mL. In the second run 30 µL of serum sample samples were diluted 100-fold up to 3 mL.  
All the samples were kept in capped containers in the fridge until the analysis was 
performed. The sample diluent was a mixture of Triton X-100, butanol, ammonia and 
nitric acid234 as summarised in Table 2.3. 
Table 2.3 Preparation of sample diluents 
Sample diluents* 
Butanol 
(99.92%)
mL 
Ammonia 
(25%)             
mL 
Triton X-100TM 
(1.0%)                     
mL 
HNO3 
(0.1%) 
mL 
Total 
volume 
mL 
1% Butanol, 0.5% v/v 
ammonia, 0.02% v/v 
Triton X-100, 0.01% 
v/v HNO3 
5 10 10 50 500 
 
* Although the blank mixture is referred to as a “diluent”, this matrix is also chemically active in terms of 
denaturing protein and complexing trace metal. 
 
1% Triton X-100 was prepared by part filling 100 mL PFA container with ultra-pure 
water, adding 1 mL of Triton X-100 and then making up to 100 mL with water. During 
preparation, every so often a foam in the solution was created, so it was placed in the 
ultra-sonic bath for about 15 minutes and the container was inverted to make sure the 
solution mixed thoroughly. Ideally, 1% Triton X-100 was prepared before the day of 
analysis to ensure complete dissolution, but the rest of the sample diluents were prepared 
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on the same day of analysis. Triton X-100, a non-ionic surfactant, is used as a diluent in 
biochemical applications to solubilize proteins, which form a stable mixture with the 
diluted sample. It has been widely considered for aerosol production and efficient 
nebulization.235 Nitric acid was added to ensure that the trace elements were maintained 
in solution, and to change the effect of the matrix upon analyte sensitivity. However, the 
acid concentration must be kept to a minimum, in order to avoid protein precipitation and 
loss of analytes.233 Butanol was added to match the carbon content of standards and 
samples and also for ionization efficiency stability233. Ammonia solution produces a clear 
homogeneous solution and keeps the diluted sample stable up to 48 h if stored at 4 °C.233 
It is useful for red cells lysis,233 preventing precipitation184 as well as improving the 
sensitivity of the determination.185  
 
The use of external calibration standards is the most common approach for quantitative 
analysis. The range of calibration standards was produced including blank by diluting 
1000 mg L-1 single element stock solution of (Zn, Cu, and Fe) to 8 standard 
concentrations (0, 1, 3, 5, 7, 10, 12, 15, 20 ppb) for each element measured. Blank and 
external calibration standards were made up in the same diluent as the samples.  
 
2.2.7 Standard reference material (SRM) 
Reference materials are required and important to support quality control and for 
validation of the developed analytical procedures. Freeze dried reference serum, normal 
level, from UTAK laboratory and SeronormTM trace elements serum level 1, were used 
to verify the accuracy of procedures that measure the levels of trace elements in serum. 
To prepare the stock solution of the reference material, the control material was 
reconstituted by adding exactly 5 mL of deionized water (recommended by 
manufacturer). It was left for 15 minutes, divided into 5 aliquots and stored in the fridge. 
The stability of these samples was only 30 days. Then the reference serum material was 
prepared in exactly the same way as the patient’s sample. 
 
2.2.8 Internal standards 
In ICP-MS, the signal changes caused by variations in sample mixture, nebulisation 
efficiency and instrument performance lead to errors which can be corrected using an 
internal standard. Therefore, the purpose of the internal standard is to compensate for 
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instrumental instability and correction for matrix effects. Ideally, the changes in the signal 
intensity of the internal standard are directly proportional to those of the analyte.  So, any 
factor affecting the analyte signal will affect the IS signal to the same extent and thus the 
ratio of the two signals remains constant and less variable than the analyte signal.236 It 
has been reported that237 both mass and ionization potential are important factors for good 
internal standard choices. On the other hand, Vanhaecke and colleagues 238 have stated 
that internal standards should be based on similarity in mass only. Considering both 
factors are important to select proper internal standards, it is also important to assess 
experimentally the performance of any internal standard before employing it for routine 
analysis.  
The use of  gallium (Ga)220,223 as internal standard has been previously reported for 
analysis of Zn, Cu, and Fe in serum. Each blank, calibration standards, reference material 
and serum samples were spiked with Ga to a concentration of 3.0 ng mL-1. Calibrations 
and analyses were carried out with and without internal standard and it was found that 
the accuracy, as indicated by consistency with the Serum UTAK reference values were 
equivalent for both procedures. However, precision and limit of detection without using 
internal standard were superior indicating that the sample matrix did not adversely affect 
the performance of the sample introduction system. Therefore, the results reported here 
were obtained without the use of internal standard and that will be discussed in the 
following section.  
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2.3 Results and discussion 
2.3.1 Blank level 
As mentioned earlier, it is very important to keep the contamination level to a minimum 
as it may lead to a negative impact on the measured concentration. Hence, in order to 
assess the contribution of contamination from sample preparation or analysis, three types 
of blanks were analysed: firstly, the calibration blank used to create the calibration curve 
alongside the standards; secondly, the procedural blanks analysed randomly in a sequence 
to monitor any contamination either from the sample diluent or the instrument during 
analysis; and finally, the rinse blank, namely the sample diluent, deionized water and 
nitric acid (2%v/v), used to flush the system between each standard and samples. 
Normally, the washing time varies between 2 to 5 min between samples, but after running 
the set of standards and the calibration verification standards between every 7-10 samples, 
the wash time was increased up to 10-15 min. In all experiments, the sequence started 
and finished with blank to check if the blank remains at similar level. Tests were applied 
to deionized (DI) water and nitric (2%v/v), acid to check the level of contamination in 
the tube for analysis. This was done by comparing between the normal falcon tube (NFT) 
(with blue lid) and the metal free tube (MFT) and an example of the results for DI water 
are demonstrated in Figure 2.1. Based on the data shown in Figure 2.1, the trend for Zn, 
Cu and Fe analysis followed the sequence: 
DI water-normal falcon tube  (NFT) > DI water-metal free tube (MFT) 
Thus, in the subsequent work, all experiments were carried out by using MF tube.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Comparison of Zn66,Cu65 and Fe57signal recorded for water blank samples in 
normal Falcon (blue) and metal free tubes (green).  
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2.3.2 Analytical performance  
Based on the calibration curve, the concentration of the elements in serum samples were 
precisely determined. Calibration curves were established by using eight different 
concentration points including zero. The plots showed a good linear relationship between 
signal intensity (cps) and concentration (ppb). The calibrations obtained for the target 
analytes (Zn66,Cu65 and Fe57) are presented in Figure 2.2. The corresponding regression 
equations of the linear plots for the three analytes in all experiments are given in the 
appendix 2. The correlation coefficient (R2) value ranged between 0.9972 and 0.9999 for 
all calibration curves. The limits of detection ranged from 0.20-0.83 µg L-1, 0.08-0.66 µg 
L-1 and 0.18-0.93 µg L-1 and the limits of quantification ranged from 0.65-2.75 µg L-1, 
0.28-2.20 µg L-1 and  and 0.59-3.11 µg L-1 for Zn, Cu and Fe, respectively. The limit of 
detection was taken to be three times the standard error of the calibration graph divided 
by the gradient applied to a plot of the calibration standards from 0-10ppb, the most 
common approach to calculate LOD and LOQ as stated in the equations below: 239 
Limit of Detection Limit (LOD) = 
𝟑𝒔𝒚/𝒙
𝒎
 (2.1)  
 
Limit of Quantification (LOQ) = 
𝟏𝟎 𝒔𝒚/𝒙
𝒎
 (2.2)  
 
Where sy/x= Standard Error of the calibration curve and m=Slope of the linear plot. 
 
In the calibration graphs, sometimes one (or possibly two) standard measurement appears 
to differ unexpectedly from the others. Thus, Grubbs’ test and Dixon’s test were used to 
exclude the outliers in all measurements of all three elements by using the following 
equations:239 
Grubb's test, G calc =
 ∣𝒔𝒖𝒔𝒑𝒆𝒄𝒕 𝒗𝒂𝒍𝒖𝒆 – 𝑿̅ ∣ 
𝑺
                        (2.3) 
Dixon’s test, D calc=∣𝒔𝒖𝒔𝒑𝒆𝒄𝒕 𝒗𝒂𝒍𝒖𝒆 − 𝒏𝒆𝒂𝒓𝒆𝒔𝒕 𝒗𝒂𝒍𝒖𝒆∣
 𝒍𝒂𝒓𝒈𝒆𝒔𝒕 𝒗𝒂𝒍𝒖𝒆 − 𝒔𝒎𝒂𝒍𝒍𝒆𝒔𝒕 𝒗𝒂𝒍𝒖𝒆
             (2.4) 
Where, X̅ and S are the mean and the standard deviation, respectively. 
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Figure 2.2 Calibration graph used to calculate Zn, Cu and Fe concentrations in serum 
samples 
y = 14092x - 593.16
R² = 0.9988
0.00E+00
7.00E+04
1.40E+05
2.10E+05
2.80E+05
0 5 10 15 20 25
Z
n
 s
ig
n
a
l 
in
te
n
si
ty
/c
p
s
Concentration/ppm
Zn66
y = 60096x - 1990.8
R² = 0.9999
0.00E+00
4.00E+05
8.00E+05
1.20E+06
0 5 10 15 20 25
C
u
 s
ig
n
a
l 
in
te
n
si
ty
/c
p
s
Concentration/ppm
Cu65
y = 5758.6x + 5167
R² = 0.9998
0.00E+00
3.00E+04
6.00E+04
9.00E+04
1.20E+05
0 5 10 15 20 25
F
e 
si
g
n
a
l 
in
te
n
si
ty
/c
p
s
Concentration/ppm
Fe57
55 
 
A comparison between the analytical features of the proposed methods for Zn, Cu and Fe 
determination and many published articles based on ICP-MS are summarized in Table 
2.4,184,83,219,221,220,217,218 Table 2.5219,221,220,217,218 and Table 2.6219,221,220,217 respectively. 
Based on the values for LOD and LOQ (Tables 2.4-2.6) and the linear dynamic range 
(LDR), it can be concluded that some of the methods outlined in Tables 2.4-2.6 exhibited 
high LOD and serious matrix interferences, whilst the low LOD reported for others may 
well be due to the different calculation methods used. Overall the proposed method 
compares favourably with other reported methods in terms of simplicity, speed, 
sensitivity, specificity and sample volume. Moreover, to our knowledge there are no 
studies reporting the successful analysis of as little as 50 μL of blood serum or plasma 
using ICP-MS. 
 
Calibrations and analyses were carried out and calculated with and without internal 
standard. It was found that the trends of the results and accuracy, as indicated by 
consistency with the Serum UTAK reference values was equivalent for both procedures. 
However, the precision and limit of detection without using internal standard were 
superior as the propagation of error from division by the internal standard signal is 
eliminated. Furthermore, there is a considerable economy in reagent use and time if 
samples and standards do not have to be spiked with the internal standard.  Therefore, the 
results reported here were obtained without the use of internal standard. The achievement 
of good accuracy without the use of internal standard is an indication that the sample 
matrix was not significantly affecting the sample introduction system because it was 
providing identical signals for equivalent analyte concentrations in both the samples and 
standards. A case can still be made for the use of an internal standard as on days when 
there was unexpected instrumental drift, the internal standard compensated for the drift 
and provided accurate answers. The choice of approach will depend on how frequently 
drift problems occur set against the overhead of using the internal standard. Added to this, 
in order to monitor the instrumental drift, one of the standards with known metal 
concentrations (10ppb) was analysed every 7-10 samples and the standards were 
recalculated relative to 10ppb. No significant differences were noticed before and after 
recalculation of the standards as demonstrated in Figure 2.3. 
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Table 2.4 Comparison of the proposed method with other reported methods for Zn 
determination* 
 
* The values of LOD in the table were based on different calculation method; ND= not detected. 
a  The LOD in the present work were calculated as three times the standard error of the calibration graph 
divided by the gradient. 
b The LOD was calculated as 10 SD above the value for 0.5% HNO3 plus the dilution factor (20 Fold). 
c ,d The LOD was calculated as 3 times the standard deviation of the analytical signal from the blank solution. 
e The LOD of acid digestion; f LOD of Alkali dilution; LOD were calculated in both methods as three times 
the standard deviation of the element concentration in the calibration blank. 
Techniques Samples 
Linear D 
range, (µg L-1) 
LOD 
(µg L-1) 
LOQ 
(µg L-1) 
Matrix and Remarks Ref. 
HR-ICP-MS Serum 0-20 
 
0.20 a 
 
0.65 
30.0 µL serum volume, simple 
dilution with 1%butanol, 0.5% v/v 
ammonia, 0.02% v/v TritonX-100, 
0.01% v/v HNO3, 100-fold 
Present 
work 
HR-ICP-MS Plasma 0–100 0.14 b 0.45 
100 µL sample volume, simple 
dilution with 0.5%HNO3 20-fold, 
220 
HR-ICP-MS  Serum 0–100 0.20 c 0.66 
100µL sample volume, 
digestion300 μL of OPTIMA 
HNO3 and 100 μL on hot plate, 
100-fold dilution 
83 
Q-ICP-MS 
Blood, 
plasma, 
urine, hair 
ND 0.63 2.1 
400 µL sample volume, diluted 
with purified water, acid, triton 
X100 and butanol. 
218 
HR-ICP-MS &          
Q-ICP-MS  
Plasma, 
Serum 
10-150 8.6 28.38 
150 µL serum volume, digestion 
with nitric acid and hydrogen 
peroxide placed in express hot 
block digester, 100-fold dilution 
219 
Q-ICP-MS 
system 
Serum 0-20 0.03 d 0.099 
The serum samples where diluted 
with 10% acetic acid and 0.1% 
Triton X-100, 10-fold 
217 
Q-ICP-MS  Serum 1-25 0.321 1.06 
2.0 mL serum volume, 1/10 
dilution with a solution of EDTA 
and NH4OH 
221 
 
Q-ICP-MS 
Whole 
blood, 
plasma 
ND 
0.14 e         
1.6 f 
0.46 ª 
5.3 b 
0.2 or 0.5 mL of human whole 
blood and serum samples were 
subjected to alkali dilution 
(ammonia solution) or acid 
digestion (nitric acid), 1:25 fold. 
184 
Q-ICP-MS  
 
Blood 5–48.33 1.5 5 
2.0 mL of prepared solution of 
65% conc. HNO3/H2O2 (2:1 v/v) 
was thoroughly ingested by 
microwave assisted acid digestion 
into a flask containing 0.5 mL 
blood. 
240 
Q-ICP-MS  
 
Serum ND 0.408 1.23 
150 µL of the serum samples were 
diluted (1:10) using the diluent 
solution: 5% 1-butanol, 0.05% 
EDTA, 0.05% triton X-100 and 
0.25% ammonium hydroxide. 
241 
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Table 2.5 Comparison of the proposed method with other reported methods for Cu 
determination* 
 
Techniques 
 
Samples 
Linear range, 
(µg L-1) 
LOD 
(µg L-1) 
LOQ (µg 
L-1) 
 
Matrix and Remarks 
 
Ref. 
HR-ICP-MS Serum 0-20 
 
0.08 a 
 
0.28 
30.0 µL serum volume, simple 
dilution with 1%butanol, 0.5% 
v/v ammonia, 0.02% v/v 
TritonX-100, 0.01% v/v HNO3, 
100-fold 
Present 
work 
 
HR-ICP-MS 
 
Plasma 
 
0–100 
 
0.15 
 
0.48 
100 µL sample volume, simple 
dilution with 0.5%HNO3 20-
fold 
 
 
220 
 
Q-ICP-MS 
Whole 
blood, 
plasma, 
urine and 
hair 
 
ND 
 
0.14 
 
0.47 
400 µL sample volume, diluted 
with purified water, acid, triton 
X100 and butanol. 
 
 
218 
 
HR-ICP-MS &               
Q-ICP-MS 
 
Plasma/ 
serum 
 
10-150 
 
0.32 
 
1.056 
150 µL serum volume, digestion 
with nitri0c acid and hydrogen 
peroxide placed in express hot 
block digester, 100-fold dilution 
 
 
219 
 
Q-ICP-MS 
 
Serum 
 
0-20 
 
ND 
 
ND 
The serum samples where 
diluted with 10% acetic acid and 
0.1% Triton X-100, 10 fold 
 
217 
 
Q-ICP-MS  
 
Serum 
 
1-25 
 
0.077 
 
0.25 
2.0 mL serum volume, 1/10 
dilution with a solution of 
EDTA and NH4OH 
 
221 
 
 
Q-ICP-MS 
 
 
Whole 
blood, 
plasma 
 
 
ND 
 
 
0.02 b 
0.22 c 
 
 
0.07a 
0.73b 
0.2 or 0.5 mL of human whole 
blood and serum samples were 
subjected to alkali dilution 
(ammonia solution) or acid 
digestion (nitric acid), 1:25 fold. 
 
 
184 
 
 
 
Q-ICP-MS  
 
 
 
Blood 
 
 
 
1–50 
 
 
 
0.303 
 
 
 
1.0 
2.0 mL of prepared solution of 
65% conc. HNO3/H2O2 (2:1 v/v) 
was thoroughly ingested by 
microwave assisted acid 
digestion into a flask containing 
0.5 mL blood. 
 
 
 
240 
 
 
Q-ICP-MS 
 
 
Serum 
 
 
ND 
 
 
0.0029 d 
 
 
0.0088 
150 µL of the serum samples 
were diluted (1:10) using the 
diluent solution: 5% 1-butanol, 
0.05% EDTA, 0.05% triton X-
100 and 0.25% ammonium 
hydroxide. 
 
 
241 
 
* The values of LOD in the table were based on different calculation method; ND= not detected. 
a  The LOD in the present work were calculated as three times the standard error of the calibration graph 
divided by the gradient. 
b The LOD of acid digestion; c LOD of Alkali dilution; LOD were calculated in both methods as three 
times the standard deviation of the element concentration in the calibration blank. 
d The LODs and LOQs were determined according to the recommendation of the International 
Conference on Harmonization (ICH) guidelines. 
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Table 2.6 Comparison of the proposed method with other reported methods for Fe 
determination* 
 
Techniques 
 
Samples 
Linear range, 
(µg L-1) 
LOD 
(µg L-1) 
LOQ 
(µg L-1) 
 
Matrix and Remarks 
 
Ref. 
HR-ICP-MS Serum 0.0-20 
 
0.18 a 
 
0.59 
30.0 µL serum volume, simple 
dilution with 1%butanol, 0.5% 
v/v ammonia, 0.02% v/v 
TritonX-100, 0.01% v/v HNO3, 
100-fold 
Present 
work 
 
HR-ICP-MS 
 
Plasma 
 
0.0–100 
 
0.08 b 
 
0.25 
100 µL sample volume, simple 
dilution with 0.5%HNO3 20-fold 
 
220 
 
HR-ICP-MS &               
Q-ICP-MS 
 
Plasma/ 
serum 
 
10-150 
 
8.6 
 
28.38 
150 µL serum volume, digestion 
with nitri0c acid and hydrogen 
peroxide placed in express hot 
block digester, 100-fold dilution 
 
219 
 
Q-ICP-MS 
 
Serum 
 
0.0-20 
 
0.69  
 
2.28 
The serum samples where diluted 
with 10% acetic acid and 0.1% 
Triton X-100, 10 fold 
 
217 
 
Q-ICP-MS  
 
Serum 
 
1-25 
 
0.002 
 
0.0066 
2.0 mL serum volume, 1/10 
dilution with a solution of EDTA 
and NH4OH 
 
221 
 
Q- ICP-MS 
 
Whole 
blood, 
plasma 
 
ND 
 
0.42 c 
0.50 d 
 
1.39 a 
1.65 b 
0.2 or 0.5 mL of human whole 
blood and serum samples were 
subjected to alkali dilution 
(ammonia solution) or acid 
digestion (nitric acid), 1:25 fold. 
 
 
184 
 
 
Q-ICP-MS  
 
 
Blood 
 
 
2.00–40.50 
 
 
0.606 
 
 
2.0 
2.0 mL of prepared solution of 
65% conc. HNO3/H2O2 (2:1 v/v) 
was thoroughly ingested by 
microwave assisted acid 
digestion into a flask containing 
0.5 mL blood. 
 
 
 
240 
 
Q-ICP-MS 
 
Serum 
 
ND 
 
0.0246 e 
 
0.0745 
150 µL of the serum samples 
were diluted (1:10) using the 
diluent solution: 5% 1-butanol, 
0.05% EDTA, 0.05% triton X-
100 and 0.25% ammonium 
hydroxide. 
 
 
241 
 
* The values of LOD in the table were based on different calculation method; ND= not detected. 
a  The LOD in the present work were calculated as three times the standard error of the calibration graph 
divided by the gradient. 
b The LOD was calculated as 10 SD above the value for 0.5% HNO3 solution plus the dilution factor (20 
Fold). 
c LOD of acid digestion; d LOD of Alkali dilution; LOD were calculated in both methods as three times 
the standard deviation of the element concentration in the calibration blank. 
e The LODs and LOQs were determined according to the recommendation of the International 
Conference on Harmonization (ICH) guidelines. 
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Figure 2.3 Calibration plots before and after recalculating the standard. 
 
2.3.3 Instrumental interferences 
There are two major types of interferences which should be taken into consideration. 
Firstly, there are interferences between elemental ions sharing the same mass, such as 
Zn64 and Ni64. Another important interference is polyatomic interferences generated by a 
combination of two or more isotopes from atmospheric and/or plasma gases. The most 
common species comprise Ar2
+, ArO+, O2
+, and N2
+. A clear illustration of this type is 
the interferences between Fe+ and ArO+ at m/z 56. As can be seen from Figure 2.4 the 
interference can be separated in ICP-SFMS with medium and high resolution. In all 
human serum samples, different isotopes were used for each element with a medium 
resolution setting (M/ΔM = 4000). The results for Zn (Zn66, Zn64), Cu (Cu63, Cu65) and 
Fe (Fe54, Fe57) were approximately the same as the natural isotopic ratio of around 1.78, 
2.30, 2.82, respectively. Thus, in the subsequent work, the following isotopes Zn66, Cu65,  
Fe57 were selected. 
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Figure 2.4 Interference on Fe+ by ArO+ at m/z 56, demonstrated in Low (A), Medium 
(B) and high (C) resolution. Figure generated using ELEMENT.exe (Finnigan MAT, 
Thermo manufacturer). 
 
2.3.4 Data of certified reference materials (CRMs)  
In order to verify measurement accuracy at low concentration, the analysis of certified 
reference materials is necessary. Two reference materials have been used before, after 
and throughout the analysis. The concentrations of Zn, Cu and Fe in batch 4 of 
SeronormTM Trace Elements level 1 (LOT 0903106) and Serum UTAK were found to be 
in good agreement with the certified values. However, Serum UTAK reference material 
was more reliable and gave more stable results.  
Over 40 days of tests over a one-year period, 4 batches of Seronorm were analysed with 
different preparation procedures as discussed in Table 2.2. The certified concentration 
ranges of Seronorm CRMs for Zn, Cu and Fe are 1.596-1.880 mg/L, 1.523- 1.859 mg/L 
and 1.23- 1.55 mg/L, respectively. In batches 1 and 2, Zn and Cu level in samples with 
dilution procedure were constantly lower than the expected reference value in contrast to 
Fe which was higher. Nevertheless, in batch 3, Zn and Fe level were higher than reference 
value but Cu almost matched the certified values. Some examples of the results for 
measured Seronorm in batch 1-4 are shown in Table 2.7. 
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Table 2.7 Selected examples of Seronorm levels (mg L-1) of Zn, Cu and Fe in different 
batches with various preparation procedures* 
Batch 
no. 
Seronorm preparation 
descriptions (dilution or 
digestion) 
Dilution 
factor 
Zn Cu Fe 
1 0.5% HNO3 
100 X 0.95 1.04 ND 
100 X 1.07 0.94 ND 
2 
0.5% HNO3 
100 X 1.65 1.68 1.44 
50 X 1.63 1.63 ND 
40 X 1.28 1.47 2.21 
20 X 1.16 1.40 1.74 
DI water 
100 X 0.76 0.66 ND 
20 X 0.65 0.65 ND 
 
1.5%HNO3+1.5%TMAH 
 
100 X 1.58 1.69 1.10 
50 X 1.37 1.46 1.00 
Seronorm digested and 
evaporated in Oven, reconstituted 
with 2%HNO3 
40 X 2.49 ND ND 
Seronorm digested and 
evaporated in hot block, 
reconstituted with 2%HNO3 
40 X 1.81 ND ND 
Seronorm digested and 
evaporated in hot block, 
reconstituted with 2%HNO3 
100 X 2.49 1.77 1.55 
3 
Seronorm digested but not 
evaporated_ centrifuge lid loosely 
closed by small pipette tip 
50 X 2.82 1.79 1.85 
Seronorm digested but not 
evaporated_ centrifuge lid pierced 
with metal needle 
30 X 1.61 1.79 1.85 
4 
Dilution with                                                                   
(1% Butanol, 0.5% v/v ammonia, 
0.02% v/v TritonX-100, 0.01% 
v/v HNO3). 
100 X 
1.67 1.70 1.44 
1.77 1.78 1.38 
1.55 1.90 1.24 
 
* The  concentrations in bold are the ones that matched with Seronorm reference value. 
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Maekawa et al. 231 has reported that selenium concentration in SeronormTM Trace 
Elements Serum (Level 2) may be in error noticeably in some batches. Over a 12-month 
period, the external reference materials were analysed extensively and the results 
confirmed a constant increase in selenium concentrations. Therefore, in the subsequent 
work, all experiments were carried out by using Serum UTAK reference material. The 
concentration average of found value, standard deviation (STDV), relative standard 
deviation (RSD) and acceptable range CRMs are summarized in Table 2.8. 
 
Table 2.8 The concentration of reference (UTAK) and found value (mg L-1) 
 Zn Cu Fe 
Reference value range 0.50-0.83 0.87-1.45 0.47-0.79 
N 20 21 23 
found value 0.68 1.16 0.60 
STDV 0.05 0.16 0.06 
RSD % 8.03 13.52 10.75 
 
 
2.3.5 Analysis of serum samples 
The study by Lu and colleagues184 has aimed to compare between alkali dilution and acid 
digestion methods in metal analysis by ICP-MS, and it suggested that alkali dilution is 
suitable for Zn and Cu serum/ blood analysis, while acid digestion was preferred for Fe. 
Another study 221 has tested four different pre-treatments on serum (1%HNO3, 
0.5%HNO3, 0.05% EDTA+ 1% NH4OH, and EDTA + 1% NH4OH+ 2% 1-butanol). The 
data indicated the best treatment for serum samples as the solution of EDTA and NH4OH. 
In addition, it has been suggested by Bocca et al.242 that simple dilutions are mainly 
selected for serum analysis, whereas blood samples may be digested.  In the present study, 
81 serum samples were collected from AMD and AD patients. Samples were analysed in 
four batches of about 20 samples within 4 days where duplicate preparations were made 
for serum, if sufficient sample was available. Single runs were performed for 20 out of 
81 serum samples because of the small sample volume available.  In the 1/100 (V/V) 
dilution, no clogging during nebulization and no particles were found in the injector tube 
throughout the run of serum analyses. This behaviour is most likely attributed to the use 
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of a glass nebulizer, short sample probe (80cm capillary, 0.5mm ID) and the low sample 
aspiration rate of 400µL/min. Higher dilution factors raise the limits of detection, but 
lower dilution factors increase the risk of particle deposits as reported earlier224. ICP-MS 
data for the analysed samples for Zn, Cu and Fe level for all samples in serum are 
summarized in the Tables demonstrated below.  
 
2.3.5.1 Quantification of zinc, copper and iron level in serum of AD patients 
Burnet243 was the first author to associate Zn deficiency with dementia, and since this 
work, several studies have discussed the crucial role of Zn in pathogenesis of AD. Many 
studies have correlated the changes in Zn to elevated brain levels. These studies are 
contradictory and the exact reasons for increased level of Zn in the brain in AD are still 
unclear. Haines and his co-workers244 have revealed no substantial differences between 
AD and control serum Zn, while Jeandel et al.245 have reported a significant decrease in 
the level of Zn and other nutrients in AD serum. On the other hand, Rulon et al.201 and 
Gonzales et al.204 have reported significant boosts of Zn levels in AD serum. Serum Zn 
seemed to be one of the risk factors associated with the development of AD. 
The measured Zn, Cu and Fe concentrations of 43 serum samples from AD patients are 
presented in Table 2.9, Table 2.10 and Table 2.11. The results revealed that the ICP-MS 
technique was able to measure directly the tested elements in 50 microliter serum samples 
in a (1:100v/v) dilution with Triton-X-100, butanol, ammonia and HNO3.  The data have 
revealed that, sample number 17 was the lowest while sample number 49 was the highest 
Zn concentration in the AD patients tested. The highest Cu level was in samples 
numbered 308 & 21, whereas the lowest Cu content is sample number 42. Sample number 
44 shows the highest Fe concentration, however sample 200 is by far the lowest. Sample 
number 80 was excluded from further data analysis as the concentration was higher than 
20ppb and thus outside the range of the calibration standards (Table 2.11). 
Several statistical tests including correlation, regression, t-tests, and analysis of variance, 
are based on the assumption that the data used are drawn from a normal population. 
However, with large sample sizes (> 30 or 40), the disruption of the normality assumption 
should not cause major problems. 246 A simple way of seeing whether a set of data is 
consistent with the assumption of normality is to plot a cumulative frequency curve. The 
percentage of cumulative frequency is calculated by using the formula below: 239 
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% cumulative frequency = 100 * cumulative frequency/ (n + 1)   (2.5) 
Where n is the total number of measurements. 
The cumulative frequency curve for the three elements in serum of AD patients yields an 
S-shape as can be seen in Figure 2.5, which means the data come from a normal 
population.  
Additionally, Zn, Cu and Fe concentrations measured in AD patients' serum were tested 
for normality of distribution using the Kolmogorov–Smirnov (K-S) test.  The original 
data where transformed into a standard normal variable (z), by using the equation 
below:239 
 
Standard normal variable, Z  = 
𝛘−µ
𝛔
              (2.6) 
Where, χ is the mesured value, µ is the mean and σ is the standard deviation. 
The distribution of Zn, Cu and Fe in AD patients was normal according to the 
Kolmogorov-Smirnov tests. The full calculations of K-S test, normal cumulative 
distribution and the normal probability plot obtained by using Minitab software of Zn, 
Cu and Fe distribution in AD patients are are summarized in Appendix 2. 
 
The one-way analysis of variance (ANOVA) is used to determine whether there are any 
statistically significant differences between the means of more than two independent 
groups.239 Thus, one-way ANOVA test was applied to compare Zn, Cu and Fe variation 
in AD patients, showing that the concentrations of these elements were significantly 
different as the F critical is smaller than the F calculated (P <0.0001). The results obtained 
from this test at 5% significance level are shown in Table 2.12 for comparison between 
Zn, Cu and Fe in the AD samples.The results illustrate that the total average of serum Zn 
in general is noticeably lower than Cu and Fe. Copper shows the highest level in 
comparison to Zn and Fe, in the case of AD. 
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Table 2.9 Total concentration (mg L-1) of Zn in serum of AD patients* 
Samples 
number 
Zn ± STDV 
Samples 
number 
Zn ± STDV 
17 0.58 ± 0.05 52 0.74 ± 0.07 
18 0.74 ± 0.07 57 0.75 ± 0.07 
21 0.99 ± 0.09 58 0.66 ± 0.06 
22 0.78 ± 0.07 64 0.79 ± 0.07 
25 0.73 ± 0.07 67 0.62 ± 0.06 
26 0.83 ± 0.08 72 0.9 ± 0.08 
27 0.84 ± 0.08 76 0.71 ± 0.07 
28 0.76 ± 0.07 77 0.72 ± 0.07 
33 0.99 ± 0.09 78 0.59 ± 0.06 
34 0.61 ± 0.06 80 0.68 ± 0.06 
35 0.98 ± 0.09 200 0.93 ± 0.09 
36 0.79 ± 0.07 201 0.93 ± 0.09 
37 0.61 ± 0.06 301 0.69 ± 0.06 
38 0.64 ± 0.06 302 0.81 ± 0.08 
40 0.86 ± 0.08 303 0.83 ± 0.08 
41 0.95 ± 0.09 304 0.61 ± 0.06 
42 0.80 ± 0.08 305 0.68 ± 0.06 
43 0.69 ± 0.06 306 0.77 ± 0.07 
44 0.69 ± 0.06 307 0.66 ± 0.06 
49 0.93 ± 0.09 308 0.92 ± 0.09 
50 0.80 ± 0.08 309 1.07 ± 0.10 
51 0.70 ± 0.07     
 
* The quoted STDV values were calculating by multiplying the measured values by the 
RSD of 20 replicates of Serum UTAK reference materal divided by 100.  
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Table 2.10 The total concentration (mg L-1) of Cu in serum of AD patients* 
Samples 
number 
Cu ± STDV 
Samples 
number 
Cu ± STDV 
17 1.50 ± 0.20 52 1.23 ± 0.17 
18 1.29 ± 0.17 57 1.70 ± 0.23 
21 1.83 ± 0.25 58 1.03 ± 0.14 
22 1.20 ± 0.16 64 1.32 ± 0.18 
25 1.04 ± 0.14 67 1.24 ± 0.17 
26 1.15 ± 0.15 72 1.09 ± 0.15 
27 1.31 ± 0.18 76 1.02 ± 0.14 
28 1.17 ± 0.16 77 0.79 ± 0.11 
33 1.35 ± 0.18 78 1.1 ± 0.15 
34 1.24 ± 0.17 80 0.98 ± 0.13 
35 1.35 ± 0.18 200 1.29 ± 0.17 
36 1.06 ± 0.14 201 1.19 ± 0.16 
37 1.13 ± 0.15 301 0.81 ± 0.11 
38 0.94 ± 0.13 302 0.98 ± 0.13 
40 1.33 ± 0.18 303 1.19 ± 0.16 
41 1.42 ± 0.19 304 1.32 ± 0.18 
42 0.77 ± 0.10 305 0.85 ± 0.11 
43 1.08 ± 0.15 306 1.25 ± 0.17 
44 1.20 ± 0.16 307 0.95 ± 0.13 
49 1.54 ± 0.21 308 1.53 ± 0.21 
50 0.95 ± 0.13 309 0.87 ± 0.12 
51 1.11 ± 0.15    
 
* The quoted STDV values were calculating by multiplying the measured values by the 
RSD of 21 replicates of Serum UTAK reference materal divided by 100.  
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Table 2.11 The total concentration (mg L-1) of Fe in serum of AD patients* 
Samples 
number 
Fe± STDV Samples number Fe± STDV 
17 0.69 ± 0.07 52 1.22 ± 0.13 
18 1.23 ± 0.13 57 0.95 ± 0.1 
21 1.19 ± 0.13 58 1.43 ± 0.15 
22 2.05 ± 0.22 64 1.16 ± 0.12 
25 1.40 ± 0.15 67 0.76 ± 0.08 
26 1.87 ± 0.2 72 1.24 ± 0.13 
27 0.96 ± 0.1 76 0.88 ± 0.09 
28 0.81 ± 0.09 77 0.56 ± 0.06 
33 2.29 ± 0.25 78 0.51 ± 0.06 
34 0.96 ± 0.10 80** 2.78 ± 0.30 
35 1.95 ± 0.21 200 1.66 ± 0.18 
36 1.09 ± 0.12 201 1.06 ± 0.11 
37 1.24 ± 0.13 301 0.56 ± 0.06 
38 0.92 ± 0.10 302 1.41 ± 0.15 
40 0.89 ± 0.10 303 1.06 ± 0.11 
41 1.76 ± 0.19 304 0.80 ± 0.09 
42 1.70 ± 0.18 305 0.86±0.09 
43 0.66 ± 0.07 306 0.95 ± 0.10 
44 0.53 ± 0.06 307 0.77 ± 0.08 
49 1.02 ± 0.11 308 0.52 ± 0.06 
50 1.29 ± 0.14 309 1.35 ± 0.15 
51 0.81 ± 0.09     
 
* The quoted STDV values were calculating by multiplying the measured values by the 
RSD of 23 replicates of Serum UTAK reference materal divided by 100.  
** Sample number 80 of Fe was above the calculated linear dynamic range (20ppb) in 
the diluted samples.  
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Figure 2.5 The cumulative frequency curve for the measurements of serum Zn, Cu and 
Fe in AD patients.  
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Table 2.12  ANOVA: One-factor with  (n = 43) of serum Zn, Cu and Fe detected from 
AD patients. 
 
2.3.5.2 Quantification of zinc, copper and iron level in serum of AMD patients 
In the present investigation, sera of 38 AMD patients were analysed for Zn, Cu, and Fe 
by ICP-MS. The results are shown in Table 2.13, Table 2.14 and Table 2.15. ICP-MS 
was able to measure directly the selected elements in 50 microliter serum samples in a 
1:100 (v/v) dilution with sample diluent as mentioned in section 2.3.5.1. The 
concentrations of Zn are usually lower than Cu and Fe. The data revealed that, sample 
number 51 was the lowest while sample number 39 was the highest Zn concentration in 
the AMD patients tested. The highest Cu level was in sample number 21, whereas the 
lowest Cu content is sample number 53. Sample number 23 shows the highest Fe 
concentration, however sample 43 is by far the lowest. Sample numbers 51, 57 and 58 
were excluded from further data analysis as the concentration of the diluted serum was 
higher than 20ppb and thus outside the range of the calibration standards (Table 2.15). 
The cumulative frequency curve for the three elements in AMD patients' serum produces 
an S-shape as can be seen in Figure 2.6 indicating that the data come from a normal 
population. In addition, Kolmogorov–Smirnov (K-S) method was applied to test for 
normality. The distribution of Zn, Cu and Fe in AMD patients was normal according to 
the Kolmogorov-Smirnov tests. The full calculations of K-S test, normal cumulative 
distribution and the normal probability plot obtained by using Minitab software of Zn, 
Cu and Fe distribution in AMD patients are summarized in Appendix 2. 
SUMMARY             
Groups Count Sum Average Variance     
Zn66-AD 43 33.35 0.78 0.02     
Cu65-AD 43 50.68 1.18 0.05     
 Fe57-AD                     42 47.03 1.12 0.19     
ANOVA             
Source of 
Variation 
SS df MS F P-value F crit 
Between Groups 4.07 2.00 2.03 23.36 2.41E-09 3.07 
Within Groups 10.89 125.00 0.09       
              
Total 14.96 127.00         
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Table 2.13 The total concentration (mg L-1) of Zn in serum of AMD patients* 
Samples 
number 
Zn ± STDV 
Samples 
number 
Zn ± STDV 
21 0.87 ± 0.08 42 0.62 ± 0.06 
23 0.7 ± 0.07 43 0.85 ± 0.08 
24 0.71 ± 0.07 44 0.59 ± 0.06 
25 0.63 ± 0.06 45 0.68 ± 0.06 
26 0.65 ± 0.06 46 0.75 ± 0.07 
27 0.71 ± 0.07 48 0.98 ± 0.09 
28 0.86 ± 0.08 49 0.57 ± 0.05 
29 0.69 ± 0.06 51 0.52 ± 0.05 
30 0.66 ± 0.06 52 0.74 ± 0.07 
31 0.85 ± 0.08 53 0.56 ± 0.05 
32 0.84 ± 0.08 55 0.65 ± 0.06 
33 0.95 ± 0.09 56 0.72 ± 0.07 
34 1.02 ± 0.10 57 0.78 ± 0.07 
35 1.04 ± 0.10 58 0.86 ± 0.08 
36 1.26 ± 0.12 59 0.88 ± 0.08 
37 1.19 ± 0.11 60 0.66 ± 0.06 
38 0.62 ± 0.06 61 0.73 ± 0.07 
39 1.33 ± 0.12 62 0.57 ± 0.05 
41 1.32 ± 0.12 63 0.77 ± 0.07 
 
* The quoted STDV values were calculating by multiplying the measured values by the 
RSD of 20 replicates of Serum UTAK reference materal divided by 100.  
 
  
71 
 
Table 2.14 The total concentration (mg L-1) of Cu in serum of AMD serum patients* 
Samples 
number 
Cu ± STDV 
Samples 
number 
Cu ± STDV 
21 1.92 ± 0.25 42 1.22 ± 0.16 
23 1.41 ± 0.18 43 1.04 ± 0.13 
24 1.02 ± 0.13 44 1.61 ± 0.21 
25 0.87 ± 0.11 45 1.37 ± 0.18 
26 0.93 ± 0.12 46 1.49 ± 0.19 
27 1.07 ± 0.14 48 0.98 ± 0.13 
28 0.83 ± 0.11 49 1.21 ± 0.16 
29 1.42 ± 0.18 51 1.09 ± 0.14 
30 0.77 ± 0.1 52 1.15 ± 0.15 
31 1.03 ± 0.13 53 0.85 ± 0.11 
32 1.33 ± 0.17 55 1.01 ± 0.13 
33 1.16 ± 0.15 56 1.20 ± 0.15 
34 1.48 ± 0.19 57 0.98 ± 0.13 
35 0.91 ± 0.12 58 0.95 ± 0.12 
36 1.31 ± 0.17 59 1.07 ± 0.14 
37 1.15 ± 0.15 60 1.01 ± 0.13 
38 0.99 ± 0.13 61 1.16 ± 0.15 
39 1.34 ± 0.17 62 1.14 ± 0.15 
41 0.92 ± 0.12 63 0.98 ± 0.13 
 
* The quoted STDV values were calculating by multiplying the measured values by the 
RSD of 21 replicates of Serum UTAK reference materal divided by 100.  
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Table 2.15 The total concentration (mg L-1) of Fe in serum of AMD serum patients* 
Samples 
number 
Fe ppm ± STDV 
Samples 
number 
Fe ppm ± STDV 
21 1.29 ± 0.14 42 1.30 ± 0.14 
23 2.06 ± 0.22 43 0.51 ± 0.05 
24 1.26 ± 0.14 44 1.26 ± 0.13 
25 1.06 ± 0.11 45 1.68 ± 0.18 
26 1.18 ± 0.13 46 1.63 ± 0.17 
27 1.88 ± 0.20 48 1.11 ± 0.12 
28 0.99 ± 0.11 49 1.08 ± 0.12 
29 1.31 ± 0.14 51** 3.22 ± 0.35 
30 0.96 ± 0.10 52 1.60 ± 0.17 
31 0.87 ± 0.09 53 1.72 ± 0.18 
32 2.20 ± 0.24 55 1.32 ± 0.14 
33 1.83 ± 0.20 56 1.25 ± 0.13 
34 0.63 ± 0.07 57** 3.43 ± 0.37 
35 1.52 ± 0.16 58** 3.17 ± 0.34 
36 1.03 ± 0.11 59 0.74 ± 0.08 
37 0.84 ± 0.09 60 2.41 ± 0.26 
38 1.24 ± 0.13 61 1.64 ± 0.18 
39 1.68 ± 0.18 62 1.13 ± 0.12 
41 1.59 ± 0.17 63 0.68 ± 0.07 
 
* The quoted STDV values were calculating by multiplying the measured values by the 
RSD of 23 replicates of Serum UTAK reference materal divided by 100.  
** Samples number 51,57 and 58 of Fe were found higher than calculated linear dynamic 
range (20ppb) in the diluted samples.  
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Figure 2.6 The cumulative frequency curve for the measurements of serum Zn, Cu and 
Fe in AMD patients.  
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One-way ANOVA test was applied to compare Zn, Cu and Fe variation in AMD patients, 
showing that the concentrations of these elements were significantly different as the F 
critical is smaller than the F calculated (P <0.0001). The results obtained from this test at 
5% significance level are shown in Table 2.16 for comparision between Zn, Cu and Fe in 
AMD patients.The results illustrate that the total average of serum Zn in general is 
noticeably lower than Cu and Fe. Iron shows the highest level in comparison to Zn and 
Cu, in the case of AMD. 
 
Table 2.16 ANOVA: One-factor with  (n = 38) of serum Zn, Cu and Fe detected from 
AMD patients. 
 
 
2.3.5.3 Associations between age-related macular degeneration and Alzheimer 
disease 
Alzheimer disease and age related macular degeneration are chronic diseases associated 
with aging.247 Both diseases share similar pathogenesis pathway and environmental risk 
factors thus some authors named AMD ‘Alzheimer disease in the eye’.248,249 Aging, 
obesity, unhealthy diet, atherosclerosis, hypertension, and smoking are the common risk 
factors.248,77 Although genetic background seems to be different between these diseases, 
cellular aging pathology have parallel association in the retina and brain tissues. As the 
growing age of the population has increased and age is the most common risk factor, 
these two age-related diseases have recently received a great deal of attention from 
researchers.249,77  
SUMMARY               
Groups Count Sum Average Variance       
Zn66-AMD 38 30.38 0.80 0.04       
Cu65-AMD 38 43.37 1.14 0.06       
Fe57-AMD                     35 46.46 1.33 0.20       
ANOVA               
Source of Variation SS df MS F P-value F crit   
Between Groups 5.27 2.00 2.64 26.91 3.29E-10 3.08   
Within Groups 10.58 108.00 0.10         
                
Total 15.86 110.00           
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The retina is similar to other areas of the brain and an integral section of the central 
nervous system (CNS), it is derived from the neural tube of the CNS. Both brain and the 
retina have blood-tissue barriers feature. Retinal degeneration affects patients with in 
Alzheimer’s disease.250 AMD and AD share several pathological features such as 
inflammation, inreased oxidative stress, vitronectin and amyloid-β accumulation.248,249 
Amongst the common markers of both AMD and AD are extracellular deposits consisting 
of primarily comparable aggregated proteins in both diseases.77 In AMD, the yellow 
deposits that are located between the retinal pigment epithelium and Bruch’s membrane 
(BM) are called drusen. Large and confluent drusen are substantial risk factors for 
developing choroidal neovascularisation (AMD).249 On the other hand, in AD, the 
deposits in the brain are characterised by amyloid-β-containing senile plaques.248,249 
Although Amyloid-β is accumulated in the drusen and in the brain, the phenotype is 
different between AD and AMD, and the latter is not generally considered an amyloid-
deposit disease. 248,249,251,252 In addition, the cells affected by Aß and the area of Aß 
deposition in the retina or brain are different between AMD and AD.249 With increasing 
age, the small amounts of Aß deposit in the normal brain and in the normal retina 
increases and thus the accumulation of Amyloid-β 42 oligomers cause chronic 
inflammation and therefore contribute to blood–retinal barrier dysfunction.248,249,253 In 
AMD, choroidal blood flow is decreased, similarly, cerebral blood flow is 20% lower in 
AD patients in comparison with age-matched controls.248,254,255   Klaver et.al256 (the 
Rotterdam study) investigated the incidence of both diseases in 1,438 patients above the 
age of 75 years and followed up examination for an average of 25.2 months. Patients with 
advanced AMD showed an increased risk of Alzheimer’s disease occurrence. The risk 
was decreased after adjustments for smoking and atherosclerosis, suggesting a common 
pathogenesis for neuronal degeneration. This finding was confirmed by other 
studies257,258 which observed a raised incidence of cognitive impairment in patients with 
AMD in the Age-Related Eye Disease Study (AREDS). Hoh Kam et al. (2010)259 
demonstrated that Aß accumulation occurred with aging even in the normal mouse retina 
and human retina. It has been observed that patients with AD usually have visual and 
retinal abnormalities such as failure and damage of the central visual pathways, optic 
nerve and ganglion cell degeneration and reduction of the thickness of the retinal nerve 
fibre layer.249  The data suggested that a related pathogenic mechanism may occur 
between AMD and AD. Therefore, therapeutic approaches that have targeted Aß in AD 
patients can also be useful and practical to AMD.249 For example, immunotherapy 
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targeting amyloid-β has been proven effective in protecting the retinal pigment 
epithelium.260,261 
Nutritional antioxidant supplements are effective in delaying both diseases.248  On the 
other hand, Keenan et al. reported262 that the risk of AD following AMD was not raised 
according to English National Health Service. Future research is required to identify 
whether AMD and AD patients receive appropriate investigation and treatment.262 
 
2.3.5.4 Comparison of data from AMD and AD samples 
It is important to compare the random errors of the two sets of data, i.e. standard 
deviations. For each of the three elements analysed an F-test was conducted to test if 
there is significant difference between the two sample variances. For Zn, the calculated 
F-value was higher than the critical F-value (P<0.0001). Therefore, the null hypothesis 
of equal variances is rejected and there is significant difference between the two variances 
at the 5% probability level. However, for Cu and Fe the calculated F values were lower 
than the critical F values (P>0.10), thus, the null hypothesis of equal variances is retained 
and there is no significant difference between the two variances at the 5% probability 
level.  As a result, an equal variance t-test for Cu and Fe (two tailed)  and unequal variance            
t-test for Zn (two tailed) was carried out, in order to test differences in the two 
experimental means. According to the relevant t-test, the results of Zn and Cu in the 
serum showed no significant differences between AD and AMD as the calculated t value 
is smaller than the critical value at 95% confidence level.  (P>0.10). However, Fe in 
AMD patients is slightly higher than AD patients as the calculated t value for Fe between 
AD and AMD patients in serum is greater than the critical value at 95% confidence level.   
(P=0.04). The measurements of t-tests, F-tests and their critical and P-values are 
illustrated in Table 2.17 at 5% probability level. 
Another simple and fast way of representing data in a plot is the box-and whisker diagram. 
The plot depicts at a glance the spread and symmetry of the data through their quartiles. 
This alteration of Zn, Cu and Fe is outlined in the box- and whisker plots represented in 
Figure 2.7, which show the clear imbalance in the three elements in each group of patients. 
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Table 2.17 Descriptive statistics for all analysed elements in both group of patients 
showing F-calc and t-calc and P scores 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zn  AMD AD 
Mean 0.80 0.78 
Variance (S2) 0.04 0.02 
Observations 38 43 
t Stat 0.61  
P(T<=t) two-tail 0.54  
t Critical two-tail 2.00   
F (S12/S22) 2.83   
P(F<=f) two-tail 6.48E-04   
F Critical two-tail 1.69   
Cu  AMD AD 
Mean 1.14 1.18 
Variance 0.06 0.05 
Observations 38 43 
t Stat 0.71   
P(T<=t) two-tail 0.48   
t Critical two-tail 1.99   
F (S12/S22) 1.05   
P(F<=f)  two-tail 0.43   
F Critical  two-tail 1.69   
Fe  AMD AD 
Mean 1.33 1.12 
Variance 0.20 0.19 
Observations 35 42 
 
t Stat 2.05   
P(T<=t) two-tail 0.04   
t Critical two-tail 1.99   
F (S12/S22) 1.03   
P(F<=f) two-tail 0.46   
F Critical two-tail 1.71   
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Figure 2.7 Box-and-whisker plot showing the different patterns of AD and AMD concentrations in Zn, Cu and Fe, respectively. Symbols on 
each box plot represent: mean value (■), median (line in box), minimum and maximum data values (whiskers), and 75th and 25th percentile (upper 
and lower the edge of box). 
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2.3.5.5 Comparison with healthy controls 
Some published values for Zn, Cu and Fe concentrations in the serum of healthy control 
people are given in Table 2.18 and compared with AD and AMD patients' serum levels 
found in this work. In patients' samples, Zn/Fe concentrations were lower compared to 
healthy people whereas Cu levels in patients' sera were higher in comparison to healthy 
people as can be seen in Figure 2.8. This finding supports other reports in the 
literature.15,72,202,208,20,210,263  
Rembach et al72 reported that serum Zn concentration dropped around 0.4% per year with 
age. A possible reason for decreasing serum Zn level in AD patients might be the 
accumulation of Zn in the brain as amyloid plaques trap Zn which is then depleted in other 
body compartments.15 In addition, Zn deficiency and variation in AD patients could be 
related to the interaction with Cu metabolism.202 Ceruloplasmin is the major Cu-carrying 
protein which accounts for 85-95% of circulating Cu. As inflammation is potentially linked 
with AD pathogens, and ceruloplasmin levels rise during inflammation response208, serum 
levels of ceruloplasmin have been found to be higher in AD compared to healthy controls.208 
This is consistent with the higher Cu levels in AD patients found in this work. Like 
ceruloplasmin, transferrin and ferritin are the main proteins that regulate the transportation 
and the storage of Fe in the body and they are significantly decreased in the serum of AD 
patients compared to controls.263 Moreover, it was indicated that the alteration of the gene 
of both proteins is related to AD. According to this evidence, it is sensible to consider that 
Fe homeostasis might be linked with AD progression.263 In general, the concentration of 
serum Zn, Cu and Fe are likely to vary with different ages.191,207,209 In addition, these 
elements displayed differential changes with regard to gender and nutritional state.22 Further 
studies from different countries are needed to assess the correlation between serum metal 
levels in healthy people and AD/AMD patients. 
To test for significant difference between the observed and known values (apart from that 
due to random variation), the statistic t is calculated from the equation below:239   
 
t =
 (?̅?̅−µ)√𝒏
𝑺
          (2.7)      
Where x̄ = sample mean, s = sample standard deviation and n=sample size.      
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The means of the patients and the known values of the healthy control were compared for 
all elements using the equation above (2.7) of  t-test. Since the observed values of | t | is 
larger than the critical value, the data sets for all elements were significantly different at 
p=0.05, except that Fe in AMD patients was not significantly different from healthy controls 
as the t-calculated is less than the critical value, thus the null hypothesis is retained and there 
is no evidence of systematic error.      
The possibility of carrying out multi-variate analysis (e.g. PCA, MLR, cluster analysis, etc) 
on the serum analysis data was considered. However, following discussion with supervisors 
and the external collaborator, it was concluded that, due to the limited number of samples 
for which complete patient data were available, there would be insufficient statistical power 
in any conclusions drawn from multi-variate analysis at this stage and this might jeopardize 
publication of the work which is primarily concerned with the development of improved 
analytical methodology.  
        
Table 2.18 Comparison of the concentration (mg L-1 ) of Zn, Cu and Fe serum among AD 
(n=43) and AMD (n=38) patients with published values of healthy controls (n=1250 ) 
Trace 
elements 
N Age (years) 
published 
Healthy control  
Ref. 
Present 
study of AD 
patients 
Present 
study of 
AMD 
patients 
Zn 302 65.6 ±12.2 1.29 ±0.39 264  0.78± 0.13 0.80± 0.21 
Cu 716 69 ± 6.8 0.93 ± 0.18 265  1.18± 0.23 1.14± 0.24 
Fe 302 65.6±12.2 1.47± 0.65 264 1.12± 0.44 1.33± 0.45 
* All values were expressed as mean ± STDV. 
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Figure 2.8 Comparisons between Zn, Cu and Fe concentrations (mg L-1) in AD, AMD 
patients and published healthy controls. Error bars represent the standard error of the mean 
(STDV/√n), n=43 in AD patients and n=38 in AMD patients. Healthy control data were 
taken from references 254 and 255.  
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2.4   Conclusion 
Simple dilution-based procedures show successful results and provide an alternative to 
conventional acid digestion for biological materials, since precision, satisfactory accuracy, 
and instrument performance have been reported in the majority of such studies. In this study, 
we have demonstrated that high resolution sector field ICPMS is capable of determining Zn, 
Fe and Cu level in 50 µL or less of AD and AMD serum samples with satisfactory results in 
terms of LOD and precision. A minimal requirement of sample volume is important to 
preserve sample and allow researchers to accurately determine trace elements in different 
biological matrices. Although the term “sample diluent” was used in this procedure and it 
only requires adding reagents to the samples, in practise it is more than a diluent as this 
mixture is chemically active in a way that trace elements are stabilized in the solution and 
samples nebulised properly. Moreover, the preparation procedure used was compared with 
many other procedures and it was found that this matrix gives stable calibration curves, low 
blanks and reliable results with standard reference material to enable these trace elements to 
be determined in small sample volumes. To the best of our knowledge, no other published 
studies in the literature have used such a low volume of serum sample to quantify Zn, Cu 
and Fe. Because of the ubiquitous nature of the elements of interest in the environment, an 
extensive blank testing regime has been carried out, in which different sample vessels were 
tested, sample preparations were performed under careful protocol and precautions, and the 
sample introduction system was cleaned out on a regular basis in order to sustain a low and 
consistent blank, which was successfully achieved as described in the chapter. 
 
The importance of studying age related disease has significantly increased over the last 
century due to the rise of aging rate of the world population. It is still unclear whether the 
metal-related abnormalities are a cause or an effect of the retinal degeneration in AMD. 
Alteration of serum Zn, Cu and Fe levels are involved in the pathogenesis of Alzheimer 
disease. Parallel studies between AD and AMD have led to a link between the two conditions. 
Understanding the common mechanisms may provide new insights into AD and AMD 
pathogenesis and treatment. AMD and AD is a multi-factorial disease influenced by age, 
gender and combination of environmental and genetic risk factors.  The hypothesis involved 
in measuring trace elements in serum samples is to find out if there is a correlation between 
the observed levels of these trace elements and the state of the disease in individual patients. 
In this study, it was indicated that serum Fe levels in AMD patients are slightly higher than 
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AD patients, whereas serum Zn and Cu were not significantly different between AD and 
AMD patients. Furthermore, the total average of serum Zn in general is lower than Cu and 
Fe and this finding is supported by the literature as discussed earlier in the 
introduction.85,196,15,72,17  As the set of control samples was not possible to obtain, our AMD 
and AD patients were compared with published healthy control elsewhere.208,263 The results 
show a decrease in Zn and Fe serum level in AD and AMD patients compared to healthy 
controls264,263 whereas serum Cu level appears notably increased in AD and AMD patients 
compared to healthy controls.265,263 These findings are in line with those recently reported.263 
The comparisons between controls and patients will be more reliable if they were of similar 
age group and gender. Therefore, the next stage of this research will include phenotypic 
details such as, gender, age, nutrition and lifestyles of the anonymised participants. Such 
information would be derived from follow on clinical collaborations as part of a study and 
that would allow for comprehensive information and reliable comparisons. 
There is controversy about measuring bulk serum concentrations for trace elements to study 
particular pathogenesis of diseases. Although serum Zn is maintained homeostatically, it is 
still the most commonly accepted biomarker of Zn status.147 It is possible now to analyse 
trace metals in single cells which have been done in our group and reported elsewere.266 
Therefore, the work described later in chapter 4 was an attempt to look for Zn inside the cell 
as intracellular Zn may be a better measure of the biological processes involved. 
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3 Bio-imaging of Zinc in Retina Tissue by Laser 
Ablation Inductively Coupled Plasma Mass 
Spectrometry 
 
3.1 Introduction 
3.1.1 Distribution of zinc in the eye 
The highest concentration of Zn is found in the eye compared to other tissues, in particular 
retinal pigment epithelium (RPE) and choroid complex.267 The order of Zn concentration 
in ocular tissues as reviewed extensively by Galin was concluded to be as follows: retina 
and choroid > ciliary body > iris > optic nerve > sclera > cornea > lens. The Zn 
concentration in the retina and choroid is found to be around 464 ppm and 472 ppm, 
respectively.267,268 The structure of the eye is highly organised and complex. Figure 3.1 
provides a schematic illustration of the eye in general and the layers of the retina in 
particular.269 The choroid is the vascular layer of the eye containing the main supply of 
blood vessels to the retina and lying between the retina and the sclera. Bruch’s membrane 
(BM) is an elastin- and collagen-rich extracellular matrix which is involved in exchange 
of oxygen and micronutrients between the choroid and the retinal pigment epithelium 
(RPE), the RPE is a monolayer of pigmented cells which interacts with photoreceptors in 
the maintenance of visual cycle and delivers nutrients from the blood to photoreceptors. 
The retina is a complex transparent tissue consisting of several layers, a healthy retina is 
vital to clear vision as it receives light that the lens has focused, converts the light into 
neural signals, and sends these signals on to the brain for visual recognition.270 
Zinc is undeniably vital for normal functioning of the eye, as it plays a fundamental role 
in maintaining normal ocular function and retinal physiology. It is involved in several 
retinal functions including visual cycle and photoreceptor survival, photo transduction, 
and the process of neurotransmission. Additionally, Zn is thought to influence cell 
metabolism through a variety of mechanisms and may also function as part of antioxidant 
defence mechanisms in the retina.267,186,42 
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Figure 3.1 Schematic diagram of the anatomy of the eye. The section of interest (Retina) 
enlarged to show the anatomical layers. Reproduced from Caspi, 2010, with permission 
from American Society for Clinical Investigation.269 
 
Experimental evidence suggested that Zn may have positive or negative consequences on 
retinal physiology and pathophysiology of cells, depending on the localisation 
(extracellular vs. intracellular), concentration and state (bound or free).186,271 As the level 
of Zn is high in the retina, a large number of Zn ions are tightly bound to proteins and 
other molecules to regulate their structure and function in retina. Therefore, exchangeable 
Zn may be essential for participation in numerous biological processes. Excess levels of 
“free” or loosely bound metal ions can cause toxic effects.186  Like any other cells, the 
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RPE can be damaged by excessively large or excessively small amounts of Zn which can 
cause retinal cell dysfunction and pathology.272 Studies have shown in vitro 273 and in 
vivo 274 that high quantities of Zn can be harmful and lead to neuronal damage 
deterioration.271 However, low doses of Zn given therapeutically could be beneficial in 
treating some diseases. 271 
The high concentration of Zn in retinal pigment epithelium (RPE) can decrease during 
Zn deficiency. It causes reduction in: metallothionein concentration, cell/ protein 
production and activity of catalase in RPE as well as cells becoming more vulnerable to 
oxidative damage and thus neuronal death.275,40 Zinc deficiency is associated with night 
blindness, poor darkness adaptation and macular degeneration. 42,271 Another study found 
that feeding rats with a Zn-deficient diet increased the accumulation of the aging pigment 
in the retina.276 Morphological changes in retinal structures could be a cause of Cu 
deficiency.42 
 
3.1.2 Zinc in retinal physiology and related disease 
Altered metal homeostasis is frequently implicated in a wide range of disease.277 As 
discussed earlier, metal ions are known to play an important role in many age related 
diseases including AMD and retinal health. In this disease, abnormal regulation of redox 
active metal ions can provoke oxidative stress by producing cytotoxic reactive oxygen 
species (ROS).  It also extends to non-redox active metals such as Zn and Ca, which are 
cytotoxic at high concentrations and often associated with neurodegenerative diseases.278 
It is well known that, during aging, Zn homeostasis changes and may contribute to 
specific retinal disorders.186 Aging has been linked with Zn reduction in human retina 
and RPE. Age is a major cause of cellular function failure and death. Both cone and rod 
lose their mediated responses. In addition, cell density declines with age and a decreased 
cone photoreceptor in pigmented rat was observed.279 According to a study by Wills et 
al.42, the level of Zn decreases in the neuroretina of men, whereas no changes were 
detected in women. Another study280 showed the link between metallothionein (MT) and 
Zn in the retina which was thought to protect the cells from oxidative damage. MT has 
the property of releasing and binding Zn whereas Zn can stimulate MT production and if 
the need arises it can also detach itself from MT in case of low level of Zn that may follow 
rapid degeneration rate of MT. Thus, the study indicated that the elevation and reduction 
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in MT level in human RPE cells are associated with the elevation and reduction of Zn 
level.280 
chronic inflammation and oxidative stress may play significant causative roles, thus Zn 
reduction in human eyes was suggested to be a sign of age-related macular degeneration 
(AMD).281,282,40  A study by Erie et al.189 found that the concentration of Zn in the retinal 
pigment epithelium (RPE) and choroid was 24% lower in patients suffering from AMD 
than in a control group.186,189  
As a result, imaging metals in biological samples including tissue specimens in human or 
animal models is a required tool in order to understand the behaviour of metals in age-
related diseases and find a treatment or a cure.278 
 
3.1.3 Application of bio imaging by LA-ICP-MS 
Several imaging techniques have been used to study biological specimens and provide 
spatially resolved data on trace elements.283 These include scanning electron microscopy 
(SEM)284, particle-induced X-ray emission (PIXE)285, secondary ion mass spectrometry 
(SIMS)74, transmission electron microscopy (TEM)286, synchrotron-radiation XRF287, 
synchrotron X-ray fluorescence (SXRF)186/ (µSXRF)288 microscopy, X- ray fluorescence 
microscopy (XFM)276,289, laser-induced breakdown spectroscopy (LIBS)290. Inductively 
coupled plasma–mass spectrometry (ICP– MS) has been widely utilized in the life 
sciences to determine trace elements in various sample types including tissues. The 
analytical capabilities of ICP–MS are extended through the use of laser ablation (LA) 
which allows for direct analysis of elements in solid samples.291 
LA-ICP-MS is among the most versatile and commonly used techniques owing to its low 
detection limits, multi-element capability, and wide dynamic range.292,293 Contiguous 
sampling across thin sections of a tissue sample enables construction of 2D colour maps 
showing the elemental distribution across the sample. Using the latest technology can 
achieve high spatial resolution, which makes it an ideal choice to study the small scale 
features involved in the retinal complex with respect to AMD diseases.3,294 The 
applications of such bio-imaging using LA-ICP-MS are well known and have included: 
imaging of Cu and Zn in liver173 and kidney295 sections, the mapping of Cu, Zn, Fe and 
Mn in sections of brain tissue,277,296,297,292 the detection of Cu, Zn and Fe in breast cancer 
tissue298, quantitative mapping of Mg, Ca, Fe, Zn, Cu, Mn in oral mucosa293, quantitative 
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mapping of Al, Ba, La, Sr  in  teeth299, quantitative mapping of Gd in articular cartilage300 
and quantitative mapping of Ca, Mg, Zn, Cu, and Pb in patients’ blood serum and arterial 
wall sections (blood vessels).301  In 2014 Konz et al. performed quantitative imaging of 
cryosectioned human eye lenses, revealing a homogeneous distribution of Zn in the 
lens.170 A subsequent study by this group imaged the retina and RPE cells, showing a 
preferential accumulation of Zn within the RPE compared to the retina and sclera.302  
Hence, LA-ICP-MS represents a useful tool for studying the distribution of metals and 
their relationship to specific disease states and treatments. However, comparison between 
small features of similar concentration is difficult, since perceptions of these structures 
are heavily influenced by the choice of false colour scheme used to display the data.303  
 
3.1.4 Aim of the study 
As discussed earlier, Zn appears to play a crucial role in many cellular metabolic 
pathways and is found in high concentrations within the retina/choroid complex. Also, it 
is known that Zn homeostasis at systemic and cellular levels is disrupted in AMD 
patients. Therefore, restoring normal Zn balance has been suggested to slow the 
development of the disease. The most commonly used approach to restore Zn 
homeostasis in humans is oral supplementation. However, clinical trials using Zn 
supplements have given conflicting outcomes due to the lack of understanding of how Zn 
levels affect the eye. 
 
Therefore, this chapter was focused on: 
 
• Investigation of the role of supplementation on the distribution of Zn across ocular 
compartments.  
• Utilisation of LA-ICP-MS to image the distribution of Zn across the retina and retinal 
pigment epithelium in aged rats that had received a conventional or supplemented 
diet with varying amounts of Zn and Zn+ Cu for an extended period.  
• Use of a novel data processing approach to examine the relative differences between 
Zn accumulation in these compartments and evaluation of its potential for use in 
future retinal imaging experiments. 
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3.2 Methodology 
3.2.1 LA-ICP-MS 
The instrumentation experiments were performed by using laser ablation system (UP-
213, Electro Scientific Industries, Cambridgeshire, UK) incorporating a neodymium - 
doped yttrium-aluminium-garnet (Nd:YAG) laser, coupled with sector-field ICP-MS 
instrument (Element 2XR, Thermo Scientific, Bremen, Germany). The laser system was 
fitted with a low volume teardrop shaped cell which has been described elsewhere.304 The 
sections are mounted on a suitable and movable support in order to ablate the sample 
directly. Helium was used as an ablation gas, at flow rate of 0.55 L/min, and Ar was used 
as a make-up gas introduced through a Y- piece between the cell and the injector, at a 
flow rate of 0.8 L/min. A certified reference material, NIST 611 glass (National Institute 
of Standards and Technology, Gaithersburg, USA) is often used for tuning the ICP 
parameters. The system was tuned on a daily basis before each experiment by ablating 
NIST 611 multi-element standard at a high repetition rate in a raster pattern to give a 
smooth signal. The signal generated from NIST 611 ablation was used to tune for 
optimum 238U signal intensity, besides maintaining the Th/U ratio to approximately 1 and 
the ThO/Th ratio lower than 1%.  
Tissue sections were ablated by performing a series of adjacent line scans across a section 
of the slide. Vertical adjacent lines were drawn through each section, covering the 
maximum y distance of the sample. The number of lines was varied according to the size 
of the section and consequently the line length and number of lines varied between 
sections. Optimised operating conditions for the imaging study are given in  Table 3.1. 
The laser ablation parameters applied for analysis, such as laser energy, repetition rate, 
spot size and scan speed, will be discussed in the following sections individually 
according to the type of the section. 
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Table 3.1 The ICP-MS measurement parameters 
ICP-MS operating parameters Value 
Analyte Zn66* 
Radio frequency (RF) power W 1250 
Cool gas (L min-1)  15.50 
Auxiliary gas flow (L min-1) 0.95 
Sample gas flow rate (L min-1) 1.02 
Torch X position (mm) 5.2 
 Torch Y position (mm) 3.8 
Torch Z position (mm) -2.10 
Resolution Low 
Mass window 10% 
Integration window  20% 
 Settling time (s) 0.001 
Sample time (s) 0.005** 
Samples per peak 50 
 Segment duration (s)   0.025** 
Scan type E-Scan 
Detection mode   Triple 
Integration type Average 
 
*In some sections Cu63 and Ca44 were measured. 
** Time was changed according to the size of ablating section and number of elements  
     measured. 
 
 
3.2.2 Data treatment 
LA-ICP-MS can generate very large amounts of data; more than common spreadsheet 
software can handle. In addition, comparing data from intra- or inter-laboratory tests is 
relatively complicated.  
Two dimensional images of the samples were created using mainly the software IGOR 
Pro (version 6.22 A, Wavemetrics, Oregon, USA). Iolite version 2.15 an add-on to IGOR 
Pro, non-commercial download software package (Melbourne Isotope Group, Melbourne, 
Australia) was used for data visualisation.  
91 
 
The software extracts data from ICP-MS in the conventional FIN2 format and transforms 
each data point into a colour coded pixel. Therefore, the colour profile of the resulting 
image represents the distribution of the corresponding elements across the sampled region. 
The raw data were also examined using IGOR Pro’s in-built Multipeak Fitting package.  
The data were baseline subtracted and peaks were fitted to the features in each line of 
data using the optimum fit type for each peak (from a choice of Gaussian, Lorenzian, log 
normal or exponentially modified Gaussian).  The height, peak areas, peak widths at the 
baseline and full width half maxima for the choroid, retina and RPE were directly 
exported into Excel for further processing.  The peak areas were used to calculate the 
RPE/retina Zn ratio for each sample, whilst the peak widths were used to determine the 
thickness of each feature. Although this software is able to process different datasets, 
regardless of the number of files involved, occasionally it freezes due to the massive 
number of files. 
 
3.2.3 Ethics and sample collection  
Ethical approval (08/H0721/12) was obtained from the research ethics and governance 
committee of Moorfields Eye Hospital. All the necessary safety precautions were taken 
before handling the samples. Slides for LA-ICP-MS were prepared and obtained from Dr 
Imre Lengyel's group at Institute of Ophthalmology, University College London, Bath 
Street, London, UK, EC1V 9EL. 
 
3.2.4 Collection and preparation of human sub-RPE sections 
Tissues were taken from human donated eye sections, UCL Institute of Ophthalmology 
and Moorfields Eye Hospital Eye Tissue Repository within 24 hours of death. Patients 
that had been diagnosed with CNV secondary to AMD were invited to take part in the 
study initially at the same Hospital. The thickness of the section was 20-30 µm and it was 
taken from underneath the RPE cell layer, so it includes: drusen, Bruch's membrane (BM) 
and choroid.  
The first initial test was performed on three human sub-RPE sections (D1, D2, and D3) 
to identify the level of Zn and Cu. The second test was performed on 4 other human 
retinal sections (D4, D5, D6 and D7) to identify the level of Zn and Ca. The typical 
operation parameters are summarized in Table 3.2.  
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Table 3.2  Laser instrument parameters for human RPE sections D1, D3, D4 and D6 
 
ESI UP-213 laser ablation parameters 
 
Repetition frequency: ............................. 5Hz 
Line length: ............................................ 475µm 
 
For section D1: 
Laser energy: .......................................... 30% 
Scan speed: ............................................. 15µm/s 
Spot size: ................................................ 15µm 
Line spacing:  ......................................... 3 µm 
Numbers of lines: ................................... 35 lines 
Fluence: .................................................. 3.35 J/cm2 
 
For section D3: 
Laser energy: .......................................... 30% 
Spot size: ................................................ 15µm 
Scan speed: ............................................. 15µm/s 
Line spacing:  ......................................... Zero 
Numbers of lines: ................................... 42 lines 
Fluence: .................................................. 2.17 J/cm2 
 
For section D4 & D6: 
Laser energy: .......................................... 35% 
Spot size: ................................................ 25µm 
Scan speed: ............................................. 25µm/s 
Line spacing:  ......................................... Zero 
Numbers of lines: ................................... 25 lines 
Fluence: .................................................. 2.60 J/cm2 
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3.2.5 Rat retinal sections preparation  
The work described in this section was carried out at the UCL Institute of Ophthalmology 
under the supervision of Dr Imre Lengyel. 
 
Rodent models replicate many features associated with pathological changes of the outer 
retina in AMD disease and can provide valuable information which can be transferred to 
human studies.40 
 
10 months old female Long Evans rats received supplemented drinking water for a period 
of 8 months as follows: 1) normal lab water; 2) +10 mg/L zinc carbonate 3) +10 mg/L 
zinc carbonate and + 0.25 mg/L copper carbonate.  The Cu was added to avoid the 
influence of Zn induced Cu deficiency. The bottles were carefully labelled with the type 
of water (Zn supplemented or lab) and changed every 3 days. 
Calculations were based on body weight. The dose of Zn was based upon the approximate 
supplementation levels equivalent to those given to human AMD patients in the Age-
Related Eye Disease Study (AREDS 1) to examine how this treatment affects the 
condition. The rats were sacrificed at 18 months; the eye was stored in 4% PFA at 4°C 
for embedding and sectioning. The resin embedded sections were carefully dissected and 
trimmed into approximately 1 cm x 0.5 cm blocks. Samples were typically cryosectioned 
to approximately 10 µm thick and mounted on DI water washed microscopic slides 
(Fisher Scientific, UK) and stored in a cool place. All slides were cut to approximately 
1.5 cm by 1.5 cm diameter to enable each slide to fit inside the laser cell chamber prior 
to analysis. A total of 41 retina sections were analysed; 27 of which were used for method 
development, two were excluded due to major tears in the section, whilst the remaining 
12 were used for the imaging study.    
  
3.2.6 Optimisation of initial test of rat retina imaging 
The laser camera is not a microscope and limited by the camera's capabilities, so it 
provides pictures of relatively low resolution. In fact, high resolution pictures are 
probably needed and initially they were not available. Therefore, each section was 
marked and observed under the microscope (Swift Instruments International, US) and the 
microscope camera was used to capture a picture of the whole section of the retina 
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through the lens of the microscope. Several optimisation experiments were performed on 
the rat retinal sections which are summarized in the following points: 
1- Before any experiment the glass microscopic slides were tested, followed by another 
attempt using superfrost ultra plus microscopic slide (Thermo Superfrost, Thermo 
Scientific, UK), plastic/glass cover slip and membrane. 
2- Three selected slides were obtained from the UCL Institute of Ophthalmology to 
perform a preliminary test on the rat tissues. Section number 4.1 is a control slide, 9.3 
slide was rat fed with Zn diet and for slide 14.1 the rat was on Zn and Cu diet. Initially, 
only Zn was measured in all slides. An example of the optimisation of the operation 
conditions on a small and large section is summarized in Table 3.3. 
 
3- Another 12 slides were obtained from the same block to carry out further tests on the 
rat retinal tissue. In the slides where the rat was fed on Cu and Zn, both elements were 
measured. While determining two elements, some of the ICP method was slightly 
changed as a sample time of 0.002 s was used, which resulted in segment duration of 
0.02 s. In this experiment, a bigger section was ablated to improve the laser images 
visualisation. Table 3.4 and Table 3.5 illustrate the slides description and numbers 
and general LA operation parameters, respectively.  
 
4- The experimental tests were carried out for an additional 12 slides of a very thin 
section (less than 5µm) with the parameters of ~5 J cm-2 laser fluence, 5 Hz repetition 
frequency, 55 μm spot size and 55 μm s-1 scan speed, and zero spacing between 
ablated lines. As ablation requires a very long time, in this test the number of lines 
was decreased to 50 to enable ablation of 4 sections on the same day for more reliable 
comparison between non-fed and fed rat. In order to avoid signal intensity drop during 
lengthy analysis, the instrument was tuned before, after and between each section. 
 
5- A brief test was performed and two sections of the retina were scanned. Almost the 
same previous operating parameters were used; however, the repetition frequency 
was increased to 10 Hz in order to provide a smooth signal. 
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Table 3.3 Example of Laser instrument parameters for rat RPE sections 4.1, 9.3, and 14.1 
 
ESI UP-213 laser ablation parameters 
 
Repetition frequency: ............................. 5 Hz 
 
Small section: 
Laser energy: .......................................... 35% 
Scan speed: ............................................. 25 µm/s 
Spot size: ................................................ 25 µm 
Line spacing:  ......................................... Zero 
Numbers of lines: ................................... 25 lines 
Fluence: .................................................. 2.4 J/cm2 
Line length ............................................. 475 µm 
 
Large section: 
Laser energy: .......................................... 30% 
Spot size: ................................................ 55 µm 
Scan speed: ............................................. 55 µm/s 
Line spacing:  ......................................... Zero 
Numbers of lines: ................................... 80 lines 
Fluence: .................................................. 2.63 J/cm2 
Line length ............................................. 1.00 mm 
 
 
 
Table 3.4 Names and numbers of the rat retina slides 
Slide name Slide number 
Control 
2.1 
3.1 
4.1 
5.3 
Rat on Zn diet 
6.1 
7.1 
9.3 
10.2 
Rat on Zn and Cu diet 
11.3 
12.3 
14.1 
15.1 
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Table 3.5 Laser instrument parameters for 12 slides of rat RPE sections 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.7 Recommended setup and final experiment for rat retina imaging 
Final experiments were performed on 14 rat retina sections of which two samples were 
unsuccessful due to some unusual structures in the slides. Low laser energy was chosen 
in this experiment to prevent the laser from penetrating the glass slide and thus avoiding 
Zn signal interferences with the sample as discussed earlier. Table 3.6 summarizes the 
final laser instrument parameters for rat retina sections. Vertical adjacent lines were 
drawn throughout the section, covering the maximum y distance of the sample. The 
number of lines were varied according to the size of the section and consequently the line 
length is different for each section. As the feature of the retina is faded and difficult to 
focus on, the line was duplicated and refocused after every 10 lines to ensure total 
coverage of the sample in the x-axis with optimal focusing (see Figure 3.2, A). The 
spacing between each line was equal to zero as the energy level is low. Neural retina is a 
tissue with multiple concentric layers, the total thickness is around 192 µm305, excluding 
the choroid and sclera, depending on the rat type. Representative cross-section of the 
neural rat retina and retinal pigment epithelium (RPE) showing normal 
morphology305,306,307,308,309,310 and retinal layers with  thickness are shown in Figure 3.2 
(B). 
 
ESI UP-213 laser ablation parameters 
 
Repetition frequency: ............................. 5 Hz 
 
For the 12 slides: 
Laser energy: .......................................... 35% 
Scan speed: ............................................. 55 µm/s 
Spot size: ................................................ 55 µm 
Line spacing:  ......................................... Zero 
Range of lines: ....................................... (70-101) lines 
Range of Fluence: .................................. (3.60-4.51) J/cm2 
Range of line length ............................... (0.866-2.29) mm 
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Figure 3.2 (A) Schematic representation of the laser scan direction during ablation and 
the position of RPE and retina in microscopical rat retina section (4×). (B) Histological 
section of normal rat retina (paraffin embedment, hematoxylin stain) showing the 
thickness of the rat cellular organization layers of the retina/RPE and choroid complex: 
Bruch’s membrane (BM); retinal pigment epithelium (RPE); outer segment (OS); inner 
segment (IS) outer nuclear layer (ONL); outer plexiform layer (OPL) inner nuclear layer 
(INL); inner plexiform layer (IPL), ganglion cell layer (GC) and optic nerve fibre (ONF). 
Arrows (→) indicate blood vessels in the choroid. The micropscopic image (A) obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology and Figure (B) reproduced  with 
permission from S.J  Fliesler et al., 2010, licenced by ©American Society for 
Biochemistry and Molecular Biology.311  
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 Table 3.6 Typical Laser instrument parameters for 12 rat retina sections and one human 
retina section 
ESI UP-213 laser ablation parameters 
 
Repetition frequency .............................. 10 Hz 
Laser energy ........................................... 30% 
Scan speed .............................................. 25 µm/s 
Spot size ................................................. 25 µm 
Line spacing  .......................................... Zero 
Range of lines......................................... (160-250) lines 
Fluence: 
6.1 (Zn diet)............................................ 1.43 J/cm2 
4.1(control) ............................................. 1.17 J/cm2 
12.1(Zn& Cu diet) .................................. 1.44 J/cm2 
10.2 (Zn diet).......................................... 1.37 J/cm2 
5.3 (Control) ........................................... 1.35 J/cm2 
11.3 (Zn& Cu diet) ................................. 1.14 J/cm2 
3.1 (Control) ........................................... 1.91 J/cm2 
9.3 (Zn diet)............................................ 1.17 J/cm2 
2.1 (Control) ........................................... 1.23 J/cm2 
7.1 (Zn diet)............................................ 1.20 J/cm2 
15.1 (Zn& Cu diet) ................................. 1.61 J/cm2 
14.1 (Zn& Cu diet) ................................. 1.17 J/cm2 
Human retina  ......................................... 1.26 J/cm2 
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3.3 Results and discussion 
3.3.1 Blank test and contamination 
Zinc is a vital and ubiquitous element present in trace amounts in a large amount of 
routine lab equipment. Zinc contamination could increase from unpredicted sources; it is 
important that all parts and equipment used in the experimental analysis are tested for the 
possible presence of contaminants.312 Since the glass microscope slides contained 
background levels of Zn, the laser fluence required careful optimisation to ensure 
complete ablation through the sections, whilst minimising penetration of the glass slide.   
 Sample gas was tested alone and the Zn66 signal was relatively high. The gaseous 
interferences involved in the ablation could lead to broadening of the signal generated 
when the analyte is transported through the tube. It has been reported that using helium 
as a carrier decreases the peak width, as does minimizing the ablation cell volume and 
the length and diameter of the transfer tube.313  
Several blank tests were performed on different microscopic slides to check the level of 
Zn content in the glass. Two different laser patterns were chosen to scan the blank slide: 
either applying lines (spot size 15 µm, repetition frequency 5 Hz) or drilling down using 
50 shots on the same area, repetition frequency 1 Hz and spot size 15 µm. The laser 
energy was set up on 60% in both cases. A clean/blank microscopic glass slide was 
ablated and showed that the slide itself contains unexpectedly high level of Zn due to its 
presence in nature. Figure 3.3 illustrates the signal intensity of Zn in the ablated glass 
slide with 60% energy.  Accordingly, to minimise ablation of the glass, the energy has 
been reduced and tested at 50%, 40%, 30% and 25%.  
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Figure 3.3 An example of time- resolved peaks showing Zn66 signal intensity of the blank 
glass slide at laser energy of 60%. 
 
Attempts were carried out on alternative material slides including: superfrost ultra plus 
microscopic slide, glass coverslip, plastic sheet slides and Millicell membrane to find an 
appropriate slide that contained less Zn. It was very difficult to focus on the plastic sheet 
slide and white membrane. Due to their low thickness, these were fixed to a glass slide 
using double sided sellotape to prevent them from moving during ablation. 
The signal intensity of Zn ranged between 2000-3000 cps for the different ablation energy 
and that indicated either low background or, more likely, that limited ablation of the slide 
had occurred due to the focussing issues described above. The glass cover slip produced 
similar results to a glass microscope slide, whereas, the superfrost ultra plus microscopic 
slide resulted in by far the highest signal intensity, reaching up to 2×10-6 cps. Overall, the 
signal intensity in all glass slides was decreased by decreasing the laser energy. Besides 
these slides, PTFE/ Teflon coated microscope slides or Zn free slides were tried but they 
were costly. 
Another solution to minimise ablation of a microscopic glass slide is to mount a coating 
on the slide to act as a barrier between the sample and the glass. A clear nail polish (Miss 
Beauty No.1) which is available commercially was used by Craig314 as it is hardwearing 
and adheres strongly to most surfaces.  It was noted that Zn is not present in the content 
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of the nail polish used.  In addition, it was postulated that the nail polish layer coating 
would potentially prevent the laser from ablating through the glass even at full power 
(Sejal Odedra, MSc research project, Loughborough University, 2015).  
The blank results were sent to UCL Institute of Ophthalmology to enable the tissues to 
be mounted on the most appropriate slide. However, it was agreed to use normal 
microscopic slide washed by deionized water as long as the Zn signal was differentiated 
between the resin used to embed the sections and the retina. After cutting the slide, a 
compressed air duster can be sprayed on the surface of the slide before analysis to remove 
any dust or contamination. 
 
 
3.3.2 Optimisation of drusen test 
Several age-related disorders of the central nervous system are characterized by 
extracellular protein accumulation and deposition, frequently interfered by metals such 
as Zn, Ca, Fe and Cu.315 These metals which become trapped within Bruch’s Membrane 
(BM) affect its structure and function with adverse consequences such as oxidative stress 
and inflammation.40  Although Ca, Fe and Cu have been implicated as leading causes of 
AMD pathology, the concentration and distribution of these metals in sub-RPE deposits 
was not known.315 Drusen aggregation appears naturally with age and is able to push into 
the neural retina after distorting and disrupting through the RPE.316 The composition of 
sub-RPE deposits is very complex as they contain abundant amounts of proteins and 
lipids in addition to unusual and high concentrations of Zn.317 This is suggested to trigger 
the oligomerization of proteins with Zn and is directly implicated in the formation and 
accumulation of drusen and thus likely to be a crucial factor in AMD pathogenesis. In 
2014, Lengyel and Flin et al.315 determined the concentration of Ca, Cu and Fe and 
compared these with Zn in sub-RPE deposits from an 86-year-old donor eye with 
diagnosis of early AMD. They found that Zn and Ca regularly existed in all deposits but 
reached the highest concentration in soft drusen.315 
Seven human retinal sections obtained from the elderly donor showed deposits in the 
macula, and the microscopic images were obtained from UCL Institute of Ophthalmology 
as illustrated in Figure 3.4. Attempts to scan two sections were not successful due to 
instrumentation issues. Adjacent line scans were performed initially over  a 475 µm × 
630 µm area of the slide using LA-ICP-MS to analyse the general distribution of Zn and 
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Zn/Cu in drusen in a small section of the RPE tissue as shown in Figure 3.5 and Figure 
3.6 respectively. These clearly show regions of high Zn intensity, which seem to correlate 
to features in the microscope image.  In addition, a difference in signal intensity between 
the tissue itself and the blank slide is also shown. Figure 3.6 shows dual analysis of Cu 
and Zn, however, the image does not appear as high in intensity as Figure 3.5. The reason 
is that the instrument used for this analysis is not designed to allow simultaneous multi-
element detection. Thus, the instrument switched rapidly between measurement of the 
two different elements (in a few ms), but certainly this switch means less time is spent 
measuring each element, and this resulted in missing a key feature in the Zn signal, whilst 
measuring Cu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Microscopic image of 40× magnification of human retinal section (obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology). The black deposits are drusen 
and the small yellow spots inside the drusen are calcium deposits. 
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Figure 3.5 Top: microscopic image of a 475 × 630 µm section underside of human retina 
tissue (D1), obtained using the built-in microscope on the UP-213 laser ablation system. 
Bottom: LA-ICP-MS image of the same section, showing the distribution of Zn in drusen. 
Complete laser parameters are given in Table 3.2. The edge of the section seems be 
contaminated as it contains a  high level of Zn.(possibly from the glass cutter used to cut 
the slide) 
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Figure 3.6 Left: microscopic images of a 475 × 630 µm section of underside of human 
retina tissue (D3) obtained using the built-in microscope on the UP-213 laser ablation 
system. Right: LA-ICP-MS images of the same section, showing the distribution of Zn 
(top) and Cu (bottom) in drusen. Complete laser parameters are given in Table 3.2. 
 
As mentioned earlier, Ca is highly enriched in drusen in addition to Zn.315 It had been 
expected to find Ca in sub-RPE deposits, as calcification had been reported in relation to 
aging and AMD318, 319 and calcium is the most abundant metal in the cornea followed by 
Zn.320 
Further tests were performed on the human RPE sections that contain drusen. The 
following Figures illustrate the distribution of Ca in (Figure 3.7) and Zn in (Figure 3.8) 
in a small section of the underside of the RPE tissue. As can be seen from section D4, the 
regions show a high Ca intensity, which seem to correlate to features in the microscope 
image.  25 lines were not enough for scanning throughout the section to create a good 
image, and that led to pixelated images. Section D4 is lower in resolution than section 
D3. Owing to the lack of human retinal sections, the test was directed to rat retinal 
imaging instead of drusen test as discussed in the sections below. In general, it is 
important to commence similar studies on isolated sub-RPE deposits from donor eyes of 
varied ethnic background. 
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Figure 3.7 (A) Microscopic image of a 475 × 625µm section of underside of human 
retina tissue (D4), obtained using the built-in microscope on the UP-213 laser ablation 
system. (B) LA-ICP-MS image of the same section, showing the distribution of calcium 
in drusen. Complete laser parameters are given in Table 3.2. 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 (A) Microscopic image of a 475 × 625µm section of underside of human 
retina tissue (D6) obtained using the built-in microscope on the UP-213 laser ablation 
system. (B) LA-ICP-MS images of the same section, showing the distribution of Zn in 
drusen. Complete laser parameters are given in Table 3.2. 
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3.3.3 Optimisation of small and large rat retina sections 
Several tests were carried out on small and large rat retina sections. In the small sections, 
25 lines were scanned with 25 µm spot size; however, the section was blurry and did not 
exhibit clarity and good quality. Furthermore, such small sections are not necessarily 
representative of the entire tissue.  Therefore, an additional 80 lines were scanned over 
4.4 mm × 1.0mm area of the slide. Figure 3.9 and  Figure 3.10 illustrate an example of 
small and large rat retina imaging (the microscopic images were supplied by UCL 
Institute of Ophthalmology). In the large imaging section, the contrast between certain 
sections and the surrounding retina tissue can be observed, and it also appeared clearer 
than the small one.  As the initial experiments showed promising results, further 
investigations were carried out on a large scale.  
 
 
 
 
 
 
Figure 3.9 (A) Microscopic image of a 475 × 625µm section of rat retina tissue, obtained 
using the built- in microscope on the UP-213 laser ablation system. 
(B) LA-ICP-MS images of the same section, showing the distribution of Zn. The rat was 
on Zn diet. Complete laser parameters are given in Table 3.3. 
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Figure 3.10 Right: Microscopic image of 5× magnifications of a section of rat retina 
tissue (obtained from Dr Imre Lengyel, UCL Institute of Ophthalmology). left: LA-ICP-
MS image showing the distribution of Zn. (A) Control (B) Rat on Zn diet and (C) Rat on 
Zn & Cu diet. The yellow spots in images A&B were dust contamination that contain 
high level of Zn. The colour scale depicts the signal intensity in counts per second (cps). 
Complete laser parameters are given in Table 3.3. 
 
 
3.3.4 Second optimisation test and data processing 
12 slides were scanned in large retina sections and the levels of Zn and Cu were measured. 
Some of the images were successfully constructed but others showed very low quality. 
Figure 3.11 shows an example of successful laser image results. The resin did not cover 
the whole slide, thus the scan ablated the glass slide and both edges gave a high Zn signal. 
Different issues were encountered during the recording of these images, in particular: a 
bug in the software which prevented the generation of FIN2 files, the RF generator 
suddenly switching off after the full scan, some high oxide ratios and difficulty of 
focusing on such thin and unclear features of the retinal section. As the laser techniques 
will damage the sample to an extent and some sections did not generate data due to these 
issues, the comparisons between the sections could not be completed, and ablation of new 
retinal sections was required. 
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Figure 3.11 An example of LA-ICP-MS image of a 1.8×5.6 mm section of retina tissue 
from a rat on a Zn diet (6.1) , showing the distribution of Zn.The colour scale describes 
the signal intensity in counts per second (cps). Complete laser parameters are given in 
Table 3.5.  
 
 
3.3.5 Third optimisation test  
12 sections were scanned, and in this experiment 4 sections were run on the same day for 
more reliable comparison between supplemented and non-supplemented rat. As can be 
seen in Figure 3.12 both Zn and Cu were mapped in control section and Zn & Cu 
supplemented rat section. In addition, Zn was measured in the section where the rat was 
on Zn diet and control. The signal intensity of the Cu is very low and can almost be 
discounted; whereas the Zn signal is higher. The tear-drop shaped ablation cell used for 
the analysis has previously been reported to produce peak widths of less than a second 
for a single laser shot.304  Single detector sector-field instruments, such as the one used in 
this study, are not ideal for multi-element analysis of such transient signals due to the 
slow and sequential rate at which they detect each isotope. In other words, whilst the 
instrument was measuring Zn, data for Cu was not acquired (and vice-versa). 
 The retinas in some sections were missing, as the series of adjacent line scans were not 
long enough to cover the detached retina. This is because the feature of the retina was not 
clear while drawing the lines due to the relatively low resolution image and low resolution 
of LA camera especially if the retina was detached from the RPE. The system was re-
tuned between each section and signal intensities of Th and U were monitored. The signal 
variation of Th and U between each section ranged between (14%-4%) and (10%-7%), 
respectively. 
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The preliminary data processing was to select data from one-line scan per image and 
represent that in a graph as illustrated in Figure 3.13 (control). The first peak shows the 
retina and the second shows the RPE. To compare the signal intensity of both peaks 
between control and test sample would be inaccurate, however, using the relative ratios 
between retina and RPE enables comparison between different sections. The data were 
selected from each peak and manually summed. In the control section, the sum of the 
signal intensity of the retina, resin and RPE are 1.63E+05, 3.04E+05 and 3.02E+05. The ratio 
of the RPE/Retina is 1.86 and RPE/resin 1.00 and retina/resin 0.54. In the other Zn 
supplemented rat section, the ratio of the RPE/Retina is 1.16. 
Repeating the retina imaging was required for reliable comparison. The present data was 
based on only one line, which is not representative of the whole section.  Therefore, 
subsequent improvements include the following: Scanning various numbers of lines 
throughout the section, drawing a long line in a large section to cover the RPE and the 
retina in the imaging especially if they are detached. Cu showed very low signal and 
switching swiftly between two elements led to reduction in analysis time and thus signal 
intensity. Therefore, the focus was switched to Zn alone for the imaging study.   
 
The test was performed on retinal sections with 10 Hz repetition frequency to provide a 
smooth signal. As fewer lines were scanned, a blurred image was generated. Large 
ablation section with 10 Hz repetition rate will be used in the final experiment. 
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Figure 3.12 Example of 4 LA-ICP-MS rat retina images recorded on the same day, with 
the signal intensity of Th & U on NIST glass between each section. A- LA-ICP-MS image 
of a 2.8×0.866 mm section of rat retina tissue, showing the distribution of Zn (I) and Cu 
(II) in control slide (5.3). B- LA-ICP-MS image of a 2.8×1.05 mm section of rat retina 
tissue, showing the distribution of Zn(I) and Cu (II), the rat was on Zn& Cu diet (14.1). 
C- LA-ICP-MS image of a 2.8× 0.838 mm section of rat retina tissue, showing the 
distribution of Zn in control slide (5.3). D- LA-ICP-MS image of a 2.8×0.895 mm section 
of rat retina tissue, showing the distribution of Zn. The rat was on Zn diet (10.2). The 
colour scale depicts the signal intensity in counts per second (cps). Complete laser 
parameters are summarised in Table 3.5.  
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Figure 3.13 LA-ICP-MS imaging of a section of retina tissue (control sample). Top panel: 
LA-ICP-MS image of the 2.8 x 0.84 mm section showing the distribution of Zn66 (signal 
intensity, cps).  Middle panel: the raw signal intensity for one line of the above image 
(arrow indicates location and scan direction).  Bottom panel: Smoothing of the above data 
using a 5 point moving average. The colour scale depicts the signal intensity in counts 
per second (cps). 
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3.3.6 Final and recommended procedure for rat retina sections 
It is a challenging task to determine small features in specific areas in the eye that remain 
biologically relevant but need to be large enough to allow the elements to be detected. 
The choice of colour scheme used to provide an accurate representation of the data can 
have a powerful influence on the apparent structure presented within the data. A colour 
scheme is a series of colours that are presented in a certain colour space with 
corresponding values. This can allow each value within the data to be replaced or mapped 
effectively with its allocated colour for display. A grayscale is the most common, simplest 
and cheapest colour scheme available for publication. However, the limitation of this is 
the ability of the human eye to distinguish between colours, which is influenced by 
brightness of surrounding regions, and that effect is known as simultaneous contrast. 
Therefore, adding colours is beneficial because it raises the dynamic range of a colour 
pattern.303,321 Although Rainbow colour scheme (represented in Figure 3.13 as an 
example) is by far the most popular and frequently used in scientific visualisation 
(appearing in 48 of the articles on MS imaging examined by Bunch and colleagues), they 
could result in a significantly misleading representation of the data.303 While there is no 
preferable single colour scheme that should be used, human perception of colours should 
be taken into consideration and avoiding a large number of objects is also recommended 
as it may have an adverse impact on data representation.303 A black-red-yellow colour 
scheme with 5 colour gradients was applied for this data set.  Studies have shown that 
people intuitively identify red and yellow colours as high values322, thus this colour 
scheme presented a clear contrast of high intensity features against the dark, low signal 
intensity background.   
Twelve  rat retina sections were successfully imaged to determine and compare the 
distribution of Zn in the retina and the RPE. High resolution images are extremely 
important for clear visualization as well as for matching anatomical features. Thus, these 
were acquired from UCL Institute of Ophthalmology to enable correlation between 
features in the LA images and the microscopic pictures. An example of 3 different 
microscopic and LA-ICP-MS images are shown in Figure 3.14 , Figure 3.15 and Figure 
3.16 showing the qualitative Zn distribution in control slide (2.1), Rat on Zn diet (7.1) 
and rat on Zn and Cu diet (15.1), respectively. The remaining images are presented in  
chapter 8 (appendix 3). The microscopic images are not always identical with the LA-
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ICP-MS image as they are two different sections. The purpose of the stained image is to 
represent the features of the retina clearly and the non-stained sections were ablated to 
avoid the contamination of Zn during staining. Therefore, a slight difference will be 
noticed due to the different sectioning. Comparison of the anatomical details in the visible 
microscopic images of the rat sections with the Zn distribution in the ICP-MS images 
shows good correlation, illustrating the usefulness of LA-ICP-MS in the characterisation 
of the metalloprotein distribution within the structure shown.  
 
As can be inferred from the rat retina images (Figure 3.14-3.16 and remaining images in 
the appendix) there is no specific and consistent pattern that all control and fed rat  
sections follow. However, preferential accumulation of Zn in the RPE, compared to the 
retina, was clearly observed for all sections analysed.  An apparent narrowing of the Zn 
distribution in the RPE in the Zn fed rats was observed. The layers of the retina are not 
very clear because of the reduction of the signal and that will be discussed in the future 
work. 
 The laser energy was chosen to be 30% and the ablation was achieved on a large section 
(exact dimensions are described in Figure 3.14, Figure 3.15 and Figure 3.16). At this 
energy level, the top of the slide surface effectively has just been skimmed without 
ablating the glass (slight visible ablation craters seen).  This led to a noticeable difference 
in signal between the samples and the blank areas surrounding the samples. The concern 
of ablation of a large section is the lengthy acquisition time. Various generations of mass 
spectrometers especially sector-field instruments were not designed to accomplish short 
duration signals.323 For instance, imaging Zn only across a 6×2.5 mm tissue section with 
a spot size of 25 µm might take up to 8-10 hours. Therefore, only two sections could be 
run per day. Other researchers have recently developed improvements to increase the 
speed of the analysis, through design of fast-washout LA instrumentation.324 To evaluate 
the instrument drift, 3 lines were scanned on NIST glass before and after each sample. 
The intra-day response was approximately 10% variation, while the inter-day variation 
showed around 12%. 
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Figure 3.14 High resolution imaging of a section of rat retina tissue. Top: Microscopic 
image of a 4.0×1.3 mm section of rat retina tissue (obtained from Dr Imre Lengyel, UCL 
Institute of Ophthalmology). Bottom: corresponding LA-ICP-MS image showing the 
distribution of Zn in control slide (2.1). The colour scale depicts the signal intensity in 
counts per second (cps). Complete laser parameters are given in Table 3.6. 
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Figure 3.15 High resolution imaging of a section of rat retina tissue. Top: Microscopic 
image of a 4.50×1.88 mm section of rat retina tissue, (obtained from Dr Imre Lengyel, 
UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-MS image showing 
the distribution of Zn in rat on Zn diet (slide 7.1). The colour scale depicts the signal 
intensity in counts per second (cps). Complete laser parameters are given in Table 3.6. 
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Figure 3.16 High resolution imaging of a section of rat retina tissue. Top: Microscopic 
image of a 6.25 ×2.52 mm section of rat retina tissue, (obtained from Dr Imre Lengyel, 
UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-MS image showing 
the distribution of Zn in rat on Zn & Cu diet (slide 14.1). The colour scale depicts the 
signal intensity in counts per second (cps). Complete laser parameters are given in Table 
3.6. 
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3.3.7 Final data processing 
As discussed earlier, the aim of the current work was to achieve a reliable comparison 
between the retina and RPE within each section in order to identify changes in the 
distribution of Zn between rats receiving supplementation versus those in the control 
group. In order to compensate for any intra and inter-day variation in instrumental 
sensitivity, relative ratio of the peak area has been applied instead of absolute signal for 
reliable comparisons. Twenty ablated lines were randomly selected from each section for 
data processing. The data files acquired in each experiment represented the signal 
intensity in (FIN2) format. Initially, the raw data produced from each scanned line was 
plotted and the areas of RPE and retina were selected manually by selecting visually the 
start and end of each peak, then calculating the sum of the signals between these points. 
This time-consuming method was found to introduce variance depending on how the start 
and end points of each region were manually defined. Subsequently, this method was 
replaced by a Macro programme, which generated laser images. The corresponding area 
of RPE/Retina was selected to produce the time plot and calculate the sum. However, this 
procedure was still not practical, as it produced poor images and was time consuming. 
Various attempts have been applied on IGOR pro software, by drawing a square manually 
on each produced peak and then the software generates a report with peak area 
results. Clearly this procedure was not satisfactory as the results produced may vary 
depending on how the peak was manually defined. Finally, easy and fast data analysis 
was performed by using Multi Peak Fitting 2 package in IGOR Pro (Wavemetrics, USA). 
IGOR Pro’s Multipeak Fitting package was employed to enable automated identification 
of the retina and RPE and to obtain the integrated signal areas for these features. A 
Gaussian fit was found to be optimal for modelling all the features identified. A typical 
workflow for processing the recorded data into a suitable format for image operation 
programs is represented in Figure 3.17 and the key for the Figure described in Table 3.7. 
Figure 3.18, Figure 3.19 and Figure 3.20 illustrate examples of the fitted data from one-
line scan per image and demonstrate how Gaussian peaks can be fitted to the data to 
obtain the integrated signal areas for the retina and the RPE. The baseline noise was 
subtracted from all data. The peak area of RPE and retina were selected for individual 
line and then the relative ratio of RPE/retina was applied for the 20 lines per section. 
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Figure 3.17 Typical workflow for imaging by LA-ICP-MS and data processing. the key for the Figure described in Table 3.7. 
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Table 3.7 Key for Figure 3.17 explaining data processing steps 
Images workflow 
A 
Each single line of ablation produced individual data file (a comma separated 
value (.csv) file format), containing the signal intensity (CPS) data per unit point 
of time.  
B 
The folders of data of each experiment (eg. 200 lines) were uploaded into   
IGOR Pro programme and generated 200 time-resolved peaks. 
C Then the data was processed and the images were created 
Gaussian workflow 
D 
Each data file (A) generated from each line were combined into one Excel sheet, 
using the app (LA-ICP-MS RDP v0.17, Reid-IT Limited, Loughborough UK)  
E 
The combined Excel spread sheet was uploaded into Iolite add-on to calculate 
Gaussian peak of selected lines 
F 
Each Gaussian peak produced spread sheet of the average of the peak area, 
height and width 
G 
All spread sheets for the 20 line/ per experiment were combined for final 
calculation in one spread sheet using the app (LA-ICP-MS RDP v0.17, Reid-IT 
Limited, Loughborough UK) 
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Figure 3.18 Top: LA-ICP-MS image, showing the distribution of Zn66 (cps) in a 4.53×1.34 
mm section of rat retina tissue (control-4.1).  Bottom: Example data for one ablated line from 
each image (arrow in the corresponding image indicates the location and scan direction of 
the line).  Gaussian peaks were fitted to the choroid (peak 0) RPE (peak 1) and retina (peak 
2). Complete laser parameters are given in Table 3.6. 
 
  
≥10 
8 
0 
4 
6 
2 
Zn
66
 
×10
3
cps 
Retina 
RPE 0.4 mm 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Top: LA-ICP-MS image, showing the distribution of Zn66 (cps) in a 4.50×1.41 
mm section of rat retina tissue (rat fed with Zn- 9.3). Bottom: Example data for one ablated 
line from each image (arrow in the corresponding image indicates the location and scan 
direction of the line).  Gaussian peaks were fitted to the choroid (peak 0) RPE (peak 1) and 
retina (peak 2). Complete laser parameters are given in Table 3.6. 
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Figure 3.20 Top: LA-ICP-MS image, showing the distribution of Zn66 (cps) in a 5.00×1.39 
mm section of rat retina tissue (rat fed with Zn& Cu diet-11.3). Bottom: Example data for 
one ablated line from each image (arrow in the corresponding image indicates the location 
and scan direction of the line).  Gaussian peaks were fitted to the RPE (peak 0) and retina 
(peak 1). Complete laser parameters are given in Table 3.6. 
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The total average of the relative ratio of Zn RPE/retina peaks area and the standard deviation 
for the 12 rat retina sections are summarized in Table 3.8. Overall, the highest average 
RPE/retina ratio of 1.91 was observed for the group that received combined Zn and Cu 
supplementation, compared to an average ratio of 1.51 for rats receiving Zn supplementation 
alone and 1.52 for the control group (Figure 3.21). However, significant variability was seen 
between different locations within the same sample (average within sample RSD of 33%) 
and between the 4 rats analysed in each group (intra-group RSD of 30, 18 and 34 % for the 
control, Zn and Zn+Cu groups, respectively). Therefore, the difference between the three 
differentially fed rat groups was not statistically significant for the relatively small group of 
twelve rats investigated here. The association between the three groups of rats was 
investigated using a one-way analysis of variance (ANOVA).  P-values appeared higher than 
0.10 (ANOVA, α=0.05, p=0.44), suggesting that the three groups of rats are not significantly 
different. 
 
Table 3.8 The average of the relative ratio of the Zn peak area of RPE and retina* 
  
* The relative ratio of Zn in RPE/retina is expressed as a mean and standard deviation 
(STDV) of 20 scanned lines  
Sample 
description 
Sample 
number 
RPE/Retina  
area ratio 
 
STDV 
 
RSD % 
Control 5.3 0.98 0.42 42 
Control 4.1 1.39 0.49 35 
Control 2.1 1.65 0.66 40 
Control 3.1 2.05 0.64 30 
Zn fed rat 7.1 1.30 0.41 31 
Zn fed rat 9.3 1.32 0.41 31 
Zn fed rat 10.2 1.52 0.35 23 
Zn fed rat 6.1 1.90 0.61 32 
Zn+ Cu fed rat 15.1 1.08 0.22 20 
Zn+ Cu fed rat 14.1 1.75 0.84 48 
Zn+ Cu fed rat 11.3 2.20 0.71 32 
Zn+ Cu fed rat 12.1 2.60 0.9 34 
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Figure 3.21 Comparisons between the RPE/retina Zn level in 4 sections of control and Zn 
fed rat and Zn+ Cu Fed rat. Sections are presented in order of increasing RPE/retina Zn peak 
area ratio. Error bars represent the standard error of the mean, n=20 scanned lines. 
 
The widths of the fitted peaks were used to compare the thickness of the imaged features. 
Figure 3.22 shows the variation in the width of the RPE and retina peaks for the three 
conditions studied. It is clear that retinal peak width is far higher than RPE. The thickness of 
the retina was approximately equivalent for all samples, but a thinning of the RPE was 
observed for the supplemented rats. As mentioned earlier, the data set narrowing was seen 
in the RPE of the Zn fed rat, therefore, the retina and RPE peak width of the control and fed 
rat were calculated and compared. Based on one-way ANOVA (p<0.001), the control peak 
width of RPE was found higher than fed rat. These data are in good  agreement with earlier  
reported findings189 which indicated that Zn supplementation may be linked with a reduced 
Zn level in the RPE-Choroid complex in AMD patients. Evaluating the thickness of the retina 
is essential to help in the signs and diagnoses of some ocular and neurological disease.250,325  
Alamouti and Funk reported that both retinal and nerve fibre layer thickness are significantly 
reduced with age.326 The reason for this reduction is due to the death of retinal neuronal 
ganglion cells and the loss of axonal cells in the optic nerve.325 A recent study in 2017 found 
that age, ethnicity, and smoking status also play an important role in RPE-BM thickness 
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variation.327 Further investigation is needed as this finding has important implications in the 
understanding of the Zn function within the retina.  
 
 
Figure 3.22 Comparison between the Retina and RPE Zn peak width in control and fed rat. 
Peak width presents the full width at half maximum (FWHM). Error bars depict the standard 
error of the mean, n=60 lines. 
 
3.3.8 Further application used for imaging  
3.3.8.1 Rat section  
D-Plot is an interface software designed for scientists, engineers, and other technical workers 
who are interested in creating presentation-quality X-Y plots and/or contour plots of data. D-
Plot can also produce a waterfall plot, a 3D bar chart, a simple wireframe mesh and D-Plot 
graphs can manipulate 2D and 3D data from a variety of sources in many different formats. 
The images that were produced before by IGOR Pro software, were applied to another 
professional imaging application called D-plot. An example of one rat retina section 
processed by D-plot is represented in Figure 3.23. 
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Figure 3.23 An example of one LA-ICP-MS rat retina section processed by D-Plot imaging 
programme, showing the distribution of Zn. The colour scale depicts the signal intensity in 
counts per second (cps). Complete laser parameters are given in Table 3.5. 
 
 
3.3.8.2 Comparisons between human and rat sections and enhanced data processing 
The structure of the eye is extremely complex and organized, indicating the high degree of 
specialty that is necessitated to maintain its function. Representative microscopic section 
distributed into distinct histological layers of the normal human retina with the               
thickness 328,329,330,331,327,332,333 are shown in Figure 3.24 using optical coherence tomography 
(OCT) and spectral- domain optical coherence tomography (SD-OCT) for thickness 
measurement. The retina is approximately 0.5 mm thick (excluding the choroid). However, 
the retinal thickness shows greatest variations depending on the position of the retinal 
structure (central retina, or peripheral retina, foveal floor, foveal rim, nasal, or temporal). In 
addition, age, ethnicity and smoking status play an important role on RPE-BM complex 
thickness.327  
In humans, experimental access to sections of the eye is difficult to achieve, yet one section 
of human retina has been acquired from UCL Institute of Ophthalmology. Zinc had 
noticeable distributions in a human retina section and the biologically important Zn plays 
vital roles in retinal function. 
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Figure 3.24 Microscopic images of 5× (A) and 20× (B) magnifications of  normal human 
retina section, showing the thickness of the human cellular organization layers of the retina 
and choroid complex using optical coherence tomography (OCT) and spectral- domain 
optical coherence tomography (SD-OCT). The following layers are shown: Bruch’s 
membrane (BM); retinal pigment epithelium (RPE); outer segment (OS); inner segment (IS) 
outer nuclear layer (ONL); outer plexiform layer (OPL) inner nuclear layer (INL); inner 
plexiform layer (IPL), ganglion cell layer (GC) and optic nerve fibre (ONF). Both 
micropscopic images obtained from Dr Imre Lengyel, UCL Institute of Ophthalmology. 
 
 
The human retina image was generated using a recently developed custom Live Code based 
application. This new programme was created by Peter Reid in collaboration with Amy 
Managh (LA-ICP-MS ImageTool v0.33, Reid-IT Limited, Loughborough UK).334 The 
technique developed was applied to a specimen taken from a post-mortem section of a human 
eye and the image is shown in Figure 3.25. The image was acquired using the parameters 
given in Table 3.6. 
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This image, generated in 2015, is believed to be the earliest image of the human retina 
produced using LA-ICP-MS, pre-dating a 2018 paper reporting such imaging.302 The same 
data processing technique was used by A. Managh 323 to identify and integrate 197Au 
individual peaks obtained from a single Au labelled macrophage323, however this is the first 
time that the imaging data processing approach was applied to a retina section. There are a 
great number of advantages of this programme including automation of image generation, 
based on user defined image parameters. This represents a substantial time saving since it is 
computationally more efficient and reproduces the images 10 times faster than IGOR Pro. 
To illustrate, 200 lines ablated from the human retina section generates 200 FIN2 files and 
each of these files have 3270 data points, producing an image in less than 1 minute. Whereas 
IGOR Pro. generates the image in less than 10 minutes. Processing the huge amount of data 
points in a few minutes would be a considerable saving of time if this tool is used in the 
future. The retinal layers are not very clear in Figure 3.25 and in order to distingush between 
each layer a new laser instrument with high resolution is required.  
 
The image (Figure 3.25) was compared with the rat section and it can be seen that the fidelity 
of the image collected here corresponds to the rat's section shown previously, and as such 
we can be confident that it is reliable. It is clear the differences between the rat retina and the 
human retina are due to the lack of the anatomical macula features in rats. The thicknesses 
of both rat and human retina were measured by calculating the peak width and the data 
processed from one scanned line selected from the central image. Figure 3.26 shows that the 
width of the human RPE/retina is far higher than control rat, as would be expected. The 
human RPE/choroid complex is about 7-8 times wider than Rat RPE/choroid complex, 
whereas the human retina is 2 times wider than the rat retina. Indeed, the thickness of the 
RPE-choroid complex in the human retina is much wider than the retina because the RPE-
choroid complex is highly enriched with Zn whereas the retinal layers are less concentrated 
with Zn and with the old laser system it was challenging to distinguish the different retinal 
layers. Detection is complicated by the small size of the features present in the eye, which 
necessitates the use of a high-resolution approach for their imaging. Further research with 
more subjects and highly sensitive techniques may help to clarify these age-related changes 
and gender-related differences in thickness of the retinal layer.  
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Gender and age are considered as significant factors that may have an impact on retinal 
function and structure. 335 As a consequence, the thickness of several retinal layers has been 
found to differ according to gender and age.330 Zinc and copper levels in RPE and choroid 
complex in AMD patients’ eyes was decreased by 23% compared to healthy people. The 
patient donors were subjected to Zn and Cu supplementation, suggesting the important role 
of metal homeostasis on AMD and in retinal health. However, no difference was found in 
retinal Zn and Cu levels between AMD patients and healthy subjects. 189 Therefore, while 
analysing the thickness of the retinal layers, the status of the subject (healthy or patient), age, 
and gender should be taken into consideration.330  
Human studies such as AREDS can be expensive and take many years. An accurate animal 
model can help to understand the developments of novel therapies of AMD. There are several 
advantages of the non-human animals such as mice, rats, rabbits, rodents, including: low cost, 
rapid disease progression that allow more efficient studies and easily amenable to genetic 
manipulation. While there are numerous models which mimic many of the important 
pathological features of AMD, none of them reproduces all human characteristics. In 
addition, mice and rats lack an anatomical macula. In spite of all the anatomical differences, 
several animal models have been created for studies of AMD and the human retina, although 
developing a model that imitates AMD features has been challenging as the disease involves 
complex processes involving both genetic and environmental factors.336 All in all, 
examination of the effects of Zn supplementation in animal models and Zn status in humans 
have shown some exciting observations. These highlight the need for further research into 
the role of Zn in the healthy and pathological aging retina. 
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Figure 3.25 LA-ICP-MS image of a 1.66 ×1.88 mm section of human retina tissue, showing 
the distribution of Zn. It was processed by LA-ICP-MS ImageTool v.0.31. The colour scale 
depicts the signal intensity in counts per second (cps) and complete laser parameters are 
given in Table 3.6. 
 
 
 
 
 
 
 
 
 
 
 
               
Figure 3.26 Comparison of the Zn peak width between human and rat retina and RPE-
choroid complex. 
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3.4 Conclusion 
Zinc appears to play a crucial role in many cellular metabolic pathways and is found in high 
concentrations within the retina/choroid complexes. It is well known that Zn homeostasis 
changes during aging, thus contributing to several specific retinal disorders.  
The present study was carried out on aged and long term Zn supplemented rats. For the first 
time, the application LA-ICP-MS was successfully used for mapping the relative 
concentration of Zn across 12 retina sections of rat given either a conventional or a Zn-
supplemented diet. Various ways of data analysis have been considered. Clearly processing 
the data manually was unsatisfactory, not practical and time consuming because it is 
subjective and the results generated were inconsistent on different days. Therefore, the need 
of a way to produce the same result every day is crucial. A novel data processing method 
was used to evaluate the differences in Zn content in the retina and RPE. For reliable 
comparisons between supplemented and non-supplemented rats, the relative ratio of the 
RPE/retina peak areas was used in order to allow for intra and inter day variation of absolute 
signal. The ocular features were well modelled by a Gaussian function which effectively 
smoothed the data and facilitated calculating the peak area ratio. An alternative view is that 
the data should not be smoothed as the individual peaks (spikes) within each peak may 
represent biological features. Although the relative Zn peak area in the RPE/retina did not 
vary significantly between the control and Zn fed rat, the distribution of the Zn was 
concentrated in a much narrower band across the RPE of the fed rat. Whilst a biological 
explanation of narrowing Zn distribution would be speculative at this stage, it could be 
argued that according to the Zn concentration increase it could become trapped and 
precipitate in a narrow  band in the RPE where the plaque starts to form. Retinal thickness 
variation is an important factor to study as it could be an indication of some ocular disease 
including AMD. 
Although the resolution used in this study is comparable with the highest resolution LA-ICP-
MS retinal imaging reported by a recent study302, spot sizes below 25 µm are needed to 
determine whether the spikes correspond to biological features or noise. Higher resolution 
was not possible in this instance due to the sensitivity limitations of the system.  Instrument 
design plays a fundamental role in improving elemental bio-imaging. In recent years a 
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number of groups have introduced modifications to increase the speed of the analysis, 
through design of fast-washout LA instrumentation and implementation of faster data 
acquisition.323,324,337,294,338 These innovations are now starting to reach the market.  The 
implementation of these increasingly faster and more efficient laser systems, with potential 
to reach ~1 µm resolution, will enable detailed imaging at higher sensitivity. Due to the 
massive amount of data generated (4238 data points per one line scanned), there is also a 
need for increased automation to speed up the data processing. The new automated 
programme created by Peter Reid in collaboration with Amy Managh (LA-ICP-MS 
ImageTool v0.33, Reid-IT Limited, Loughborough UK)334 is very promising for the future. 
The data presented here is a small-scale depiction to evaluate the method. A more detailed 
study, involving a greater number of replicate animals, will be required to fully assess the 
biological significance of the results presented here. More comprehensive understanding on 
the influence of Zn supplementation levels and their distribution could be the key for better 
treatment of AMD.  
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4 Bio-imaging of Zinc in Milli cell membrane by Laser 
Ablation Inductively Coupled Plasma Mass 
Spectrometry 
 
4.1 Introduction 
Bruch’s membrane (BM) is a unique thin cellular structure in the eye, located between the 
retina and choroid. BM partially regulates nutrients, oxygen, fluids and metabolic waste 
products between the retina and overall circulation. It has been established that the molecular, 
structural and functional properties of BM depend on age, genetic composition, 
environmental factors, retinal location and disease condition. The variations occurring in BM 
with age include increased accumilation of Ca in elastic fibres, increased crosslinkage of 
collagen fibres and increased income of glycosaminoglycans. In addition, advanced 
glycation end products (AGEs) and fat accumulate in BM. The age-related changes in BM 
may affect healthy photoreceptor cells, and lead to progression of diseases such as age-
related macular degeneration (AMD).317 Barzegar Beforoei has reported that morphological 
examination of ultra-thin sections from the eyes of aged rats following Zn supplementation 
revealed significant thinning of the Bruch’s membrane at the peripheral retina.40 
Retinal pigment epithelium (RPE) is a continuous monolayer of differentiated and pigmented 
cells located between the photoreceptor and choroidal circulation. Among the ocular tissues, 
the highest concentration of  Zn is present in the RPE-choroid complex. The principal roles 
of RPE are carrying of nutrients, ions, and water, absorption of light and defence against 
photooxidation.339 As such, RPE plays an important function in the metabolic exchange 
between the photoreceptor outer segments and blood circulation. Many of the RPE's 
functions depend on Zn, from pigmentation to enzymes involved in phagocytosis.270,340 Here 
we hypothesized that RPE cells in cultures receive insufficient supply of Zn for optimal 
differentiation, if extra Zn is not added to the culture medium. Thus, extra Zn (125 uM) was 
added to the apical side (top of the membrane with cells) but not the basal side since RPE 
phagocytes contain high levels of Zn. Factor H (FH) is genetically associated with age-
related macular degeneration (AMD), characterised by the presence of sub-retinal pigment 
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epithelial (RPE) deposits in which FH and Zn were present. Therefore, the  focus  of this 
study is to identify if Zn concentrations across the membrane would show a concentration 
gradient due to the addition of Zn and/or its secretion from RPE. For example, if more Zn 
accumulates just beneath the cells, then this would be interesting to explore the effect of the 
Zn on the protein deposit (FH) formation beneath the cells. An additional aim was to compare 
varying Zn levels (within and outside the cell) in the culture media (RPE cell culture) using 
LA-ICP-MS. 
 
4.2 Methodology 
4.2.1 LA-ICP-MS 
Several tests were performed for optimizing the operational conditions. The final LA-ICP-
MS parameters for this analysis are shown in Table 4.1. 
Table 4.1 Laser instrument parameters for RPE cultured sections 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repetition frequency    10 Hz 
Laser energy     40-50% 
Scan speed     12-15 µm/s 
Spot size     12-15 µm 
Line spacing     Zero 
Range numbers of lines   (130-200) lines 
Range of fluence    (6.66- 7.93) J/cm2 
Range of line length    (0.42-1.10) mm    
 
ESI UP-213 laser ablation parameters 
 
135 
4.2.2 Slide preparation 
All slides for LA-ICP-MS were prepared by Po-Jung Poa supervised by Dr. Imre Lengyel at 
Institute of Ophthalmology, University College London, Bath Street, London, UK, EC1V 
9EL. OCT-embedded human RPE cells (Human foetal cells, ScienceCell research 
laboratories) were cultured on a filter membrane (Millicell PIHA01250, Merck Millpore) 
and treated with Zn (0-125µM) during culture. Cells will not pass through the membrane as 
the pore size of the membrane is around 0.45 µm. The Zn form is zinc sulphate. The filter 
membrane is a semi permable diffusable membrane and it mimicked the Bruch’s membrane. 
The EpiCM culture medium recommended by the cell manufacturer was replaced by Miller 
medium. This medium was supplemented with 0.5% retinal extract and various 
concentrations of Zn were applied to the apical chamber after one week of seeding, while the 
basal chamber contained pure Miller medium. The thickness of sections was about 10-20µm. 
Four groups of slides were prepared for LA-ICP-MS analysis:  
• Section 1: cell cultured with 125µm Zn 
• Section 2: Cell cultured without Zn (0 µm) 
• Section 3: No cells cultured but with 125µm Zn 
• Section 4: No cells cultured but with 0µm Zn (the membrane) 
The membrane (Figure 4.1,A) is made of mixed cellulose ester and it is like a filter 
paper. It was coated with laminin to help cell attachment and then the cell was placed 
on the top as illustrated in Figure 4.1, B. 
Figure 4.1 Picture of membrane and explanation of its use in cell culture. Reproduced with 
permission from Po-Jung Poa, UCL Institute of Ophthalmology,2015. 
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4.3 Results and discussion 
A daily supplementation of 80 mg Zn is recommended to AMD patients. Consequently, the 
effects of Zn on human primary RPE cells were studied by culturing these with µM levels 
Zn in the medium. Several tests were carried out on 11 sections to map the Zn level in the 
human RPE cell sections. All tests were applied in the section where cells were cultured and 
treated with 125µm of Zn. An example of a successful initial testing is shown in Figure 4.2 
(section A and B). Cells might have detatched during sectioning, due to the cutting presuure 
applied to the sample, thus the cells were pushed away from the membrane. Yet, that should 
not affect the presence of Zn within the membrane, if there is a difference in Zn concentration 
across the membrane (see Figure 4.2 section B). Instead of doing DAPI-staining on every 
single section to know the exact locations of attached and detached cells, the sections were 
re-prepared with careful sectioning as shown in Figure 4.3. The microscopic images 
(Florescence microscope, Nikon SMZ1500, TRITC) were obtained from Po-Jung, UCL 
Institute of Ophthalmology.  
In conclusion, at this stage the presented images show the principles and early results of 
mapping RPE human cell culture embedded on filter paper which mimicked the Bruch’s 
membrane. The concept of this study is novel and it has not been applied before. In addition, 
this study reports for the first time the application of LA-ICP-MS for mapping RPE human 
cells. It is challenging to detect such a small sized feature around 15-20 µm in diameter for 
a single RPE cell. It would be powerful to continue this study in the 4 section types to 
understand the effect of Zn on sub-RPE deposits and RPE cells treated with and without Zn. 
This work has illustrated the feasibility of using LA-ICP-MS for imaging in such a study and 
showed a great potential to be progressed in the future which may help us to understand the 
effectiveness of Zn supplementation on reducing AMD disease progression. 
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Figure 4.2 Top: microscopic image of 2.4×0.61mm (A) and 1.95×1.10 mm (B) of human 
RPE cell section, obtained from Po-Jung Poa (UCL Institute of Ophthalmology). Bottom: 
LA ICP-MS images of the same section, showing the distribution of Zn in attached and 
detached cell with the membrane treated with 125µm of Zn. The colour scale depicts the 
signal intensity in counts per second (cps).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Top: microscopic image of 3.0× 0.42 of human RPE cell section, obtained from 
Po-Jung Poa (UCL institute of ophthalmology). Bottom: LA ICP-MS images of the same 
section, showing the distribution of Zn in attached and detached cell with the membrane 
treated with 125µm of Zn. The colour scale depicts the signal intensity in counts per second 
(cps).  
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5 Quantification of Zn in Buffers in Subcellular 
Extraction Kit by  ICP-MS 
 
5.1 Introduction 
In order to determine the cell distribution of Zn, a cell partitioning technique has been used. 
The CalbioChem ProteoExtract® Subcellular Proteome Extraction Kit (obtained from Merck, 
UK) divides cell components into four functional compartments; the cytosol, cell membrane, 
nuclear fraction and cytoskeletal sections. Each of these fractions has a particular function 
within the cell. The cell fractionation kit provides “four fractions with decreased proteome 
complexity”341. When the extraction buffers are added, the cytosolic proteins are released, 
followed by the membranes and membrane organelles (which are solubilised in Extraction 
Buffer II), then the nuclear proteins are released, and finally, the cytoskeleton components 
are solubilised in Extraction buffer IV.341 
The research group had some experience previously in separating out the protein/DNA from 
different compartments of cells to study the distribution of platinum from chemotherapy 
drugs229, and a further interest arising from that work is to look at the intra-cellular 
distribution of other metals such as Zn, Cu and Fe. In this work the aim was to measure the 
distribution of Zn in each compartment of the cell and thus determine where the Zn 
accumulates. However, it was found that the reagents used in the cell partitioning kit were 
contaminated with the metal of interest. Therefore, this work was directed towards cleaning 
up the reagents successfully instead of testing the cell partitioning kit on actual cells. The 
developed method for cleaning up the reagents ought to be valid in the future research work. 
 
5.2 Methodology 
The analysis was performed on a sector-field inductively coupled plasma mass spectrometer 
(SF-ICP-MS) (Thermo Scientific, Element 2 XR, Bremen, Germany). The instrument was 
fitted with platinum sampler and skimmer cones (ICPMS cones Ltd., Chester, UK), and a 
sample introduction system equipped with a conical glass concentric nebulizer (Glass 
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Expansion, Victoria, Australia), and a Cyclonic spray chamber (Glass Expansion, Victoria, 
Australia). The sample flow rate was set to provide a flow of approximately 400 μL/min. A 
PFA nebulizer and PFA bottles and MF tubes were used. 
A multi-elemental standard solution (10 mg/mL) was diluted 100 fold (0.1 ppm) with 2% 
HNO3. ProteoExtract® Subcellular Proteome Extraction Kit (obtained from Merck, UK) 
contained the following: Wash Buffer (100ml), Extraction Buffer I (22ml), Extraction Buffer 
II (22ml), Extraction Buffer III (11ml) and Extraction Buffer IV (10ml). From the extraction 
buffers I-IV 40 µL were taken and diluted up to 4mL with deionized water (18 M-Ω, from a 
Milli-Q water purification system, Millipore Corporation, Bedford). 
Several steps and tests were successfully carried out to clean the buffers. Glass wool and 
Chelex-100 were used for this purpose. For the preparation of Chelex 100, 4 g of Chelex was 
weighed and 20 ml of water was added. 50 ml each of 2% &10% HNO3 were prepared. In 
order to test the level of Zn contamination in both glass wool and Chelex-100, the final 
procedure was performed as follows: 
• The glass wool was soaked in 10 % HNO3 for 24 hours.  
• The following day, 10% HNO3 was diluted to 2% HNO3 to be analysed to check Zn 
contamination level. 
• Firstly: Glass wool was assembled in 2 pipette tips. 
• 3 ml of DI water was poured on the top of one of the pipette tips to rinse the glass 
wool. 
• Then 3 ml of DI water was added and the eluate was collected in a 15 ml MF tube. 
• 10 samples of DI water eluate were collected (sample 1 was the earliest eluate and 
sample 10 was the last eluate). 
• The same procedure was performed in the second pipette tip with 2%HNO3. 
• Secondly: Glass wool and Chelex were assembled in another 2 pipette tips. 
• 10 eluates of H2O and 2%HNO3 were collected as in the above procedure (Figure 5.1 
illustrates the procedure). 
• The same pipette tips were used to pass buffer through after cleaning the Chelex and 
glass wool with DI water and 2%HNO3. 
140 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 
 
 
 
 
 
 
 
 
Figure 5.1 Explanation of the Procedure of cleaning glass wool and Chelex-100. 
 
5.3 Results and discussion 
A full magnet scan was performed on each of the 4 buffers. The buffer was then analysed 
specifically for Zn. Table 5.1 shows the Zn signal (cps) of blanks before and after running 
the 4 buffers. In general, the scanned 4 buffers displayed no significant difference between 
them, and were found to be much higher when compared with 1 ppb standards (4.57E+04). 
As can bee seen from the table the blanks were affected after running the buffers. Therefore, 
the cleaning procedure was applied. 
20 eluate samples of DI water and 20 eluate samples of 2% HNO3 were collected after 
cleaning with both glass wool and Chelex and analysed by ICP-MS. The signal intensity of 
Zn66 of the soaked nitric acid is very high as expected (8.49E+06 cps). An example of Zn66 
signal intensity test of the DI water collected after the glass wool and Chelex cleaning is 
shown in Figure 5.2 and Figure 5.3 showing the reduction of Zn66 in buffers 1 and 2 before 
and after Chelex. Cu signals were similarly reduced after cleaning. 
1- 2% HNO
3
 
2- H
2
O 
Collecting 20 analyte in tubes after 
adding H
2
O and HNO
3 
then analyse 
them by ICP-MS 
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Table 5.1 An example of one of the run of the buffers to check Zn66 level 
 
 
 
 
 
 
In conclusion, a deposition of a white residue was noticed on the ICP-MS cones following 
analysis of the kit reagents. It was thought that this phenomenon may be attributed to the 
presence of salts, EDTA and mixtures of ionic and non ionic detergents within the cell 
partitioning buffers. Therefore, this experiment was applied to investigate and reduce the 
contamination levels in order to enable such cell partitioning kits to be used to measure intra-
cellular distribution of ubiquitous elements, particularly Zn. Future work would include the 
development of an online cleaning system using the above reagents in a flow system to 
streamline the removal of the high levels of Zn found in the cell partitioning buffers. 
 After cleaning the buffers, a cell partitioning experiment could be performed on a RPE cell 
culture to investigate how the Zn is distributed and in which cell fraction the Zn is most 
concentrated. Subsequently, the cytosol fraction, for instance, could be separated, detected 
and quantified by coupling either  online gel electrophoresis (GE) or HPLC to ICP-MS to 
examine the Zn containing proteins (albumin, α2-macroglobulin and metallothionein), and 
also for Cu containing ceruloplasmin and Fe containing transferrins. Once the methodology 
is fully developed, this technique could be applied to blood samples from AMD patients and 
a healthy control group.  
 
  
Buffers and blanks Zn66 signal intensity 
Before: DI water   3.43E+03 
2%HNO3 1.00E
+04 
Buffer 1 7.25E+05 
Buffer 2 8.24E+05 
Buffer 3 8.03E+05 
Buffer 4 8.21E+05 
After: DI water 8.33E+05 
2%HNO3  1.97E
+04 
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Figure 5.2 An example Zn66 signal intensity test of buffer 1 and buffer 3 before and after 
chelex cleaning with HNO3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 An example Zn66 signal intensity test of the DI water collected after the glass 
wool and chelex cleaning. Sample 1 represents the first eluate collected and the sample 10 
represents the tenth eluate collected. 
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6 Conclusion and Suggestion for Future Work 
 
Simple dilution-based sample preparation procedures have enabled successful quantification 
by ICP-MS of Zn, Cu and Fe in small volumes of serum from AD and AMD patients, 
providing an alternative to conventional time consuming procedures and being amenable to 
automation. To the best of our knowledge, no other published studies in the literature have 
used such a low volume (30 µL) of serum for such an analysis. Due to the ubiquitous nature 
of the elements of interest in the environment, great care was taken to avoid contamination 
in the analytical protocol and extensive testing was carried out to validate the procedure. 
Compared to other procedures,241,342 the use of ammonia, Triton X-100 and nitric acid in the 
matrix for serum samples provided stable performance over extended periods and was 
efficient at keeping the sample introduction system clean and free from clogging. The 
accuracy of the analytical technique was tested by using reference materials. Serum UTAK 
was found to be more stable than Seronorm and the analytical results of the former showed 
very good agreement with the certified value.  
 
 The sample preparation procedure ought to be easily automated. Moreover, flow injection 
technology coupled to ICP-MS possesses advantages including lower sample consumption 
without affecting the analytical performance, and is simple and fast with higher sample 
throughput. Recently, the use of advanced functional materials in solid phase extraction (SPE) 
to remove complex matrices and pre-concentrate target analytes for trace element 
determination by ICP-MS, has been an active field.215 The methodology could be extended 
and coupled to a separation/preconcentration step for other ultra-trace elements. 
  
The importance of studying age related diseases has significantly increased over the last 
century due to increased longevity of the world population. Alterations of serum Zn, Cu and 
Fe levels are associated with the pathogenesis of AD/AMD diseases. Parallel studies between 
AD and AMD have led to a potential link being made between the two conditions. 
Understanding the common mechanisms may provide new insights into AD and AMD 
pathogenesis and treatment. In this study, it was indicated that Cu and Fe concentration 
appear to be higher than Zn in both AD and AMD in accordance with earlier  
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reported studies for the meta-analysis which was discussed in the introduction 
section.85,196,15,72,17  Furthermore, serum Fe levels in AMD patients were slightly higher than 
in the AD study participants, whereas serum Zn and Cu were not significantly different 
between AD and AMD patients. It was not possible to obtain a set of control samples, thus 
our AMD and AD patients were compared with published data for healthy controls (aged 
60+).208,263 The results show a decrease in Zn and Fe serum level in AD and AMD patients 
compared to healthy controls264,263 whereas serum Cu level appears notably increased in 
AD and AMD patients compared to healthy controls.265,263 It seems that a decreased level of 
serum Zn, and increased serum Cu & Fe contribute in these diseases. The comparisons 
between controls and patients will be more reliable if they were of similar age groups and 
gender. Therefore, the next stage of this research will include phenotypic details such as, 
gender, age, nutrition and lifestyles of the anonymised participants. Such information would 
be derived from follow on clinical collaborations as part of the study, and would allow for 
comprehensive information and reliable comparisons. Additionally, for trace metal status, it 
is important to monitor any alteration in other factors during disease such as inflammation, 
cholesterol metabolism, oxidative stress, and homocysteine homeostasis. Therefore, 
combining several biomarkers and applying proteomic and metabolomic profiles are 
effective approaches for the development of serum-based diagnostic tests for age-related 
diseases such as AD/AMD. 
Although measuring serum Zn is the most commonly accepted biomarker of Zn status, there 
is still controversy about measuring serum levels as a realistic way of studying the pathogenic 
pathway of diseases, as serum Zn concentrations are under tight homeostatic control and may 
not reflect changes in Zn intake and status. However, circulating Zn levels remains the most 
widely used method to determine Zn status, despite the known limitations. In addition, 
monitoring metal ions concentration in blood/serum is regarded as essential and needed on a 
regular basis in order to diagnose and prevent diseases linked with their deficiency and 
toxicity. 
 
Bioimaging techniques are necessary for elucidating the role of metals in neurodegenerative 
diseases. Advancements in methodology are essential for greater understanding into the 
localization and distribution of metal ions at the cellular and tissue level, and their role in 
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disease development and progression. Zinc appears to play a crucial role in many cellular 
metabolic pathways and is found in high concentrations within the retina/choroid complexes. 
It is well known that Zn homeostasis changes during aging, thus contributing to several 
specific retinal disorders. Several imaging techniques have been used to study some trace 
elements in ocular tissues including GF-AAS, NAA, ICP-MS/ICP-OES,267,186,42,343 , 
SXRF186, µSXRF288, PIXE320,344, XFM 276,289. The applications of bio imaging by using LA-
ICP-MS reported in the literature are wide-ranging, and spatially resolved trace elemental 
data have been obtained from various biological specimens. However, there have been few 
reported studies of the distribution of Zn in the retina using LA-ICP-MS. In 2014 Konz et al. 
performed quantitative imaging of cryosectioned human eye lenses, revealing a 
homogeneous distribution of Zn in the lens.170 A subsequent study by this group in 2018 
imaged the retina and RPE cells, showing a preferential accumulation of Zn within the RPE 
compared to the retina and sclera using LA-ICP-MS.302  
 
Detection of the small sized features present in the eye is challenging and complicated. This 
study reports for the first time the application of LA-ICP-MS for mapping relative 
concentrations of Zn across the retinal tissue of rats given either a conventional or a Zn-
supplemented diet. The dose of Zn was based upon the approximate supplementation levels 
equivalent to those given to human AMD patients in the Age-Related Eye Disease Study 
(AREDS 1) to examine how this treatment affects the condition. A novel data processing 
method was used to evaluate the differences in Zn content in retina and RPE, taking the 
relative ratio of RPE/retina peak areas instead of the absolute signals. This procedure 
minimised human error from visually interpreting the small differences in the data.  By fitting 
Gaussian peaks to all individual laser line scans in this study, the data were effectively 
smoothed to help calculate the peak area ratio. An alternative view is that the data should not 
be smoothed as the individual spikes within each peak may represent biological features. 
Although the resolution used here is comparable with the highest resolution LA-ICP-MS 
retinal imaging reported by others302, spot sizes below 25 µm are required to determine 
whether the spikes correspond to biological features or noise and to distinguish between the 
different layers of the retina.  
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It was concluded that the relative Zn peak area in the RPE/retina did not vary significantly 
between the control and Zn fed rat, however, the distribution of the Zn was concentrated in 
a much narrower band across the RPE of the supplemented rat. The increased Zn level in the 
rat supplemented with Zn and Cu indicate that Cu has an influence on Zn levels. Multi-
element analysis (Zn and Cu in this case) is required to enable an understanding of the role 
of Cu and Zn together. Further research in this area with more sensitive LA-ICP-MS 
instrumentation may enhance the work and give more specific assignments and further 
explanations. 
Instrument design plays a fundamental role in improving elemental bio-imaging. In recent 
years a number of groups have introduced modifications to increase the speed of the analysis, 
through design of fast-washout LA instrumentation and implementation of faster data 
acquisition 294,323,324,337,338 (Loughborough University have produced a design now marketed 
by ESI). These innovations with possible modifications are expected to reach out to a wider 
market; currently few sites in the world have them. By increasing image acquisition speed 
and resolution without loss of sensitivity, the analysis time would be reduced significantly 
with larger numbers of samples analysed in a shorter time. The implementation of these 
increasingly faster and more efficient laser systems, with potential to reach ~1 µm resolution, 
will enable detailed imaging at higher sensitivity.  
The arrival of the latest generation laser ablation platforms is expected to facilitate imaging 
of small features in ocular tissue with higher speed, sensitivity and spatial resolution than 
was possible during this PhD project. A good example of the future work is illustrated in 
Figure 6.1 which shows a recently acquired image, which was produced by ablation of a 
retinal section at Loughborough University by Dr Amy Managh using ESI's prototype 'NWR 
Image' Platform.  The small section of stained rat retina tissue was ablated with a 1µm spot 
size, which enables individual cells in the outer nuclear layer to be clearly 
distinguished.  This has huge implications for future work in retinal imaging.   
Due to the massive amount of data generated (>4000 data points per one line scanned), there 
is a need for increased automation to speed up the data processing. The new software (LA-
ICP-MS ImageTool v0.33, Reid-IT Limited, Loughborough UK)334 created by Peter Reid in 
collaboration with Amy Managh is promising for fast imaging and data processing in  future 
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work. The present study was carried out on aged and long-term Zn supplemented rats and 
the data presented here is a small-scale depiction to evaluate the method. A more detailed 
study, involving a greater number of replicate animals, and incorporating newer 
developments in imaging technology as outlined above, will be required to fully assess the 
biological significance of the results presented here.  
Figure 6.1 Recently acquired example of high resolution imaging of a section of retina tissue 
(control sample) obtained from Dr Imre Lengyel, UCL Institute of Ophthalmology. Left 
panel: Microscopic image of rat retina tissue. Right panel: corresponding LA-ICP-MS image 
of 250×220µm section showing the distribution of Zn66 (cps) which was sampled using a 1 
micron laser spot size at Loughborough University using ESI's prototype 'NWR Image' 
Platform. Picture courtesy of Dr Amy Managh, Loughborough University. 
 
 
An active research area in the LA-ICP-MS field is the investigation of calibration strategies, 
where it is important to avoid matrix effects, aerosol transport effects, plasma fluctuation, 
laser sample interaction, solid deposition, and mass discrimination. Quantification strategies 
for liquid samples are much more straightforward than those for solid samples,  due to the 
difficulty of obtaining matrix-matched standards for solids. Although external calibration is 
the most commonly recognised approach for quantitative elemental bio imaging by LA-ICP-
MS, the limited availability of CRMs for a wide variety of matrices makes the normal routine 
analytical procedure of producing validated quantitative data a significant challenge. Hence, 
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most of the applications still depend on in-house prepared matrix-matched standards for 
quantitative analysis. Most of the calibrations using matrix-matched standards for biological 
tissue analysis are based on the use of homogenised tissue spiked with the elements of 
interest (such as using spiked homogenised human eye lenses as standards)170, or powders of 
CRMs pressed into pellets.167 Spiked gelatin standards were used in quantifying Zn in human 
retina and RPE.302  Different strategies for elemental quantification in biological tissues using 
LA-ICP-MS reported in the literature include internal standardization, external calibration, 
standard addition, isotope dilution, matrix matched standards, film coating and ink jet 
printing. 176,284,345,346,347,292 
The retina is part of the central nervous system, and if Zn in the retina is bound in the same 
way as Zn in the brain, then it is likely that the total histochemically active (free) Zn is only 
around 10% of the total. Excess levels of “free” or loosely bound metal ions may cause toxic 
effects. The histochemical approaches have limitations in mapping Zn all over the retina as 
they can determine only loosely bound Zn. As the level of Zn is high in the retina, a large 
number of Zn ions are tightly bound to proteins and other molecules to ensure normal retinal 
function. Therefore, it is useful to combine elemental bio-imaging with molecular imaging 
techniques to provide complementary information to study the relationship between Zn and 
protein in human eye sections. For instance, the combination of LA-ICP-MS and matrix-
assisted desorption/ionisation (MALDI) MS has broad potential to map the distribution of 
specific analytes bound with protein or molecules within biological systems. This technique 
could be applied to the retinal tissues or any biological tissue to enhance the growing field 
of spatially-resolved proteomics and thus get broad information and detect relationships 
between proteins associated with disease and specific trace elements. Grey et.al reported348 
experiments using MALDI-MS to identify the distribution of integral membrane proteins in 
human and bovine lens and retinal tissue. Also, Zn is mainly associated with low molecular 
mass proteins (e.g. MTs), hence quantitative speciation of Zn and other essential trace 
elements employing HPLC-ICP-MS to study their protein binding profile is highly important 
to gain a comprehensive understanding of the essential impact of metals and metal-binding 
proteins in the retina and RPE (or eye). The combination of LA-ICP-MS with LC-MS/MS 
and MALDI-MS is crucial to build protein-specific maps of tissue sections. Another 
bioimaging technique which showed a high potential for the analysis of metalloproteins in 
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ocular tissue sections is LA-ICP-MS using metal-tagged immunoprobes. This recent 
analytical technique can provide elemental and molecular information necessary to 
understand the roles of proteins in retinal sections.349 Identifying and quantifying total 
(tightly and loosely bound) Zn in the different layers of the retina is crucial for future studies 
to achieve a better understanding of the functional importance of endogenous trace elements, 
possible toxic effects and their participation in retinal diseases. 
Several aspects of the homeostasis of Zn and Cu in the retina are only partly understood and 
more research is required to elucidate these issues. More comprehensive information is 
essential to understand how Zn and Cu are carried on by the retina from blood; the turnover, 
interaction between RPE cells and photoreceptors together with their direct and/or indirect 
exchanges. Moreover, the influence of these metals on the pathogenesis of diseases including 
AMD needs additional study as modulating levels may provide a feasible therapeutic strategy. 
 
Recommendations for strategies to bring enhancements in sensitivity, reliability of results, 
speed of experiments and data collection are listed as follows:338,350,284,266,324 
 
• Sector-field ICP-MS, as used in this work, delivered adequate sensitivity for the 
applications described, but suffers from an inability to measure multiple isotopes in rapid 
succession (i.e. within the timeframe of a single LA peak). Quadrupole mass analysers 
are the most common choice in current ICP-MS instruments, due to their low cost and 
rapid scan capability. The best choice for simultaneous multi-elemental analysis could 
be TOF mass spectrometers. However, these two mass spectrometers provide 10-50 fold 
less sensitivity than sector-field instruments. Therefore, the best type of mass 
spectrometer for biological samples is still unclear and no commercial ICP-MS 
instrument available has all the desired attributes for highly sensitive multi-element 
analysis and bio-imaging. 
 
• The LA cell design and the transfer tube affect the dispersion of the sample aerosol, 
sample transport efficiency and signal profile. Minimizing ablation cell volume and 
transfer tube length result in a low dispersion and thus allows fast and sensitive line 
scanning, fast wash-out time and reduced peak width. 
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• The use of ultra-short pulse lasers reduces target heating, minimizes volatility and 
fractionation, and improves accuracy and precision. Femtosecond lasers have the 
potential to further advance image resolution, making new research areas possible. 
 
• 2D LA-ICP-MS imaging technique has led to a relatively new generation of 3D LA-ICP-
MS imaging using acquisition of sequential layers of the target and developing this 
imaging approach would be extremely beneficial in biological/analytical research in the 
future. 
 
• Improving sample stage automation and consistency of laser stage positioning would 
allow controlled scanning over a large area. 
 
• Single cell imaging by LA-ICP-MS can provide appropriate information about metals' 
uptake and mobility, metabolic routes, metallodrugs and NPs' behaviour and release. 
Single cell analysis is valued in pharmaceutical research and development of new drugs. 
However, spatial resolution of LA-ICP-MS still needs improvement to facilitate imaging 
at the single-cell and cell organelles scale range. 
 
• Software development is needed to manage the large and complex data sets produced by 
new laser systems, in particular when applied to clinical diagnosis. Software automation 
would be useful in a commercial instrument, to complement the increased analysis speed. 
 
• The most significant aspect is waiting for these research findings to be commercialised 
because for bio-medical applications systems have to be robust, automated and easy to 
use. 
 
Overall, the determination of key elements in biological samples such as serum, tissues and 
cells shows great potential. The biomedical research community seems to be moving towards 
looking at individual cells, and individual cell processes, so measuring elements within the 
cell or within specific biological structures, such as measuring Zn in RPE cells as mentioned 
earlier, is a promising direction for future research. 
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Appendix 2 – Supplementary figures data for chapter 2 
 
Table 8.1 Figures of merit (regression equations, correlation coefficient (R2), and limit of 
detection and quantification) of  serum Zn, Cu and Fe in all experiments 
Zn66 Linear equation R² LOD LOQ 
EXP 1 y= 13802x + 6611.2  0.9972 0.20 0.65 
EXP 2 y = 14503x + 1103.5 0.9997 0.39 1.30 
EXP 3 y = 14092x - 593.16 0.9988 0.57 1.91 
EXP 4 y = 5565.6x + 4939.5 0.9972 0.83 2.75 
       
Cu65 Linear equation R² LOD LOQ 
EXP 1 y = 52106x + 6270.6 0.9998 0.29 0.96 
EXP 2 y = 60096x - 1990.8 0.9999 0.08 0.28 
EXP 3 y = 55074x - 13127 0.9984 0.66 2.20 
EXP 4 y = 50795x + 8279.3 0.9977 0.63 2.09 
              
Fe57 Linear equation R² LOD LOQ 
EXP 1 y = 4647.2x + 3655.9  0.9971 0.29 0.96 
EXP 2 y = 5758.6x + 5167 0.9998 0.27 0.90 
EXP 3 y = 5004.4x + 2795.7  0.9993 0.18 0.59 
EXP 4 y = 4316.8x + 4664.8 
0.9958 0.93 3.11 
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Table 8.2 Kolmogorov–Smirnov method of Zn in AD patients* 
*For n=43 and P= 0.05, the critical value is 0.192, Since 0.080 <0.192 we can accept the null hypothesis 
that the data come from a normal population with mean 0.78 and standard deviation 0.125    
 
X            
(Zn-AD) 
Z 
Cumulative  
frequency 
Step cumulative 
distribution 
Normal cumulative 
distribution 
Difference 
0.58 -1.58 1 0.02 0.06 -0.034 
0.59 -1.46 2 0.05 0.07 -0.026 
0.61 -1.34 3 0.07 0.09 -0.021 
0.61 -1.33 4 0.09 0.09 0.002 
0.61 -1.30 5 0.12 0.10 0.019 
0.62 -1.23 6 0.14 0.11 0.030 
0.64 -1.06 7 0.16 0.14 0.019 
0.66 -0.92 8 0.19 0.18 0.007 
0.66 -0.89 9 0.21 0.19 0.022 
0.68 -0.74 10 0.23 0.23 0.004 
0.68 -0.74 11 0.26 0.23 0.027 
0.69 -0.70 12 0.28 0.24 0.036 
0.69 -0.69 13 0.30 0.24 0.058 
0.69 -0.69 14 0.33 0.25 0.080 
0.70 -0.61 15 0.35 0.27 0.078 
0.71 -0.53 16 0.37 0.30 0.072 
0.72 -0.45 17 0.40 0.33 0.068 
0.73 -0.35 18 0.42 0.36 0.056 
0.74 -0.30 19 0.44 0.38 0.058 
0.74 -0.27 20 0.47 0.39 0.071 
0.75 -0.20 21 0.49 0.42 0.066 
0.76 -0.16 22 0.51 0.44 0.074 
0.77 -0.04 23 0.53 0.48 0.052 
0.78 0.04 24 0.56 0.52 0.041 
0.79 0.08 25 0.58 0.53 0.049 
0.79 0.11 26 0.60 0.54 0.062 
0.80 0.20 27 0.63 0.58 0.047 
0.80 0.21 28 0.65 0.58 0.068 
0.81 0.30 29 0.67 0.62 0.055 
0.83 0.40 30 0.70 0.66 0.042 
0.83 0.44 31 0.72 0.67 0.049 
0.84 0.48 32 0.74 0.68 0.062 
0.86 0.65 33 0.77 0.74 0.025 
0.90 0.96 34 0.79 0.83 -0.041 
0.92 1.19 35 0.81 0.88 -0.069 
0.93 1.20 36 0.84 0.88 -0.048 
0.93 1.25 37 0.86 0.89 -0.033 
0.93 1.25 38 0.88 0.89 -0.011 
0.95 1.37 39 0.91 0.92 -0.008 
0.98 1.65 40 0.93 0.95 -0.021 
0.99 1.69 41 0.95 0.95 -0.001 
0.99 1.70 42 0.98 0.96 0.021 
1.07 2.38 43 1.00 0.99 0.009 
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Table 8.3 Kolmogorov–Smirnov method of Cu in AD patients* 
 
*For n=43 and P= 0.05, the critical value is 0.192, Since 0.093 <0.192 we can accept the null hypothesis that 
the data  coming from a normal population with mean 1.18 and standard deviation 0.234 
X           
(Cu-AD) 
Z 
Cumulative  
frequency 
Step 
cumulative 
distribution 
Normal 
cumulative 
distribution 
Difference 
0.77 -1.74 1 0.02 0.04 -0.017 
0.79 -1.66 2 0.05 0.05 -0.002 
0.81 -1.57 3 0.07 0.06 0.012 
0.85 -1.42 4 0.09 0.08 0.015 
0.87 -1.31 5 0.12 0.09 0.022 
0.94 -1.01 6 0.14 0.16 -0.017 
0.95 -0.97 7 0.16 0.17 -0.002 
0.95 -0.97 8 0.19 0.17 0.019 
0.98 -0.86 9 0.21 0.20 0.013 
0.98 -0.85 10 0.23 0.20 0.034 
1.02 -0.68 11 0.26 0.25 0.007 
1.03 -0.65 12 0.28 0.26 0.021 
1.04 -0.60 13 0.30 0.27 0.028 
1.06 -0.51 14 0.33 0.30 0.021 
1.08 -0.44 15 0.35 0.33 0.018 
1.09 -0.39 16 0.37 0.35 0.023 
1.10 -0.33 17 0.40 0.37 0.023 
1.11 -0.31 18 0.42 0.38 0.040 
1.13 -0.21 19 0.44 0.42 0.024 
1.15 -0.14 20 0.47 0.45 0.020 
1.17 -0.04 21 0.49 0.48 0.006 
1.19 0.04 22 0.51 0.52 -0.004 
1.19 0.05 23 0.53 0.52 0.017 
1.20 0.11 24 0.56 0.54 0.016 
1.20 0.11 25 0.58 0.54 0.038 
1.23 0.23 26 0.60 0.59 0.013 
1.24 0.27 27 0.63 0.61 0.020 
1.24 0.28 28 0.65 0.61 0.041 
1.25 0.31 29 0.67 0.62 0.053 
1.29 0.46 30 0.70 0.68 0.021 
1.29 0.47 31 0.72 0.68 0.041 
1.31 0.54 32 0.74 0.71 0.038 
1.32 0.60 33 0.77 0.73 0.042 
1.32 0.62 34 0.79 0.73 0.058 
1.33 0.64 35 0.81 0.74 0.075 
1.35 0.72 36 0.84 0.77 0.071 
1.35 0.73 37 0.86 0.77 0.093 
1.42 1.04 38 0.88 0.85 0.033 
1.50 1.38 39 0.91 0.92 -0.010 
1.53 1.48 40 0.93 0.93 -0.001 
1.54 1.55 41 0.95 0.94 0.014 
1.70 2.23 42 0.98 0.99 -0.010 
1.83 2.78 43 1.00 1.00 0.003 
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Table 8.4 Kolmogorov–Smirnov method of Fe in AD patients* 
X             
(Fe-AD) 
Z 
Cumulative  
frequency 
Step cumulative 
distribution 
Normal 
cumulative 
distribution 
Difference 
0.51 -1.38 1 0.02 0.08 -0.060 
0.52 -1.36 2 0.05 0.09 -0.040 
0.53 -1.35 3 0.07 0.09 -0.018 
0.56 -1.27 4 0.09 0.10 -0.008 
0.56 -1.27 5 0.12 0.10 0.014 
0.66 -1.05 6 0.14 0.15 -0.007 
0.69 -0.98 7 0.16 0.16 -0.001 
0.76 -0.81 8 0.19 0.21 -0.023 
0.77 -0.80 9 0.21 0.21 -0.003 
0.80 -0.72 10 0.23 0.24 -0.003 
0.81 -0.71 11 0.26 0.24 0.018 
0.81 -0.70 12 0.28 0.24 0.038 
0.86 -0.60 13 0.30 0.28 0.027 
0.88 -0.54 14 0.33 0.29 0.032 
0.89 -0.51 15 0.35 0.30 0.045 
0.92 -0.45 16 0.37 0.33 0.045 
0.95 -0.39 17 0.40 0.35 0.046 
0.95 -0.38 18 0.42 0.35 0.066 
0.96 -0.37 19 0.44 0.36 0.087 
0.96 -0.36 20 0.47 0.36 0.105 
1.02 -0.23 21 0.49 0.41 0.078 
1.06 -0.13 22 0.51 0.45 0.064 
1.06 -0.13 23 0.53 0.45 0.086 
1.09 -0.07 24 0.56 0.47 0.088 
1.16 0.09 25 0.58 0.54 0.045 
1.19 0.15 26 0.60 0.56 0.045 
1.22 0.23 27 0.63 0.59 0.039 
1.23 0.25 28 0.65 0.60 0.054 
1.24 0.27 29 0.67 0.61 0.066 
1.24 0.28 30 0.70 0.61 0.086 
1.29 0.39 31 0.72 0.65 0.067 
1.35 0.53 32 0.74 0.70 0.041 
1.40 0.63 33 0.77 0.73 0.033 
1.41 0.66 34 0.79 0.74 0.046 
1.43 0.71 35 0.81 0.76 0.054 
1.66 1.23 36 0.84 0.89 -0.053 
1.70 1.32 37 0.86 0.91 -0.046 
1.76 1.45 38 0.88 0.93 -0.043 
1.87 1.71 39 0.91 0.96 -0.049 
1.95 1.90 40 0.93 0.97 -0.041 
2.05 2.12 41 0.95 0.98 -0.030 
2.29 2.66 42 0.98 1.00 -0.019 
 
*For n=42 and P= 0.05, the critical value is 0.192, Since 0.105 <0.192 we can accept the null hypothesis that 
the data  coming from a normal population with mean 1.12 and standard deviation 0.44 
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Table 8.5 Kolmogorov–Smirnov method of Zn in AMD patients* 
 
*For n=38 and P= 0.05, the critical value is 0.192, Since 0.154 <0.192 we can accept the null hypothesis that 
the data  coming from a normal population with mean 0.80 and standard deviation 0.211 
 
X              
(Zn-AMD) 
Z 
Cumulative  
frequency 
Step 
cumulative 
distribution 
Normal 
cumulative 
distribution 
Difference 
0.52 -1.32 1 0.02 0.09 -0.069 
0.56 -1.16 2 0.05 0.12 -0.077 
0.57 -1.08 3 0.07 0.14 -0.070 
0.57 -1.06 4 0.09 0.14 -0.050 
0.59 -0.97 5 0.12 0.17 -0.050 
0.62 -0.87 6 0.14 0.19 -0.052 
0.62 -0.85 7 0.16 0.20 -0.035 
0.63 -0.79 8 0.19 0.22 -0.029 
0.65 -0.72 9 0.21 0.24 -0.027 
0.65 -0.70 10 0.23 0.24 -0.009 
0.66 -0.67 11 0.26 0.25 0.004 
0.66 -0.67 12 0.28 0.25 0.027 
0.68 -0.57 13 0.30 0.28 0.017 
0.69 -0.53 14 0.33 0.30 0.026 
0.70 -0.49 15 0.35 0.31 0.036 
0.71 -0.43 16 0.37 0.33 0.039 
0.71 -0.43 17 0.40 0.33 0.061 
0.72 -0.39 18 0.42 0.35 0.071 
0.73 -0.35 19 0.44 0.36 0.077 
0.74 -0.29 20 0.47 0.39 0.078 
0.75 -0.24 21 0.49 0.40 0.083 
0.77 -0.15 22 0.51 0.44 0.071 
0.78 -0.08 23 0.53 0.47 0.066 
0.84 0.19 24 0.56 0.58 -0.017 
0.85 0.24 25 0.58 0.59 -0.012 
0.85 0.26 26 0.60 0.60 0.002 
0.86 0.30 27 0.63 0.62 0.012 
0.86 0.30 28 0.65 0.62 0.032 
0.87 0.31 29 0.67 0.62 0.052 
0.88 0.40 30 0.70 0.66 0.042 
0.95 0.71 31 0.72 0.76 -0.041 
0.98 0.87 32 0.74 0.81 -0.063 
1.02 1.04 33 0.77 0.85 -0.083 
1.04 1.12 34 0.79 0.87 -0.078 
1.19 1.86 35 0.81 0.97 -0.154 
1.26 2.19 36 0.84 0.99 -0.148 
1.32 2.49 37 0.86 0.99 -0.133 
1.33 2.53 38 0.88 0.99 -0.111 
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Table 8.6 Kolmogorov–Smirnov method of Cu in AMD patients* 
 
* For n=38 and P= 0.05, the critical value is 0.192, Since 0.116<0.192 we can accept the null hypothesis that 
the data  coming from a normal population with mean 1.14 and standard deviation 0.240 
X                   
(Cu-AMD) 
Z 
Cumulative  
frequency 
Step 
cumulative 
distribution 
Normal 
cumulative 
distribution 
Difference 
0.77 -1.53 1 0.02 0.06 -0.039 
0.83 -1.30 2 0.05 0.10 -0.051 
0.85 -1.22 3 0.07 0.11 -0.041 
0.87 -1.12 4 0.09 0.13 -0.038 
0.91 -0.96 5 0.12 0.17 -0.051 
0.92 -0.91 6 0.14 0.18 -0.041 
0.93 -0.88 7 0.16 0.19 -0.028 
0.95 -0.78 8 0.19 0.22 -0.032 
0.98 -0.68 9 0.21 0.25 -0.038 
0.98 -0.66 10 0.23 0.25 -0.021 
0.98 -0.65 11 0.26 0.26 -0.001 
0.99 -0.61 12 0.28 0.27 0.010 
1.01 -0.56 13 0.30 0.29 0.015 
1.01 -0.55 14 0.33 0.29 0.033 
1.02 -0.51 15 0.35 0.30 0.044 
1.03 -0.47 16 0.37 0.32 0.052 
1.04 -0.41 17 0.40 0.34 0.053 
1.07 -0.29 18 0.42 0.39 0.033 
1.07 -0.28 19 0.44 0.39 0.052 
1.09 -0.22 20 0.47 0.41 0.052 
1.14 -0.02 21 0.49 0.49 -0.004 
1.15 0.02 22 0.51 0.51 0.004 
1.15 0.05 23 0.53 0.52 0.015 
1.16 0.07 24 0.56 0.53 0.031 
1.16 0.07 25 0.58 0.53 0.054 
1.20 0.26 26 0.60 0.60 0.001 
1.21 0.29 27 0.63 0.61 0.015 
1.22 0.32 28 0.65 0.63 0.024 
1.31 0.69 29 0.67 0.75 -0.080 
1.33 0.77 30 0.70 0.78 -0.080 
1.34 0.83 31 0.72 0.80 -0.077 
1.37 0.95 32 0.74 0.83 -0.084 
1.41 1.10 33 0.77 0.87 -0.098 
1.42 1.15 34 0.79 0.87 -0.084 
1.48 1.41 35 0.81 0.92 -0.107 
1.49 1.46 36 0.84 0.93 -0.090 
1.61 1.95 37 0.86 0.97 -0.114 
1.92 3.25 38 0.88 1.00 -0.116 
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Table 8.7 Kolmogorov–Smirnov method of Fe in AMD patients 
X             
(Fe-AMD) 
Z 
Cumulative  
frequency 
Step 
cumulative 
distribution 
Normal 
cumulative 
distribution 
Difference 
0.51 -1.84 1 0.02 0.03 -0.010 
0.63 -1.57 2 0.05 0.06 -0.012 
0.68 -1.45 3 0.07 0.07 -0.004 
0.74 -1.30 4 0.09 0.10 -0.003 
0.84 -1.10 5 0.12 0.14 -0.020 
0.87 -1.03 6 0.14 0.15 -0.012 
0.96 -0.82 7 0.16 0.21 -0.044 
0.99 -0.76 8 0.19 0.22 -0.039 
1.03 -0.67 9 0.21 0.25 -0.042 
1.06 -0.59 10 0.23 0.28 -0.044 
1.08 -0.56 11 0.26 0.29 -0.032 
1.11 -0.50 12 0.28 0.31 -0.030 
1.13 -0.44 13 0.30 0.33 -0.029 
1.18 -0.32 14 0.33 0.37 -0.047 
1.24 -0.20 15 0.35 0.42 -0.070 
1.25 -0.17 16 0.37 0.43 -0.058 
1.26 -0.16 17 0.40 0.44 -0.041 
1.26 -0.14 18 0.42 0.44 -0.025 
1.29 -0.09 19 0.44 0.46 -0.021 
1.30 -0.07 20 0.47 0.47 -0.008 
1.31 -0.04 21 0.49 0.49 0.003 
1.32 -0.02 22 0.51 0.49 0.021 
1.52 0.44 23 0.53 0.67 -0.134 
1.59 0.59 24 0.56 0.72 -0.163 
1.60 0.62 25 0.58 0.73 -0.150 
1.63 0.67 26 0.60 0.75 -0.144 
1.64 0.69 27 0.63 0.76 -0.128 
1.68 0.78 28 0.65 0.78 -0.132 
1.68 0.79 29 0.67 0.79 -0.111 
1.72 0.87 30 0.70 0.81 -0.111 
1.83 1.12 31 0.72 0.87 -0.148 
1.88 1.25 32 0.74 0.89 -0.149 
2.06 1.65 33 0.77 0.95 -0.183 
2.20 1.95 34 0.79 0.97 -0.184 
2.41 2.42 35 0.81 0.99 -0.178 
 
*For n=35 and P= 0.05, the critical value is 0.192, Since 0.184 <0.192 we can accept the null hypothesis that 
the data  coming from a normal population with mean 1.33 and standard deviation 0.447 
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Figure 8.1 Normal probability plot for the Zn, Cu and Fe levels for both AD and AMD 
patients obtained using Minitab software. 
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Appendix 3 – Supplementary figures data for chapter 3 
 
 
 
Figure 8.2  Top: microscopic images of a 475 x 468 µm section of RPE tissue (D2), obtained 
using the built-in microscope on the UP-213 laser ablation system. Bottom: LA-ICP-MS 
image of the same section, showing the distribution of Zn. The colour scale depicts the signal 
intensity in counts per second (cps). 
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Figure 8.3 Top: Microscopic image of a 4.5×2.33 mm section of rat retina tissue, (obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-
MS image showing the distribution of Zn in control slide (5.3). The colour scale depicts the 
signal intensity in counts per second (cps). Complete laser parameters are given in Table 3.6. 
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Figure 8.4 Top: Microscopic image of a 5.00× 1.78 mm section of rat retina tissue, (obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-
MS image showing the distribution of Zn in control slide (3.1). The colour scale depicts the 
signal intensity in counts per second (cps). Complete laser parameters are given in Table 3.6. 
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Figure 8.5 Top: Microscopic image of a 5.00×2.19 mm section of rat retina tissue, (obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-
MS image  showing the distribution of Zn. The rat was on Zn diet (slide 10.2).  The colour 
scale depicts the signal intensity in counts per second (cps). Complete laser parameters are 
given in Table 3.6. 
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Figure 8.6 Top: Microscopic image of a 4.8×1.37 mm section of rat retina tissue, (obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-
MS image showing the distribution of Zn. The rat was on Zn diet (slide 6.1).  The colour 
scale depicts the signal intensity in counts per second (cps). Complete laser parameters are 
given in Table 3.6. 
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Figure 8.7 Top: Microscopic image of a 4.5 ×1.55 mm section of rat retina tissue, (obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-
MS image showing the distribution of Zn. The rat was on Zn& Cu diet (slide 15.1).  The 
colour scale depicts the signal intensity in counts per second (cps). Complete laser 
parameters are given in Table 3.6. 
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Figure 8.8 Top: Microscopic image of a 4.53×1.41 mm section of rat retina tissue, (obtained 
from Dr Imre Lengyel, UCL Institute of Ophthalmology). Bottom: corresponding LA-ICP-
MS image showing the distribution of Zn. The rat was on Zn& Cu diet (slide 12.1).  The 
colour scale depicts the signal intensity in counts per second (cps). Complete laser 
parameters are given in Table 3.6. 
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Appendix 4 –Presentations, conferences and training records 
Conferences and Presentations 
The work contained in this thesis has been presented in poster format. This includes 
presentations /attending at scientific conferences as well as departmental meetings. 
 
Annual meeting/conference: The 3rd ZINC-UK meeting, UCL 
Institute of Ophthalmology, London 
Annual meeting/conference: The 4th ZINC-UK meeting, 
University of Central Lancashire 
 
 
28/02/2011    
 
18/07/2011 
 
Department Research Network Meeting 
Poster titled: A Metallomics Study of Zn Biology in Relation to 
Age Related Macular Degeneration, Loughborough University 
 
25/04/2012 
 
Research School of Health and Life Sciences Student 
Conference  
Poster titled: A Metallomics Study of Zn Biology in Relation to 
Age Related Macular Degeneration, Loughborough University 
 
28/05/2012 
 
The 6th Saudi International Conference - SIC 2012 
Poster titled: A Metallomics Study of Zn Biology in Relation to 
Age Related Macular Degeneration, Brunel University 
 
11/10/2012  
14/10/2012 
 
University Research Network Meeting 
Poster titled: Bioimaging of Zinc in retina tissue by Laser 
Ablation Inductively Coupled Plasma Mass Spectrometry, 
Loughborough, UK 
21/05/2014 
 
European Winter Conference on Plasma Spectrochemistry 
Poster titled: Bioimaging of Zinc in retina tissue by Laser 
Ablation Inductively Coupled Plasma Mass Spectrometry, 
University of Münster, Germany 
  22- 26/02/15 
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Training 
A list of the Loughborough University lectures, staff development and safety courses, 
workshops and seminars attended during the course of the PhD is provided below: 
 
Inaugural lecture: From Laboratory to Clinic-Analytical Chemistry in 
Action, Professor Barry Sharp 
 
08/02/2012 
 
RSC lecture: Mass spectrometry simplified: ambient ionization and 
miniature mass spectrometers, Professor R. Graham Cooks 
 
23/02/2012 
 
Departmental lecture: Atomic and Molecular Spectroscopy lectures 
(CMP052) 
 
26/10/2010   
28/10/2010 
 
Departmental lecture: Mass Spectrometry and Associated Techniques 
lectures (CMP051) 
 
16/11/2010   
23/11/2010   
30/11/2010 
  
 
Workshop: Thermo Scientific Gas and Liquid Phase 
Chromatography Workshops, University of  Reading 
 
13-14/07/2011 
 
Workshop: 10th East Midlands Proteomics Workshop, Loughborough 
University 
 
02/11/2011 
  
 
Training: ICP-MS, including Fixing problems-Mass calibration- 
Mantenance (David Douglas, Claire Camp). 
 
17/12/2010  
02/03/2011   
03/03/2011  
31/03/2011 
15/06/2011 
 
Training: Gel electrophoresis/GE-ICP-MS ( Razi Haider) 
 
22/11/2010  
10/12/2010        
16-19/08/2011 
 
Training: LabVIEW training day: National instruments Ltd 
 
01/03/2011 
 
Training: LTQ (Dr. Tamer Shoeib, Aref Zayed, Sarah Taylor). 
 
24/03/2013 
26/07/2012 
01/06/2011 
 
Training: Basic LC-MS  (Aref Zayed) 
 
01/06/2011 
 
Training: Nano LC (Thermo scientific) 
 
31/02/2014 
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Training: LA-ICP-MS (Amy Managh) 
 
05/12/2013  
23/01/2014 
Training: Igor Iolite programme (visualisation and processing of mass 
spectrometric data), by Amy Managh 
 
Training: D-plot Programme (Grant Craig) 
17/01/2014 
 
Training: Lab Demonstration CMB010 
 
17/05/2012 
 
Training: Cell Culture Training  
Sport science/Chemical bioengineering, John Pugh 
17/03/2014 
20/03/2014 
31/03/2014 
03/04/2014 
07/04/2014 
10/04/2014 
 
 
Safety seminar: Good laboratory practice, Professor Paul Thomas 
 
 
22/02/2012 
13/11/2013 
Safety seminar: Flammable materials, Anish Patel 
 
  14/03/2012 
Safety seminar: Fire extinguisher training, Rod Harrison  
16/04/2012 
Safety seminar: Liquefied gases, Cryogenics, Claire Camp  
18/04/2012 
Safety seminar: Corrosive materials, Paul O'Hara  
23/05/2012 
Safety seminar: Pressurised gasses, Shuo Kang  
06/06/2012 
Safety seminar: Electrical Hazards, Iain Kirkpatrick  
05/07/2012 
Safety seminar: High pressure/high temperature operation, Tom Smith   
 26/09/2012 
Safety seminar: Radioactive materials and ionizing radiation, 
Monica Felipe-Sotelo 
 
25/10/2012 
Safety seminar: Vacuum Systems, Neil Devenport/Caitlyn Da Costa  
22/11/2012 
Safety seminar: Waste disposal, Nolwenn Derrien   
 16/01/2013 
Research Seminar: Inorganic  
24/10/2010 
Research Seminar: Physical & Analytical     
06/01/2011 
 
Research Seminar: Analytical, Ridiochem, Inorganic  
 
23/02/2011 
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Research Seminar: Better Instrumentation and Measurements through 
Spectrochemical Research, by Prof. Gary Hieftje   
 
29/03/2011 
 
Research Seminar with Prof. Derek Tocher (UCL), Dr. Claire Eyers 
(University of Manchester). 
 
07/12/2011 
 
Research Seminar with Prof. Keith Oldham (Trent University, Canada) 
 
28/03/2012 
 
Research seminar: From the electronics of molecules to molecular 
electronics, Professor Paul Low. 
 
30/05/2012 
 
Research Seminar: Surface Mobility, Structure Modulation and Host-
Guest Effects in Supramolecules 
 
07/06/2012 
 
Research Seminar: Introduction to statistics for researchers 
 
24/07/2012 
 
Research Seminar: with  Dr Malachy McCann from NUI Maynooth, 
‘Syphilis, MRSA and Cancer – Cures Containing Metal Ions 
 
17/10/2012 
 
Research Seminar: with Prof. Patrick Guiry (UCD),  
 
24/10/2012 
  
 
Graduate school course: Postgraduate Research Students Induction 
 
02/11/2010 
 
Graduate school course: Database in Focus - Web of Science 
 
24/11/2010 
 
Graduate school course: Finding Resources for your Literature Review 
and Beyond 
 
18/01/2011 
 
Graduate school course: RefWorks 
 
10/02/2011 
 
Graduate school course: Qualitative Analysis - an Introduction to 
Collecting and Analysing 
 
25/02/2011 
 
Graduate school course:  
Excel 2007 Intermediate - Pivot Tables and Pivot Charts 
 
25/05/2011 
 
Graduate school course: Teaching Skills                                                                               
Preparing to teach and promoting learning/ Supervising practical 
activities (3 parts) 
 
28/03/2011
04/04/2011  
26/05/2011 
 
Graduate school course: Getting Noticed - The Databases that Help 
you Choose Where to publish 
 
9/06 2011 
 
Graduate school course: Blood Borne Viruses and other Pathogens 
 
12/01/2012 
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Graduate school course:  
Excel 2010 - An Introduction course-part 1  
Excel 2010 - An Introduction course- part 2  
Excel 2010 - An Introduction course- part 3 
13/02/2012 
14/03/2012 
21/03/2012 
 
Graduate school course:  
Writing your Thesis with Word 2010A  
Writing your Thesis with Word 2010B 
 
21/11/2012 
28/11/2012 
  
 
Webinar: Identifying and Quantifying the Uncertainty Associated with 
Instrumental Analysis.         
 
Webinar: Rapid Quantitative Analysis of Immunosuppressant Drugs in 
Blood and Plasma by LC-MS/MS in Clinical Research.  
 
27/10/2011  
 
 
15/11/2011 
 
 
Meeting with Dr. Imre Lengyel UCL Institute of Ophthalmology, 
London 
 
 
17/11/2011 
18/12/2013  
12/02/2014 
 
Meeting: Project meeting with sport science, Professor Mark Lewis 
 
28/06/2012 
 
 
Meeting: Skype sessions with Dr. Imre Lengyel UCL Institute of 
Ophthalmology, 
 
06/03/2014                    
07&26/02/2014 
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Appendix 5 –Articles to be submited 
 
1- Determination of Zn, Cu and Fe in Patients' Serum using Micro-
Sampling ICP-MS and Sample  Dilution. 
 
Tharwat N. Abduljabbara,b , Helen J. Reida, Neda Barzegar-Befroeidc, Tunde Petode, 
Imre Lengyelc,d and Barry L. Sharpa* 
To be submited to Talanta.  
 
Abstract 
A high-throughput, sensitive and rapid method was developed for the determination of Zn, Cu and 
Fe in small volumes (30 µL) of human serum using inductively coupled plasma mass spectrometry 
(ICP-MS). The sample preparation procedure employed simple dilution of the serum samples by 100-
fold with 1.0 % butanol, 0.5 % v/v ammonia, 0.02 % v/v Triton X-100 and 0.01 % v/v HNO3. The 
reliability of the method was evaluated using serum UTAK certified reference material, and the 
results matched well with the certified values. The method was applied to determine Zn, Cu and Fe 
in 81 human serum samples from Alzheimer disease (AD) and age related macular degeneration 
(AMD) patients. No significant difference was found in Zn and Cu levels between AD and AMD 
patients, whereas the content of Fe in AMD patients was slightly higher than in AD patients. The 
results showed a decrease in serum Zn and a notable increase in serum Cu in both AD and AMD 
patients compared to healthy controls, but Fe serum levels in AMD patients were not significantly 
different from the controls. 
Keywords: AD; AMD; ICP-MS; Serum analysis; Trace elements.  
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2- Bio-imaging of Zinc in Retina Tissue by Laser Ablation Inductively 
Coupled Plasma Mass Spectrometry 
 
Tharwat N. Abduljabbara,b, Amy Managha, Helen J. Reida, Imre Lengyelc, Barry L. 
Sharpa* 
To be submited to Analytical and bioanalytical chemistry. 
 
Abstract 
Elemental bio-imaging using laser ablation inductively coupled plasma-mass spectrometry 
(LA-ICP-MS) was employed to image Zn in twelve rat retina sections. The rats were given 
either a conventional, a Zn or Zn/Cu-supplemented diet to study the correlation between diet 
and specific retinal disorders. LA line scans were run approximately orthogonal to the retina 
which showed that that the Zn was largely concentrated in the retinal pigmented epithelium 
(RPE) and the retina. It was found that the distribution of Zn across these features was well 
modelled by a Gaussian distribution and this was used to evaluate differences in the relative 
uptake of Zn across the ocular features. The difference between the three differentially fed 
rat groups was not statistically significant for the relatively small group of twelve rats 
investigated here. However,  The distribution of Zn in the RPE was found to 
be significantly  narrowed in the rats receiving both Cu and Zn supplementation.Thus 
elemental imaging, as demonstrated here, is shown to be a powerful means of studying the 
uptake of Zn in the eye.  
 
Keywords: AMD; LA- ICP-MS, bioimaging, Retina, Zinc 
 
 
 
 
 
 
